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Replicate Tests for the Detection and Correction of Errors 
in Anti-Human Globulin (AHG) Tests:
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Replicate blind AHG tests with weak lgG anti-D sensitised red cells revealed 
that 32% of workers caused 5 per cent or more false negative errors by using excessive 
agitation in reading techniques. The common quality control procedure of adding 
strongly sensitised cells to all negative AHG tests cannot reveal this type of error. 
Furthermore, strongly sensitised control cells may create an illusion of safety because 
AHG giving a false negative test with weak antibody in a serum sample may still show 
a reassuringly strong positive in the control test. “ In-house” assessment of all staff and 
automatic cell-washers by blind replicate tests is recommended as an effective way of 
improving AHG test performance, thus reducing many of the errors involving false 
negative AHG tests seen year after year in External Proficiency Trials.
Keywords: anti-human globulin tests, cell washers, centrifuges, errors, quality 
control, optimum conditions, replicate tests, spin tests
Introduction
A high incidence of false negative anti-human globulin (AHG) tests has been 
reported by blind External Proficiency Test Surveys in the USA [1, 2, 3], Canada 
[4], UK [5] and Australia [6]. In addition to the failure to detect many weak 
antibodies (Table 1), it was also noted in one USA trial [2] that a sample of 
strongly sensitised (3+/4 +  ) red cells was recorded by 13.7 percent of participants 
as giving only weak 1+ /2+  reactions.
It is possible that many of these failures were due to excessive agitation at 
the reading stage of tests. Hence, the common quality control procedure of adding 
red cells strongly sensitised with IgG anti-D to all negative AHG tests could not 
reveal the false negatives found in these surveys. However, partial neutralisation of 
AHG as a cause of some false negatives cannot be excluded, because strongly
l VSP Utrecht, T o k y o  
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Antibodies F a i lu re  rates
Weak 1 + 7-30  %
Moderate to strong +  +  to +  +  + 1-4%
Strong sensitised RBC +  +  + /+  +  +  +  Anti-D 0— 1 % negative tests
13.7% obtained only 1+/2 +
sensitised (3+/4 +  ) red cells may still react with partially neutralised AHG reagents 
that would be unable to agglutinate more weakly sensitised red cells [7]. The com­
mon practice of using strongly sensitised red cells is a poor control system, as it may 
create an illusion of safety when the AHG reagent is partially neutralised for some 
reason, or when the error is the result of physical disruption of agglutination.
The Development of Blind Replicate Tests (7)
A Joint Working Party of the ICSH/ISBT realised that External Proficiency 
Tests assess only one or two workers in each laboratory, and that these studies 
have failed to identify the causes of error shown year after year. Blind replicate 
tests were therefore carried out with red cells weakly sensitised with IgG anti-D 
as a means to establish the incidence and cause of failures among a large number of 
technical personnel. The system was simple and proved useful for training pur-
Table 2
AHG test failures due to over-agitation at the reading stage
M a n u a l ly  washed ( x 4) 36 replicate + / + +  anti-D-tests* 
R e a d in g  Method
Pip e t te  transfer to slide A gi ta t io n / sh ak e
Failures Number of staff Number of staff
Nil 31 37
Up to 5% 1 29
6 -2 0 % 0 16
21-50% 0 15
Total 32 Total 97
* Anti-D concentration 0.2—0.27 IU/niL
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Table 1
False negative errors with AHG tests in External Proficiency Test Surveys
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poses. There was a high rate of correlation between failure to detect antibody 
(false negatives) and unacceptable reading techniques. The examination of test 
results recorded by 129 staff members in 19 laboratories revealed that 97 per cent 
of staff using direct pipette transfer to a slide had no failures, compared with 38 
per cent who used a tube-agitation reading method; details are shown in Table 2.
Assessment of Technical Proficiency and Correction of Errors (7)
We recommend that all personnel doing antibody screening and compatibil­
ity testing should be evaluated by means of blind replicate tests to assess their com­
petence to perform AHG tests. A standard antiserum containing 0.8 to 1.0 lU/mL
R e a d in g  method**
A nti -D  X R t r 
D ilu tion  ( IU/m L) Pipet te  transfer  
to  slide
“ Agita tion 
o r  T ip  and  Roll”
“ S h a k e ”
S/2257 low avidity
Neat (0.8) +  +  + +  +  + +  + / +  +  +
3 (0.3) +  + +  + +
4 (0.2) + + ±
S/Pot 1 high avidity
128 (0.5) c c c
256 (0.25) +  +  + +  +  + +  +
1024 (0.12) + /+  + + /+  + ±
5000 (0.015) +  sensitivity 
limit
±
* All tests manually washed (X 4), mixed with 2 vol AHG, spun 30s at 200 RCF.
** For explanation of terms see Appendix B.
anti-D should be used. The details of this procedure are given in Appendix A. 
It is advisable to give immediate tuition to any workers who are shown to have 
faulty technique in washing and/or reading. Such training must be followed by 
further blind replicate trials to verify improvement in the procedure and to restore 
the confidence of the person concerned.
Details of various reading methods are given in Appendix B. It is not the 
purpose of this report to recommend a particular reading method, but we do sug­
gest that fewer problems of interpretation will be encountered if the first method 
listed is used. (See Appendix B and Table 3.)
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Table 3
Comparison of different reading methods for the spin-tube AHG tests* to show the inferior 
sensitivity of the shake-tube method
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Assessment of the Efficiency of Cell Washing Machines (7)
The Joint Working Party of the ICSH/ISBT also assessed the efficacy of 139 
cell-washing centrifuges in 35 laboratories. Fifty examples (36 per cent) of false 
negatives were found in replicate tests using red cells weakly sensitised with IgG 
anti-D. However, the association of false negative AHG tests with poor reading 
technique made detailed assessment impossible, because all laboratories that 
showed greater than 10 per cent automated-centrifuge errors used reading tech­
niques that included faulty agitation or shaking to examine the cell button.
We do, however, have sufficient information with Sorvall, Dade, and Diacent 
machines to provide a protocol (Appendix C) that provides reasonable assurance 
of reliable AHG test performance. We stress that these tests can only be done suc­
cessfully by personnel whose reading technique is acceptably sensitive.
Optimum Conditions and Quality Control of AHG Tests
Replicate tests with weakly sensitised cells are very useful for the demonstra­
tion of false negatives, whether due to inadequate washing or to excessive shaking 
of tests. However, reliable test performance also depends on the correct procedure 
being used at all stages of the test. We have therefore included recommendations 
for the quality control of each stage of the spin-tube AHG test.
Qality Control of the Anti-Human Globulin Test
The AHG test has five main variables:
1. Sensitisation of the red cells by incubation with serum.
2. Washing the cells to remove unattached serum IgG that will neutralise 
the AHG reagent.
3. Selection of a high quality polyspecific AHG reagent and use of an ap­
propriate volume and AHG quality control.
4. Use of optimum time and speed for a given centrifuge and a careful reading 
procedure to interpret the results.
5. Quality control of the complete test by adding red cells weakly sensitised 
with IgG anti-D [8a] to all negative tests and not strongly sensitised cells as com­
monly used [9, 10].
1. Sensitisation o f the Red Cells [11, 12a, 13, 14, 15, 16]
Adequate sensitisation of red cells is achieved by using a 40 : 1 ratio of serum to 
packed red cells [13, 15]. It has been established [13] that this is sufficient for 
reliable detection of weak antibodies, including most weak examples of anti-K, 
by low ionic strength saline solution (LISS) tests. Small variations in red cell con-
H aem ato log ia  21, 1988
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centration are difficult to control in routine work and to ensure safe practices we 
recommend a higher serum to packed red cell ratio of 60 : 1 [16]. This is achieved :
i) for normal ionic strength saline solution (NISS) by using 4 vol of serum if
possible [17], but not less than 2 vol of serum to 1 vol of 3 percent washed 
red cells suspended in saline or phosphate buffered saline (PBS);
ii) for low ionic strength saline solution (LISS) by using 2 vol of serum to 2 vol of
1.5 per cent red cells suspended in 0.03 mol/1 LISS [18].
iii) for low ionic additive solutions used in accordance with the manufacturers’
instructions.
The tubes should be shaken to mix the reactants, then incubated at 37 °C, prefer­
ably in a waterbath, for minimum incubation times of 15 min for low ionic strength 
tests and 45 min for tests at normal ionic strength.
2. Washing the Cells
Failure to wash adequately will leave small amounts of serum with the red cells 
during the final stage of the test. This can cause complete or partial neutralisation 
of the AHG reagent. Adequate washing can be achieved either manually or with 
cell washing machines. The latter, however, must be correctly installed and main­
tained [19, 20].
Although in theory three washes are more than adequate to remove unbound 
serum protein, we recommend four washes because of the greatly increased dilution 
of serum thus achieved. The most important points for efficient washing action are :
i) thorough mixing of the red cells to resuspend the cell button,
ii) vigorous injection of the saline wash to mix the red cells and serum thoroughly
throughout the tube,
iii) removal of as much of the supernatant fluid as possible at the end of each wash­
ing cycle.
The possibility that many false negative AHG test results are due to inadequate 
washing of tests by automated cell-washers was first reported in 1980 [19]. It is use­
ful to realise that a low level of serum contamination (around 1 in 3,000) can be 
overcome by the use of potent AHG reagents, especially by the use of 2 vol of AHG 
per test [16]. This was demonstrated in a recent Canadian trial [22]: 14 Dade and 
nine Sorvall machines, including CWls, were evaluated using replicate tests with 
IgG anti-D sensitised (1+) cells in 17 centres; 11 of which obtained better results 
with 2 vol compared to 1 vol of AHG per test.
An additional source of false negative antiglobulin tests has been reported 
by Bruce et al. [21], who showed that plasticiser(s) played a significant part in 
failures due to the use of saline stored at low pFI in certain plastic containers.
H aem ato lo g ia  21, 1988
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3. The Use o f High Quality Polyspecific Antiglobulin Reagents and Their Quality 
Control
Spin-tube AHG reagents should contain :
i) Potent anti-IgG with levels at least twice that of the minimum potency FDA
reference preparation. Tube tests performed by immediate-spin methods are 
practically free of the prozone problems that limit the anti-IgG activity of 
tile test reagents [16]. Tile tests are less sensitive than spin-tube tests and 
are not recommended for antibody screening or compatibility tests. These 
reagents, used with two volumes (70—100 pi) per test, are very resistant to 
serum neutralisation (see Table 4) and will help safeguard against failure.
ii) Adequate anti-complement activity. In conventional polyspecific reagents this
will be primarily anti-СЗс, but anti-C3d is also needed to detect red cells 
coated with complement in vivo. The serological activity of anti-C3d must, 
however, be severely restricted in order to prevent “false positive” reactions
Table 4
Anti-IgG sensitivity in the presence of partial neutralisation is related to the potency and
quantity of AHG per test
Sensitised R xr  cells Partial n eu tra li sa t io n  1 vol. 1/3000 serum/ tes t
added to negative 
A H G  tests with 
non-sensitised 
RjT cells
A H G  R 111 ISBT
*potency  ti tre  1024
A H G  F D A  Lot 16 
pote ncy titre 256
1 vol 2 vol 1 vol 2 vol
A n t i - D  l U / n t l
0.75 +  + / +  +  +  +  +  + + +  +
0.38 +  + +  + / +  +  + w + / +  +
0.15 +  + +  + / +  +  + w +
0.038 + + / +  + — v w
1 vol. =  35 /tl
GRADES OF AGGLUTINATION
c +  +  + +  + + W VW
one several smaller small microscopic
clump clumps clumps granules cells/clump
(8 -1 2 )  (4/6)
* The anti-IgG potency titre of an AHG is the highest dilution that gives a macro­
scopic +  reaction with a pool of R,r red cells strongly sensitised with IgG anti-D (75 IU/mL) 
(16).
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due to the presence of C3d on normal red cells [16]. We recommend that all 
batches of AHG should be tested to show freedom from false positive reac­
tions with red cells from CPD-A1 donor pack segments (over five days old) 
incubated with fresh serum, as in compatibility tests. These tests should not 
show macroscopic reactions, although a small proportion of weak micro­
scopic reactions is unavoidable with AHG reagents containing a desirable 
level of anti-C3d.
The routine quality control of the AHG involves:
i) The addition of a coloured dye (usually green) to the AHG reagent.
This is a very economical procedure which enables the operator to observe 
that AHG reagent has been added to each test [23].
ii) The routine quality control of the potency of the anti-human globulin reagent,
which sould be performed by separate control tests (8b, 9, 24) using an anti-D 
diluted to give + /+  + reactions with a pool of red cells from four donors 
of the phenotype R,r [7].
The use of red cells weakly sensitised with anti-D is intended to demonstrate 
whether the washed cells are still contaminated with human immunoglobulin, 
for whatever reason. This weak indicator system is more sensitive to partial 
neutralisation of the AHG then cells strongly coated with IgG.
4. Spin Phase and Reading of the Tests
The last stage begins after the red cells have been sensitised and thoroughly washed. 
AHG is added to each tube, the tubes centrifuged, and the tests read by a careful 
reading technique (see Appendix B).
Volume o f AHG Per Test
We recommend the use of two drops (70 /<1 — 100 p\) per test as being better able 
than one drop to overcome partial neutralisation due to inadequate washing of 
any test.
Final Spin Phase with AHG Reagent
The tube should be centrifuged within 15 — 30 s of adding the AHG. The centrifugal 
force used should be just enough to create a button of cells with clearly defined 
edges, but not so much as to make the button difficult to dislodge. Many combina­
tions of RCF and time give similar results. (See Table 5).
Actual centrifuge speeds and automatic timers should be checked at monthly 
intervals as part of routine quality control. We recommend the use of red cells 
weakly sensitised with IgG anti-D and a negative control to determine the optimum 
spin time and force (RCF) to obtain the best results with the AHG test. Note that
H a e m a to lo g ia  21, 1988
10 I). Voak et a!.: Correction o f  errors in AHG tests
Table 5
Combination of spin force (RCF) and time (seconds) satisfactory for spin-tube tests
R C F Spin time 
(seconds)
110 60
2 0 0 -  2 2 0 25-30
500 15
1 0 0 0 8 -  10
General guideline — doubling the RCF halves the spin time.
earlier models of machines from the same manufacturers may not have the same 
spin force as later models, e.g. the Sorvad CW2 has an optimum final spin phase of 
30 s compared to 25 s of the earlier Sorvall CW1 machine.
5. Quality Control by the Addition of Sensitised Red Cells to All Negative AHG Tests 
[8b, 24]
The purpose of these tests is two-fold:
i) To verify that the red cell washing procedure has removed all but insignificant
traces of serum, and
ii) to demonstrate that the AHG reagent has been added and is reactive.
Many laboratories use strongly sensitised cells for their control procedure in the 
mistaken belief that their procedure is satisfactory only if they see strong agglutina­
tion with the control cells. Unfortunately this practise gives a false sense of security 
since strongly sensitised control cells may react strongly with AHG that is suffi­
ciently neutralised as to be unable to agglutinate weakly sensitised cells that would 
give 1+ /2+  agglutination with fully active AHG [20].
Selection o f the Level o f Sensitisation of Control Red Cells
Table 6 illustrates an additional problem. The degree of agglutination produced 
by sensitised red cells and AHG alone will be reduced when they are added to 
non-sensitised red cells; the extent of this reduction will depend upon the Rh 
phenotype of the non-sensitised red cells for two reasons:
i) Antibody transfer from the sensitised cells to the non-sensitised cells which
have the corresponding antigen. The effect is greatest with non-sensitised 
cells that have a high antigen density [7], e.g. R.,R., cells cause a greater re­
duction than R,r cells.
ii) Physical interference reducing agglutination of sensitised cells by non-sensi­
tised cells which lack the antigen to the sensitising antibody e.g. RhD negative 
cells reduce the agglutination of anti-D sensitised cells.
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Table 6
Effect of Rh phenotype of non-sensitised red cells in reducing the anti-lgG reaction with 
sensitised red cells added to negative AHG tests
Pheno type  o f  
non-sensitised
Range o f  reac tion  str engths  in eight 
with R xr  contro lred  cells sensitised
replicate tests 
with an t i -D
test cells + +/+ + + +/+ +
rr +  + to +  +  + +  +  to +  +  + +  to +  +
R,r + +  to +  +  + + +  to +  +  + + to +  +
R,R, +  +  to +  +  + +  to +  + GW to +
Too strong Correct Too weak
Problems in the Provision o f IgG Sensitised Control Cells
In addition to the above effect, one must also bear in mind that the volume 
of anti-D serum needed to produce the desired (2+/3 + ) degree of agglutination 
is a function not only of the ‘avidity’ and concentration of the antibody, but also 
the strength of the D antigen on the red cells to be sensitised. A balance must be 
found so that when the control cells are added to a negative AHG test, a distinctly 
weaker reaction is seen in the presence of trace amounts of serum. Thus, the data 
in Table 7 indicates that Rxr red cells sensitised with neat serum containing 0.8 
IU/mL anti-D show partial neutralisation by serum dilutions of 1/2000 or higher 
levels of serum contamination, whereas R.,r red cells sensitised by the same anti-D 
concentration detect serum contamination only at dilutions much less than 1/1000. 
With this particular anti-D, only 0.27 IU/mL were needed to provide a sensitive 
control with R.,r red cells.
Table 7
Strongly sensitised red cells added to partially neutralised negative AHG tests do not demon- 
strate a reduction in anti-lgG potency
Sensitised red cells a d d e d  to negative A H G  tests
1/50
Red cells Dilution o f  
an t i -D  used 
( IU /m L )
in the presence o f  serum dilutions
sensitised
C o n t ro l  
(N o  serum)
1/3000 1 /2000 1/1000
R,r Neat (0.8) +  + +  + + w
R,r Neat (0.8) +  +  + +  +  + +  + +  +
R,r 1 in 3 (0.27) +  +  + +  + + w
* 1 vol (35 //1) of the serum dilution added to each washed (4x ) test
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The routine production of sensitised cells for daily use during 2 —3 weeks’ 
storage at 4 °C involves the problem of some antibody dissociation from the red 
cells, which is a function of diluent, temperature, storage conditions and the anti­
body concentration and affinity. This in turn means that strongly sensitised control 
cells are likely to be provided to allow for deterioration during storage.
Thus the preparation of IgG anti-D sensitised cells is a complicated procedure 
which is difficult to resolve for satisfactory bulk production.
In conclusion, we recommend the use of replicate tests with weakly sensitised 
red cells for the evaluation of personnel and cell-washing centrifuges. Replicate 
tests offer a new way to improve AHG test performance, because they enable staff 
with a poor reading technique to be identified and re-trained. When combined 
with the optimum conditions and quality control of the AHG tests described, 
this type of “in-house” assessment of staff is the only effective way of reducing 
many of the false negative errors seen year after year in External Proficiency Trials.
APPENDIX A
Protocol for the Evaluation o f AHG Reading Technique by the Use of Blind Replicate 
Tests
1. Titrate a suitable, not-hyperimmune IgG anti-D, as used for the control 
of the AHG test, against R,r red cells to find the dilution of anti-D that gave 1 + 
sensitised red cells (most workers used around 0.2 —0.3 IU/mL*).
2. Prepare a batch of sensitised cells by incubating 16 mL of the selected 
anti-D dilution with 8 mL of 3 per cent washed R,r red cells.
3. Have another person label 12 tubes for blind tests. Place 1 vol of 3 per cent 
1 + sensitised cells and 2 vol of group AB inert serum in 9 random tubes; place 
1 vol of unsensitised cells +  2 vol of group AB inert serum in the remaining tubes. 
Record the position of the various tubes.
4. Wash the tests thoroughly four times, add AHG, spin the tests and read.
5. Record the number of false negative (and false positive) results for each 
worker and analyse in conjunction with the particular reading technique used.
6. Workers with false negative errors should receive immediate tuition in 
correct procedure (see Appendix B) and washing technique.
7. Give failed workers repeat replicate tests to verify improved competence.
* Conversion of IU/mL to ug/mL (25), divide by 5, e.g. 0.3 IU/mL = 0.06 ug/mL or 
60 ng/mL.
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APPENDIX B
Reading Techniques
i) Pipette transfer o f the cell button to microscope slides
The pipette should have a wider than usual bore of 1.5 — 2 mm ID so that 
the column of cells will be short and agglutinates will have a better chance 
of reaching the slide unharmed. The tip must not be chipped or irregular. 
Do not agitate the tube at any stage.
Draw the cell button with the minimum possible suction into the stem of 
the pipette. Then gently eject the contents onto a slide while moving the 
pipette along it for about 1.5 — 2 cm.
Surface tension holds the red cells in fluid around the pipette surface and 
the movement distributes the cells over an area approximately 4 cm2. 
The angle of the pipette above the horizontal controls the width of the distri­
bution. Read the test macroscopically then microscopically if necessary.
ii) Tip and roll
Hold the tube almost horizontally (70—80°) between the thumb and first 
two fingers and slowly rotate and move back and forth, without shaking or 
agitation, until the cell button is dislodged from the tube. The free cell but- 
ton/agglutinate(s) should be allowed to move no more than 1 —2 cm down 
the tube. The test can then be read macroscopically, with the tube held 
horizontally over an illuminated light source. A x5 or x6 magnifying mir­
ror, or a x6 hand lens can be used for observing 1+ or stronger aggluti­
nates. Microscopic readings can then be obtained by:
a) examination of the tube placed horizontally on the stage of an inverted 
microscope (e.g. Olympus, model CK, magnification x60) 
or b) by transferring the tube contents to a microscope slide either by pipette 
or by touching the lip of the tube to the slide and moving the tube slowly 
along it.
tii) Gentle agitation
Hold the tube almost vertically between the thumb and first two fingers and 
then gently agitate. Use a fine tremor or gentle quiver i.e. a trembling or 
vibrating movement, but never a coarser shaking action. The test can then 
be read as described above under ‘tip and roll’!
/) Shake techniques
This type of procedure has unfortunately been developed by some workers 
from the gentle agitation procedure just mentioned. Over-vigorous action 
may reduce the expected degree of agglutination and we believe this technique 
is responsible for many false negative tests in blood transfusion work. 
The tests are read as described above.
H aem ato lo g ia  21, 1988
14 D. Voak et al.: Correction o f  errors in A HG tests
APPENDIX С
Procedure for Routine Quality Control o f Cell Washing Centrifuges 
New Equipment
Machines should only be accepted after they have been installed and adjusted 
by the agent’s representative and their washing efficiency proved by three machine 
loads of replicate tests with 1 + sensitised cells. The machines should conform to 
applicable safety standards for centrifuges e.g. BS 4402 (UK, 1982) and Electrical 
Safety Codes for Hospital Laboratory Equipment e.g. ESCHLE (UK).
rocedure With All Machines
i) Use for wash cycles with 3 mL (or more) of saline or phosphate buffered saline
pH 7.0-7.2 (PBS).
ii) Use 2 vol of potent spin-tube AHG.
iii) Determine the final spin time and RCF with AHG to give optimum reactions
without false positives due to over-spin techniques.
iv) Tubes must conform to manufacturer’s recommendations. We recommend
glass tubes, because cell buttons are far more difficult to dislodge from plastic 
tubes. 75 mm length of tube is optimal ; longer tubes have been found to cause 
inadequate washing in several makes of machines because the tube lip makes 
contact with the saline wash port and prevents the correct volume of saline 
being dispensed into the tube. Tubes of 12 or 10 mm diameter are satisfac­
tory.
v) Clean the machine daily, to avoid a build-up of serum contamination that
may cause back-contamination of tests from aerosol droplets created by 
the turbulence of the moving components of the machine.
vi) At least once a week routinely control the washing efficiency by at least one
machine load of replicate tests with 1+ sensitised cells.
Prepare the sensitised cells as in Appendix A.
a) Label 36 tubes (3 sets) and add 1 vol of the 3 per cent sensitised (1+) cells and 
2 vol of group AB inert serum to each tube.
b) Wash each machine load four times, add AHG, spin the tests and read.
c) Record and analyse the number of failures for each machine. A failure is 
a test that did not give the expected 1 +  result i.e. a “w” or negative reading.
Action on Faulty Cell Washing Centrifuges
i) The incidence of failures should be reported to the Head of Department.
The appropriate National Organisation and manufacturer should be notified 
to assist in information being circulated to all users.
ii) The machine should be taken out of routine use until the faults have been cor­
rected.
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Chronic lymphocytic leukaemia (CLL) is a lymphoproliférative disorder char­
acterized by the progressive accumulation of clonal small mature-looking lymphocytes, 
usually of B cell origin. In addition to a better understanding of many biological fea­
tures, during the last 10—15 years a great progress has been made in the prognostic 
characterization of the disease. The therapeutic achievements, however, have been less 
impressive. The possibility to identify patients with different prognosis has renewed 
interest in the treatment of this disorder. A considerable number of controlled trials 
have been performed or are in course, and new perspectives for CLL treatment are 
emerging.
Basically four different kinds of measures are used: 1) chemotherapy, 2) radio­
therapy, 3) adjuvant measures and 4) new modalities.
Keywords: chronic lymphocytic leukaemia, chemotherapy, new agents, treat­
ment
Chemotherapy
The most important tool is still chemotherapy, either single or combined. 
A great number of agents are active in CLL. Due to its efficacy and tolerance, 
chlorambucyl has been selected as the drug of choice in this disease and it can be 
given on daily or intermittent basis, usually combined with corticosteroids. It has 
been suggested that the intermittent administration might be preferable to the 
daily one and to prednisone alone, but these facts have not yet been definitively 
proven in randomized trials. The usual schedule employed in our institution and 
shared by many groups consists of chlorambucyl 0.4 mg/kg/p.o. days 1 and 2 com­
bined with prednisone 0.1 mg/kg/p.o. days 1 to 5. The treatment schedule is main­
tained for at least 6 months before evaluating the patient. The response rates are 
wide in range (35 — 90% of remissions with 8 — 40% of complete responses). 
It appears that the survival is more prolonged if the treatment is applied to pre­
viously untreated patients, and if it is given in earlier clinical stages.
* Presented as part of Plenary Session contribution at the 4th International Symposium 
on Therapy of Acute Leukaemias. February 7— 12, 1987, Rome (Italy).
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A great number of combined chemotherapy regimens have been attempted 
in CLL, although most of them in uncontrolled studies. Thus, this discussion will 
be restricted only to a few randomized trials.
There are at least 3 known studies comparing chlorambucyl to cyclo­
phosphamide, vincristine plus prednisone (COP regimen). In one [1 ], the Spanish 
Cooperative Group PETHEMA compared intermittent chlorambucyl plus pred­
nisone vs COP in CLL patients with advanced disease (stage C). The overall 
response rate was higher in chlorambucyl plus prednisone group, but this was not 
reflected in the survival. On the other hand, previously untreated patients survived 
better than those previously treated. Another randomized trial comparing inter­
mittent chlorambucyl plus prednisone with COP administered during 9 months 
in stages III, IV and progressive II was carried out by the Eastern Cooperative 
Oncology Group [2] and again, no differences were found in median survivals and 
complete remission rates. Finally, the French Cooperative Group, comparing 
daily chlorambucyl with COP regimen in stage B [3], also failed to demonstrate 
any difference in survival among both groups.
The Spanish Cooperative Group PETHEMA has activated a study in which 
untreated patients in stages B and C are randomized to receive intermittent chlor­
ambucyl plus prednisone or a combination therapy consisting of cyclophosphamide 
(160 mg/sq.m.), mephalan (6 mg/sq.m.) and prednisone (60 mg/sq.m.) for 4 
days every two weeks. Both therapeutic arms are maintained for 10 months. A 
preliminary analysis [4] performed recently has not shown a significantly better 
survival with the first treatment.
Recently, the French Cooperative Group [3] compared the standard COP 
regimen vs modified CHOP (with a relatively small dose of adriamycin, 
25 mg/sq.m.) in previously untreated patients in stage C. A longer survival was 
observed in the latter group with a plateau at approximately 75%. Since the 
median follow-up of these studies is still relatively short, the significance of these 
“plateaus” must be interpreted with caution.
The Southeastern Oncology Group has analyzed the value of cycle-active 
consolidation therapy [5]. In previously untreated patients receiving chlorambucyl 
plus prednisone during 6 months, a response rate of 78% with 22% of complete 
remissions were observed. Thereafter responders were randomized to receive 3 
months therapy with the same schedule or cycle-active therapy with Ara-C (25 
mg/sq.m. every 12 hours x 8, subcutaneously) plus cyclophosphamide (25 mg/sq.m. 
every 12 hours x8 orally) every 3 weeks. Although the number of complete remis­
sions increased in both arms of the protocol, there was no difference in the survival 
between the two groups the second arm being associated with a greater toxicity.
In summary, it appears that in advanced and/or progressive stages of CLL, 
the standard therapy schedule (chlorambucyl plus prednisone) is still the treat­
ment of choice. Encouraging results have been obtained with the modified CHOP 
regimen which deserves further trials.
A completely different problem is that of patients with CLL in early stages. 
Some trials have been performed i n this type of disease, too. In the afore-mentioned
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French trial [3] stage A patients were randomized to abstention or chlorambucyl. 
More than 200 patients entered each arm. The rate of progression to stages B or C 
was higher in the abstention group, but in contrast the mortality was higher in 
those receiving chlorambucyl. The overall survival, however, was not different 
statistically.
A similar approach was followed by the Acute Leukemia Group B [6], com­
paring in 49 patients with stable CLL in stages I and II low doses of chlorambucyl 
(0.5 mg/kg every 28 days) versus abstention. Although clinical progression was 
retarded by treatment (median of 3.8 years versus 1 year), the survival was not 
influenced.
Radiotherapy
Several types of radiotherapy, such as total body irradiation, total nodal ir­
radiation, thymic irradiation, extracorporeal blood irradiation and low-dose 
splenic irradiation have been claimed to produce good results in CLL. There is no 
general agreement on the efficacy of such modalities. The present place of radio­
therapy is its use as a palliative measure in order to alleviate symptoms caused by 
massive splenomegaly. Perhaps, it would be worth-while to further evaluate the low 
dose splenic irradiation [7] in comparison with other therapeutic regimens. This 
should be done in prospective randomized trials, some of them already in progress.
Adjuvant measures
Splenectomy can also alleviate clinical symptoms due to a huge splenomegaly 
and partially correct peripheral blood cytopenias. Despite clinical improvement, 
splenectomized patients apparently do not survive longer than nonsplenectomized 
patients [8], although no controlled studies are available. Extremely high lympho­
cyte levels can be brought down by cytoapheresis. Minor improvements of peri­
pheral cytopenias can be achieved with androgens and/or lithium. The value of 
IgG administration as prophylactic measure against increased incidence of infec­
tions, typical of CLL patients, is not known. An international randomized double­
blind trial addressing this issue is in progress [9], and a preliminary analysis has 
shown a protective efficacy of IgG administration [10].
New modalities
New therapeutic modalities, such as bone marrow transplantation, mono­
clonal antibodies, differentiation promoting agents, interferon and others have 
been tried in CLL.
There are at least 6 known cases of CLL who underwent bone marrow trans­
plantation [11, 12, 13]. The Grenoble group [11] performed in April 1984 an allo­
geneic BMT in a 43 year-old female patient in stage IV, obtaining a stable complete 
remission of nearly 3 years duration. A Spanish team from Barcelona [12] trans-
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planted in April 1986 a 40 year-old male patient in stage III, with apparently good 
result. The afore-mentioned French team [13] recently reported four additional 
allogeneic transplants with 3 deaths and only one survivor. It is interesting to note 
that apparently the malignant clone can be erradicated by intensive chemoradio- 
therapy, but for obvious reasons this approach can be only used in a reduced 
number of patients.
As far as monoclonal antibodies are concerned, only transient and incom­
plete responses have been achieved in most cases treated with T101 [14, 15]. 
In the future, it might be interesting to use non-modulating monoclonal antibodies, 
monoclonals conjugated with different cytotoxic agents (radionuclides, toxins, 
cytotoxic drugs), and anti-idiotype monoclonal antibodies in early stages.
Since it has been possible to promote differentiation of B-cells in vitro with 
phorbol esthers [16, 17] and different interferons [18], this approach is now being 
explored in vivo. The retinoic acid showed some efficacy in 2 cases of prolympho- 
cytic leukemia, but no effect in 9 patients with non-Hodgkin’s lymphoma or CLL 
[19]. It might be of interest to carry out further trials in early stages or perhaps 
with other agents.
With recombinant alpha-interferon less than 20% of patients achieve only 
a partial and transient response [20, 21, 22]. The general opinion today is that 
alpha-interferon is not useful in CLL. However, it seems that response rates may be 
higher in previously untreated patients. Thus, in future it might be interesting to 
explore such a therapy in early stages or try other interferons. Taking into account 
these facts, recently we treated 8 untreated patients with CLL in early stages, and in 
all of them a clear-cut reduction in lymphocyte count was obtained [23].
Future research
From the previous discussion, it clearly appears that after many years of 
stagnation, some progress is being achieved in CLL therapy. Many trends for 
future research in this field are emerging.
One of the important problems is to investigate whether CLL can be cured 
or not. From some anecdotal observations on bone marrow transplantation it can 
be assumed that intensive radiochemotherapy is probably capable of erradicating 
the malignant clone. But it is probable that this kind of approach could never be 
applied widely. On the other hand, not exceedingly rare cases of spontaneous 
complete remission in CLL can be observed [24], in association with different 
-  mostly infectious — clinical events. Some subtle biological modification oc­
curring during these episodes, must be responsible for the disappearance of the 
abnormal leukaemic clone. The discovery of such mechanisms might lead to the 
therapeutical application of biological response modifiers, a great challenge for 
the future. For the moment, in this context, the research should be done chiefly 
on the characterization of complete remission of CLL, as well as on the impact of 
complete remission on survival. In most clinical complete remissions (disap-
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pearance of all symptomatology and correction of peripheral blood values) the 
abnormal clone still persists. It would be of utmost importance to characterize all 
clinical remissions from a clonal point of view. In this sense, at least the proportion 
of kappa/lambda chain-bearing lymphocytes should be normalised, though ideally 
the clonal remission should be characterized by DNA rearrangement technology. 
Another interesting topic is the study of bone marrow histology in cases of CLL 
in complete remission. It is presently accepted that bone marrow patterns represent 
a very good prognostic parameter [25] and that this pathological stage can progress 
during the natural course of the disease or regress under therapy [26]. The sig­
nificance of residual bone marrow lymphoid nodules and of accompanying T-cell 
population during complete remission deserves further research. Although in 
some studies the achievement of complete remission apparently does not prolong 
the survival [5], this question should be further investigated with better definition 
of complete remissions.
Another crucial point for future research concerns the treatment of CLL 
in early stages. Since the usual clinical approach is to not treat these kinds of pa­
tients, only a few trials have been reported on the efficacy of different therapeutic 
modalities in early stages. From these studies it appears that chemotherapy is able 
to delay the progression to more advanced clinical stages, but has no benefit on 
survival [3, 6]. There is even some indication that it might be harmful [3]. 
On the other hand, it also appears clear that different therapeutic modalities are 
more active in terms of response in earlier than in late clinical stages [5, 23]. 
The key question remains unanswered: Is the therapy in early stages really needed? 
The primary aim of any medical treatment is the cure of the disease. When this is 
not possible, we try to improve the quality of patients’life and prolong their sur­
vival. CLL patients in early stages are usually symptomless. So, the chief aim of 
the therapy would be to prolong their survival. But, is it actually shortened?
Our preliminary data on this issue [27] have been reanalyzed recently. 
The survival of a series of 329 patients collected from 17 Spanish institutions was 
clearly shorter than that of the age- and sex-matched Spanish population. The me­
dian survivals were 5.3 years and 14.3 years, respectively (p < 0.001). Thus, CLL 
as a whole clearly shortens the survival. But is it also true for the early stages of 
the disease? According to the French authors [28], the survival of stage A patients 
does not seem different from that of the French population of the same age- and 
sex-distribution. In our recent analysis, the median survival of 142 stage A patients 
was 8.5 years in comparison to 14 years for the age- and sex-matched general popu­
lation, the difference between the survival curves being statistically significant 
(p < 0.01). So, from our experience it seems that the therapy might be necessary 
for survival prolongation even in early stages of CLL. But, since the benefit would 
be relatively minor, the undertaking risky treatment modalities does not seem to be 
justified. Instead, trials with biological response modifiers should be favoured 
in these early stages of the disease.
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Lymphocyte Proliferative Responses 
in Haemophiliac Patients:
Relations to Clinical and Immunological Findings
J. P. A ymard1, C. Janót1, M. E. Briquel1, F. Schooneman1, B. Legras2, P.
Alexandre1, F. Streiff1
Regional Blood Transfusion Centre, Avenue de Bourgogne, 54500 Vandoevre, France, 
departm ent of Statistics, University Hospital, Nancy, France
(Received 18 December, 1986; accepted 6 February, 1987)
Blood lymphocyte proliferative responses to mitogens were studied in 65 patients 
with haemophilia (haemophilia A: 54 patients, haemophilia B: 11 patients) in parallel 
with 39 male control subjects. As a group, patients with haemophilia did not demon­
strate abnormal proliferative responses to phytohaemagglutinin (PHA), Concanavalin 
A (ConA) and pokeweed mitogen (PWM) when compared with healthy controls. 
When the patients were analysed according to their seropositivity for antibody to human 
immunodeficiency virus (HIV), those who were positive had significantly decreased 
PHA, ConA and PWM responses. Haemophiliac patients with T4+/T8+ ratios less 
than 1 had reduced proliferative responses to PHA, ConA and PWM when compared 
to patients with ratios greater than 1. No significant difference in mitogen responses 
were found when the patients were analysed according to the presence or absence of 
palpable lymphadenopathy. Those patients with haemophilia A who had received more 
than 5x 104 units of factor VIII during the two years preceding the study showed no 
significant difference in PHA, ConA and PWM responses when compared to patients 
receiving less.
Keywords: haemophilia, T-lymphocytes, lymphocyte transformation, acquired 
immunodeficiency syndrome
Introduction
The first cases of acquired immune deficiency syndrome (AIDS) in haemo­
philia were reported in 1982 [1]. Since then several studies have demonstrated that 
haemophiliac patients may develop marked abnormalities of the immune functions 
[2—7], presumably as a consequence of infection with the human immunodefi­
ciency virus (HIV), also known as the lymphadenopathy-associated virus (LAV) 
or human T-cell lymphotropic virus type III (HTLV-III), transmitted by infused 
blood coagulation factors [8—12]. Such abnormalities of cellular and humoral 
immunity primarily occur through the preferential infection of the helper-inducer 
(T4+ or CD4 + ) lymphocyte subset [13].
In the present study we compared haemophiliac patients and healthy controls 
for “in vitro” lymphocyte proliferative responses to various mitogens. We secondly
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tried to relate any abnormal proliferative response in the patients to various clinical 
or biological parameters such as HIV serology, T 4+/T8+ blood cells ratio, palp­
able lymphadenopathy and amount of transfused factor VIII.
Patients and healthy controls
The study included 54 patients with factor VIII deficiency (haemophilia A), 
11 patients with factor IX deficiency (haemophilia B) and 39 healthy male controls 
(volunteer blood donors and healthy, non-infected children admitted to the 
Department of Pediatrics for minor surgery or bone marrow donation). The age 
distribution of patients did not differ from that of controls and is summarized 
in Table 1. None of the 65 patients had AIDS according to the CDC (Center for 
Disease Control) definition [14] ; 17 of them, however, had persistent palpable 
lymphadenopathy (haemophilia A : 16 patients; haemophilia B : 1 patient) (Table 
2). None of the patients and controls had a known history of drug abuse, homo­
sexuality, travel to the West Indies or Central Africa, sexual relations with people 
from these countries. All clotting factor preparations used by the patients were 
obtained from healthy volunteers in metropolitan France.
Materials and Methods
Table 1
Age distribution of patients and controls
Age (years)
M ean  d: 1 S D  Range
Controls (n =  39)
Haemophiliacs (n =  65)
Haemophilia A (n =  54) 
Haemophilia B (n =  11)
27 + 1 5  2 -56
22 + 1 3  2-57
22 +  14 2 -57
2 5 + 9  10-41
Table 2
Patients with palpable lymphadenopathy and HIV serology
H IV  HIV
seroposit ive seronegative
Patients with palpable 11 6
lymphadenopathy (n =  17) 
Haemophilia A (n =  16) 
Haemophilia B (n =  I)
10 6
0
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Peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized 
venous blood by density gradient centrifugation on Ficoll Hypaque (Lymphoprep, 
Nyegaard, Oslo).
“ /я vitro” lymphocyte proliferative responses to mitogens
“In vitro” lymphocyte proliferative responses to the following mitogens were 
evaluated using conventional methods : phytohaemagglutinin (PHA) (Wellcome 
Research Laboratories, Beckenham, England), concanavalin A (ConA) (IBF 
Laboratories, Villeneuve La Garenne, France) and pokeweed mitogen (PWM) 
(IBF Laboratories, Villeneuve La Garenne, France). PBMC were resuspended at
I X 109 cells/1 in RPMI 1640 (Gibco) containing 10% foetal calf serum (Seromed, 
Biochrom AG, Berlin, Western Germany) and antibiotics (penicillin : 300 IU/ml, 
streptomycin : 200 /ig/ml). PBMC were incubated in flat-bottom wells (Microtest
II Tissue Culture Plate, Falcon) at 1 x 10° cells/well. PHA, ConA and PWM were 
used at final concentrations of 2 /tg/ml, 5 /rg/ml and 0.1 /<g/ml respectively. Incuba­
tion was continued for 4 days in a fully humidified atmosphere of 5% CCL in air 
with addition of !H-thymidine 18 hours before harvesting for liquid scintillation 
counting (specific activity : 2 ^Ci/well). All tests were performed in triplicate. 
Results were quantified as counts per minute (CPM).
Lymphocyte surface marker studies
T helper/inducer (T4+ or CD4 + ) and T suppressor/cytotoxic (T8+ or 
CD8 + ) cells were identified among PBMC using murine monoclonal antibodies 
(Coulter Clone T4 and T8, Coulter Electronics, Hialeah, Florida, USA) and 
a fluorescein-conjugated goat anti-mouse immunoglobulin serum (Coulter Clone 
GAM-FITC, Coulter Electronics). The percentages of fluorescein-labelled cells 
were determined with fluorescence microscopy (Laborlux 11, Leitz, Wetzlar, 
West Germany). Absolute values were calculated from peripheral blood lympho­
cyte and monocyte counts.
HIV serology
Haemophiliacs and controls were tested for antibodies to HIV by enzyme- 
linked immunosorbent assay (ELAVIA, Pasteur Institute, Paris, France) [15] and 
western blot as a confirmatory test in seropositive haemophiliacs.
Statistical analysis
The results were expressed as mean + standard deviation (1 SD). Intergroup 
comparisons were performed with the Wilcoxon rank sum test. For correlations 
between pairs of variables within each group the Spearman’s rank correlation 
coefficient (rs) was calculated. In all cases, the level of significance was p < 0.05.
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Results
Lymphocyte responses “in vitro" : comparisons between haemophiliacs and controls
Lymphocyte proliferative responses to PHA, Con A and PWM are shown 
in Table 3. They did not differ in haemophiliacs and haemophilia A and haemo­
philia B subgroups as compared to the control group. Comparison between haemo­
philia A and haemophilia B subgroups as well showed no significant difference.
Lymphocyte responses “in vitro” and HIV serology
Antibodies to HIV were found in 18 of the 65 haemophiliacs (27.7%), in­
cluding 16 patients with haemophilia A (29.6%) and 2 patients with haemophilia B 
(18.2%). All healthy controls were seronegative. Seropositive patients had sie-
C o n t ro l  •
(no  mitogen  P H A #  C o n A #  P W N #
ad d e d )
Contro ls  (n =; 39) 0.86  ± 0.47 186.74 ± 74.85 121.09 ±  69.13 58.76 ± 30.25
Haemophiliacs (n =  65) 1.23 ± 1.11 197.83 + 87.69 124.68 + 80.47 52.64 + 32.52
• Haemophilia A (n =  54) 1.17 ± 1.12 201.06 + 83.18 131.20 + 77.78 52.04 + 32.45
• Haemophilia B (n =  11) 1.52 ± 1.10 181.96 + 110.50 92.66 + 89.54 55.60 + 34.30
• Seronegative patients 1.39 + 1.23 217.56 + 82.81 138.12 + 80.63 60.74 ± 30.53
(n =  47)
• Seropositive patients 0.82 + 0.59 146.32 + 80.70* 89.59 + 70.56* 31.47 + 28.33*
(n =  18)
• T4+/T8 +  >  1 (n =  47) 1.45 + 1.22 216.73 ± 79.95 139.88 + 80.25 60.84 + 30.96
• T4+/T8+ <  1 (n =  18) 0.67 + 0.42 148.47 + 89.93* 85 + 68.14* 31.23 + 26.78*
• No lymphadenopathy 1.35 ± 1.22 210.21 ± 88.28 129.69 + 77.65 57.11 ± 38.80
(n =  48)
• Lymphadenopathy 0.89 + 0.64 162.88 + 78.18 110.55 + 88.87 40.01 ± 32.08
(n =  17)
• Factor VIII <  5x 104U + 1.24 + 1.23 211.78 + 78.56 136.63 ± 77.68 54.02 ± 30.84
(n =  41)
• Factor VIII >  5+ 104U+ 0.95 + 0.60 167.25 + 91.41 114.09 + 78.65 45.78 ± 37.73
(n =  13)
•  Responses are expressed as CPMx 10_3 (Mean +  1 SD)
+ Patients with haemophilia A: amount of transfused Factor ѴІИ during the 2 years 
preceding the study
* p <  0.05 (Wilcoxon rank sum test)
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Table 3
Lymphocyte proliferative responses in patients and controls
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nificantly depressed PHA and PWM responses as compared to seronegative pa­
tients (Table 3). The ConA response in seropositive patients was lower than those 
observed in seronegative patients and controls: the differences, however, did not 
reach statistically significant level (p > 0.05).
Lymphocyte responses “in vitro” and T4+/T8+ ratio
Eighteen of the 65 haemophiliacs (27.7%), including 15 patients with haemo­
philia A (27.8%) and 3 patients with haemophilia B (27.3%), had an inverted 
blood T4+/T8+ ratio (<1). PHA, Con-A and PWM responses in patients with 
inverted T4+/T8 + ratio were significantly lower in comparison with patients 
showing T4+/T8+ ratio >  1 (Table 3). Lymphocyte proliferative responses to 
mitogens were directly correlated to the T4+/T8+ ratio (PHA: rs = 0.40, 
p < 0.002; ConA: rs = 0.38, p < 0.003; PWM: rs = 0.39, p < 0.002).
Lymphocyte responses “in vitro” and palpable lymphadenopathy
Seventeen of the 65 patients (26.2%) had palpable lymphadenopathy. PHA, 
Con-A and PWM responses in these patients did not significantly differ from those 
of patients without lymphadenopathy (Table 3). HIV seropositivity, however, 
was significantly more frequent among patients with palpable lymphadenopathy 
(11/17: 64.7%) as compared to those without lymphadenopathy (6/48: 12.5%) 
(chi-square test: p < 10-4). All but one patient with palpable lymphadenopathy 
had haemophilia A (Table 2).
Lymphocyte responses “in vitro” and amount o f transfused factor ѴП1
Fifty-four patients had factor VIII deficiency (haemophilia A). When the 
amounts of transfused factor VIII during the 2 years preceding the study were 
analysed, those patients who had received more than 5 x 104 units of factor VIII 
during the 2 years preceding the study did not show significantly depressed re­
sponses to PHA, ConA and PWM as compared with those receiving less (Table 3). 
The lymphocyte response to PHA and PWM was inversely correlated to the 
amount of transfused factor VIII (rs = —0.35, p <0.05) and rs =  —0.27, p <0.05 
respectively) whereas a marginally significant inverse correlation was found 
with ConA response (rs = —0.26, p = 0.057).
Discussion
The mitogens PHA and ConA chiefly stimulate the T lymphocyte subset 
whereas PWM is an activator of bothB and T lymphocytes [16]. Recent studies 
have demonstrated that asymptomatic haemophiliacs have abnormal “in vitro” 
responses to PHA [17—19], PWM (17) or ConA [18 — 20].
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The present study shows that “in vitro” lymphocyte proliferative responses 
to PHA, ConA and PWM do not significantly differ in haemophiliac patients as 
compared to those from healthy controls. Within the hemophilic population, 
however, the results of our study indicate marked abnormalities of the lymphocyte 
response in different subgroups. Patients with T4+/T8+ ratios less than 1 have 
significantly reduced proliferative responses to PHA, ConA and PWM: this is 
in accordance with the findings of other investigators (17). Our study also demon­
strates an association between HIV seropositivity and reduced proliferative re­
sponse to PHA and PWM. As a subgroup, the 17 patients with palpable lymph- 
adenopathy did not exhibit significantly decreased mitogen responses as compared 
to the other patients. They had a mean T4 + /T8+ ratio lower than patients without 
palpable lymphadenopathy : the difference, however, was not statistically signifi­
cant (1.27 + 0.85 versus 1.71 + 0.89: p > 0.05).
The 18 seropositive patients had a mean period of clinical follow-up of 15 
months (range: 0 to 29 months): among them, only one patient developed full­
blown ATDS and died of disseminated candidiasis and brain toxoplasmosis 22 
months after his initial study which displayed a low T4+/T8+ ratio (0.32) and 
decreased responses to PHA, ConA and PWM (23.3 x 10* CPM, 14.4 x 10:i CPM 
and 3.8 x 103 CPM respectively). So, we suggest that concomitant reductions of 
T4+/T8+ ratio and mitogen responses may have a predictive value for the devel­
opment of AIDS in HIV seropositive haemophiliac patients. Longitudinal clinical 
studies of these patients should help to resolve this point.
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Platelets were found to defend themselves against hypoosmotic swelling by 
a regulatory volume decrease mechanism, similar to that of T-lymphocytes. An oligo- 
mycin C sensitive Cl“ -channel and a Ca2+-dependent, quinine- and trifluoperazine- 
sensitive K+-channel play a significant role in the process: platelets lose K + and Cl-  
(and consequently water) through these. Activation of platelets accelerates the volume 
regulatory mechanism in spite of the fact that the Na+/H+ exchange process, activated 
simultaneously, works against volume decrease. The most rapid volume regulation 
was observed in activated platelets with inhibited Na+/H + exchange process.
Keywords: platelet, swelling, shrinking, regulatory volume decrease, Ca2+- 
dependent K+-channel, Cl- -channel, Na+/H+ exchange
Introduction
Human T-lymphocytes suspended in hypoosmotic (Na)-based media were 
shown to swell transitorily and then to restore their original cell volume by a regu­
latory volume decrease (RVD) process [1, 2, 3]. Detailed studies suggested that 
at a critical osmotic volume increase a Ca2+-sensitive K +-channel and a Cl- - 
channel open through which K+ and Cl-  flow out from the cells followed by an 
osmotically coupled water efflux. In agreement with this assumption, in high-K + 
hypoosmotic media osmotic swelling is followed by a secondary volume increase 
as K+ and Cl~ flow into the cells according to their concentration gradient, and 
water follows them. The findings showing that this secondary volume increase 
could be enhanced by the addition of the K +-ionophore gramicidin and abolished 
by the inhibitors of the Cl “-channel mean further support of the above interpreta­
tion [4]. Unlike T-lymphocytes, human B-lymphocytes and granulocytes do not 
restore their volume after osmotic swelling. With this in mind we decided to exam­
ine whether human platelets are able to regulate their volume under anisoosmotic 
conditions.
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Materials and Methods
The applied chemicals: quinine, propionic acid, gramicidin, thrombin, tri­
fluoperazine, indomethacin (SIGMA Chemical Company, St. Louis, MO, USA) 
A23187, forskolin (Calbiochem, La Jolla, CA), EGTA, oligomycin C (Serva 
Feinbicchemica, Heidelberg), amiloride (Merck, Sharp and Dohme, Rahway,
N. J.), chloropromazine (EG1S, Budapest) were of reagent grade. Nigericine was 
a kind gift of Professor L Horváth, methoxyverapamil (D-600) was a present of 
Professor Valerie Kecskeméti (Semmelweis University Medical School, Budapest).
Platelets were prepared from freshly drawn human ACD-blood by centri­
fugation. 20 platelet-rich plasma (PRP) was diluted in 1 ml reaction-buffer. 
Platelet count of this suspension was: 1 — 2.1010/1, the reaction buffer contained: 
137 mM NaCl, 27 mM KC1, 0.3 mM Na2HPO„ 12 mM NaHCO:i, 2 mM CaCl,,
1 mM MgCl2, 5.5 mM glucose, and 5 mM HEPES (N-2-hydroxiethylpiperazine 
ethane sulfonic acid) in distilled water. 20 pi of this platelet suspension was diluted 
in 5 ml of 0.16 M NaCl, 0.16 M KC1, or 0.16 M choline chloride, and the mean 
volume of platelets was measured. After the first volume measurement, drugs were 
added to the platelets as specified, and the suspension was kept at room tempera­
ture for 2 min.
To induce hypoosmotic shock 5 ml distilled water was added to 5 ml of plate­
let suspension. Volume measurements were done 30 seconds, 1, 2, 3, 4, 5, 10 and 
15 minutes after the shock.
The mean volume of platelets was determined electronically by a Coulter- 
type PS L-l Laborscale + PSA-1 Analyser (Medicor, Budapest) apparatus. A capil­
lary of 70 /un diameter was used for the measurements: the apparatus was cali­
brated with latex beads and mean platelet volume (MPV) values were registered.
For the detection of the N a+/H + exchange process the swelling of platelets 
was followed in an isoosmotic Na propionate medium as described by Sarkadi 
et al. [5]. The isoosmotic Na propionate medium contained: 140 mM Na propio­
nate, 1 mM CaCl2, 2 mM MgCl2, 1 mM glucose, 20 mM tris hydroximethyl- 
aminomethane (pH 6.8). 20 /tl of the platelet suspension prepared in the reaction 
buffer was diluted in 5 ml Na propionate medium, MPV was measured and the 
suspension kept at room temperature for 2 min without any addition or with the 
addition of the drugs to be examined. Serial volume measurements were done at 
30 seconds, 1,2, 3, 4, 5, 10 and 15 minutes.
Results
Under our experimental conditions (capillary diameter, platelet count) 
the shape change accompanying the activation of platelets in isoosmotic media 
did not influence the values of volume measurements, and aggregation did not 
occur. Swelling in hypoosmotic medium and the consequent volume changes could 
be well detected; for the detection of the shrinkage caused by a hyperosmotic 
medium, however, the apparatus was not suitable.
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Fg. 2. Effect of drugs on the RVD of platelets in hypoosmotic NaCI media. 1. No addition, 
2. 1 mM ouabain, 3. 1.5 pM TFP, 4. 0.25 mM quinine, 5. 1 pg/ml oligomycin C. One of 12
similar experiments
3 * H aem ato log ia  21, 1988
As shown in Fig. 1., platelets swelled in hypoosmotic media and in low-K+ 
media, this was followed by a rapid regulatory volume decrease (RVD) almost 
complete within 10 min. This process was unaffected by the increase of extracellular 
Ca'2+ concentration, but it was impeded by the presence of a Ca2+-chelator or Ca2 + - 
antagonist. 1 mM methoxy-verapamil (D-600) inhibited RVD completely, whereas 
1 mM EGTA and 100 pm indomethacin resp. caused a partial inhibition (Fig. 1). 
Lower concentrations of D-600 inhibited RVD partially.
Regulatory volume decrease was not influenced by ouabain, whereas it was 
inhibited completely by 100 — 250 pM quinine, 1.5 — 3 pM trifluoperazine (TFP)
Fig. 1. The role of Ca2 + in the RVD of platelets in hypoosmotic NaCI media. 1. No addition, 
2. 1 mM Ca CE, 3. 1 mM D-600, 4. 1 mM EGTA, 5. 100 pM indomethacin. One of 12 similar
experiments
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and almost completely by 1 /tg/rnl oligomycin C (Fig. 2). Other anti-calmodulin 
drugs (10 /iM chloropromazine, 1 /<M R 24571) acted like TFP, 100 /<M dipyri­
damole like oligomycin C.
When hypoosmotic shock was induced inahigh-K + medium rapid swelling 
was not followed by a volume decrease, but by a secondary volume increase that 
could be inhibited by 1.5--3 ;tM TFP. Secondary volume increase could be en­
hanced and TFP-inhibition suspended by the K +-ionophore gramicidin. Oligo­
mycin Cin 1 /rg/rnl concentration inhibited secondary swelling, irrespective of the 
presence or absence of gramicidin (Fig. 3). High (250-500 /tM) concentrations of 
quinine were needed to inhibit secondary volume changes as effectively as 3 /tM 
TFP.
Rothstein and coworkers [6] as well as our team [7] reported the existence 
of regulatory volume decrease in platelets at the Second European Congress of 
Cell Biology, Budapest. In the experiments of the Canadian group amiloride 
— an inhibitor of the N a+/H + exchange process — accelerated regulatory volume 
decrease. Under our experimental conditions inactivation of Na+/H + exchange 
(by substituting Na+ with choline in the medium, or by adding 100 pM amiloride) 
caused no significant change in the rate of regulatory volume decrease.
On the other hand, based on the principle described by Sarkadi et al. [5], 
by the measurement of the swelling of platelets in isoosmotic Na propionate me-
Fig. 3. Secondary volume increase of platelets in hypoosmotic KC1 media. 1. No addition, 
2. 0.5 /<M gramicidin, 3. 3 /(M TFP, 4. 0.5 /гМ gramicidin +  3 pM  TFP, 5. 1 yttg/ml oligomycin 
C (+  0.5 pM  gramicidin) One of 12 similar experiments
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dium we could detect the N a+/H + exchange process in our platelet preparations. 
Swelling was completely inhibited by 100 /iM amiloride, but reappeared if the 
ionophore nigericin transporting N a+ and H + ions was added to the system 
(Fig. 4).
The N a+/H + exchange detected by the swelling of platelets in Na propionate 
medium could be reduced by 100 //M indomethacin and accelerated by thrombin (the 
thrombin effect being insensitive to indomethacin) (Fig. 5). Swelling was slightly 
reduced by 1 —2 ;tM forskolin, an activator of the adenylate cyclase enzyme.
Fig. 4. Effect of amiloride +  nigericin on the swelling of platelets in isoosmotic propionate. 
1. No addition, 2. 100 pM  amiloride, 3. 0.5 pM  nigericin, 4. 0.5 pM  nigericin +  100 pM  
amiloride. One of 8 similar experiments
Fig. 5. Effect of thrombin and indomethacin on the swelling of platelets in isoosmotic pro­
pionate media. 1. No addition, 2. 100 pM  indomethacin, 3. 0.05 U/ml thrombin (+  indo­
methacin). One of 6 similar experiments
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Fig. 6. Effect of thrombin and A23187 on the RVD of platelets in hypoosmotic NaCl media. 
1. No addition, 2. 0.05 U/ml thrombin, 3. 10 gM  ADP. One of 6 similar experiments
In N a+-based medium regulatory volume decrease following a hypoosmotic 
shock was fast and complete if platelet activators (thrombin, ADP) were added 
to the system (Fig. 6). In this case, when platelets were activated, RVD could be 
further accelerated by the addition of amiloride (Fig. 7).*
* Note: When the freshly prepared platelets were used immediately, speed and amilo­
ride sensitivity of the RVD process, even without activators, approached the results shown by 
lines 3 and 4 of Fig. 8.
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Fig. 7. Effect of thrombin +  amiloride on the RVD of platelets in hypoosmotic NaCl media. 
1. No addition, 2. 100/rM amiloride, 3. 0.05 U/ml thrombin, 4. 0.05 U/ml thrombin + 100 gM  
amiloride. One of 4 similar experiments
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Discussion
The present investigations indicate that human platelets have an osmotic 
volume regulatory mechanism. The Ca2+-dependence of the process (cf. Fig. 1) 
and its drug — (quinine, calmodulin-antagonist) — sensitivity (cf. Fig. 2) suggest 
that th< Ca2+-sensitive K +-pathway, the so-called Gárdos-channel is involved 
in the phenomenon. The oligomycin C and dipyridamol inhibition refer to the 
participation of a conductive Cl “-channel. Most probably — like in T-lympho- 
cytes — at a critical point of osmotic swelling K + and Cl-  channels open, and 
through them platelets lose KC1 (and osmotically coupled water). Secondary 
volume increase of platelets demonstrated in hypoosmotic high-K+ media is in 
agreement with this explanation. In K+-medium, due to the known K+-quinine 
antagonism [8], a specific quinine inhibition of the K + channel cannot be expected. 
Calmodulin antagonists, however, inhibited K.+ -transport preferentially, as in­
dicated by the restoration of the secondary volume increase if the system contained 
gramicidin which forms an artificial K +-channel through the membrane. D-600 was 
an effective inhibitor of secondary volume increase, too. Since D-600 and grami­
cidin together caused the disruption of some platelets, in this set-up the selective 
inhibition of the K +-channel by D-600 could not be proven. Oligomycin C inhibi­
tion persisted even when the K +-ionophore gramicidin was added, confirming 
the assumption that the CD-transport — the activity of which is essential for 
regulatory volume changes — was specifically inhibited by oligomycin C.
The above discussed transport processes seem to be basically identical with 
those participating in the RVD mechanism of T-lymphocytes. In platelets, how­
ever, one has to consider the eventual activation of the amiloride sensitive Na+/H + 
exchange by Ca2+ [9], when N a+ uptake accompanying swelling may reduce 
regulatory volume decrease. Data concerning platelet activation upon the addition 
of distilled water were reported [10], our osmotic shock procedure, however, did 
not seem to activate Na+/H + exchange. Due to the propionate technique, we were 
able to detect the operation of N a+/H + exchange in our platelet preparations. 
The basis of the detection is that from an isoosmotic solution of Na propionate 
the not dissociated, permeable propionic acid enters the platelets and decreases 
[pH];. For H +-ion equilibration H +/N a+ exchange is activated and the entering 
N a+ forms Na propionate with the propionic acid that penetrated the cells. 
To achieve equilibrium distribution further propionic acid enters the platelets, 
this induces further H +/N a+ exchange with the above described consequences. 
As a final result, if H +/N a+ exchange functions, Na propionate (plus water) enters 
the platelets and causes a marked swelling. If the N a+/H + exchange mechanism 
of platelets is inhibited by amiloride, swelling can be restored by supplementing 
the system with an artificial N a+-H + carrier, like nigericin (cf. Fig. 4). The reduced 
swelling observed in propionate medium in the presence of indomethacin and 
forskolin resp., can be explained by their well-known [Ca]; reducing effects, and 
the Ca-sensitivity of the N a+-H + exchange process. The ineffectiveness of indo­
methacin in the presence of thrombin, the most potent physiological activator of
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platelets, is in good agreement with the efficient [Ca]; increment evoked by throm­
bin, even if cyclooxygenase is inhibited [11]. If regulatory volume decrease was 
accelerated by platelet activators, amiloride caused a further acceleration (cf. Fig. 
7), indicating that under these circumstances N a+/H + exchange was activated and 
reduced the speed of the volume regulatory system. It can be presumed that like 
in other cells [12] the activation of the N a+/H + exchange mechanism enables 
platelets to regulate their volume in hyperosmotic media. Our present instrumenta­
tion, however, was not sufficient for the experimental confirmation of this pos­
sibility.
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Periodical follow-up evaluations at intervals from 3 to 6 months of haematocrit, 
blood volume and ferrokinetic, during a 2.5 year period were performed in 18 poly­
cythaemia vera (PV) patients to find the most characteristic parameters for the deter­
mination of the erythropoietic system functional activity. Our results suggest that in PV 
it is advisable to carry out further determination of red cell volume to determine 
exactly the degree of erythrocytosis. ^
We found that plasma iron turnover (PIT) followed by 59Fe are the first
parameters to return to normal and the first to alter after a prolonged period of a normal 
ferrokinetic status. We suggest these may be used as the most reliable indicators for 
the haematological control of PV.
Keywords: haematocrit, polycythaemia vera, plasma r,9Fe clearance, plasma iron 
turnover, red cell volume
Introduction
Ferrokinetic studies are of great importance in the characterization and 
investigation of erythropoiesis disorders. The erythroid tissues activity can be 
measured with 59Fe bound to plasma transferrin [2]. Although haemoglobin and/or 
haematocrit levels are used for measuring red blood cell concentration, these do not 
always indicate the degree of anaemia or polycythaemia. Only the determination 
of the blood volume presents more precise data related to the anaemia or erythro­
cytosis in patients [12]. On the basis of blood volume changes polycythaemia is 
classified as absolute or relative. An essential criterion of absolute polycythaemia 
is the existence of an increased circulating red cell mass which can be determined 
by a direct red cell volume measurement with 51Cr [1].
Polycythaemia vera (PV) is a disease characterized by a marked increase 
in erythropoiesis, which can be either accompanied or not by an increase in leuko­
cyte and platelet production. The increased circulating red cell mass causes an 
increased blood viscosity with a tendency to thrombosis and haemorrhage. The fre­
quency of these complications in PV necessitates the regular follow-up of these 
patients by investigations which can detect early signs of increase in erythropoietic 
proliferation.
V SP  U trech t, T okyo  
A kadém ia i K iadó, Budapest
42 Y. Garcia et al. : Ferrokinetics in polycythaemia vera
The aim of this paper is to present the periodical follow-up of this 18 PV 
patients by measuring haematocrit, blood volume and the results of ferrokinetic 
studies in order to find the most sensitive parameters for the detection of increase 
in erythropoietic activity. This can enable us to apply therapeutic measures well 
before the occurrence of the characteristic symptoms of increased blood volume.
Material and Methods
Eighteen PV patients, nine males and nine females were studied. The mean 
age was 67.6 years with a range of 48 to 87 years. The diagnosis was established 
in agreement with the Polycythaemia Vera Study Group [1]. Duplicate micro- 
haematocrits, serum iron, blood volume determination with 51Cr, and ferro­
kinetic study with 59Fe were performed in each patient [3 — 5, 9, 10].
The ferrokinetic study was always performed 24 hours after the blood volume 
measurement at 9 a.m., with the patient in a fasting state. These investigations 
were conducted on 18 patients who had not received any kind of previous treat­
ment, after performing phlebotomies and giving them 5 mCi of 32P. The studies 
were repeated periodically at intervals from 3 to 6 months during a 2.5 year follow­
up. The number of patients studied in each stage ranged from 17 to 18. The time of 
the first study was considered as time zero (TO). One case was excluded from the 
study after twelve months of follow-up because this patient did not comply to 
the time schedule of the control investigation.
The parameters analyzed during the 30 months follow-up were: haematocrit, 
blood volume and circulating red cell mass in ml/kg wt, respectively, serum iron,
plasma 5<JFe clearance |5UFe t !I 2 , and plasma iron turnover (PIT) in mg/24 h and
mg/kg wt.
In the statistical analysis, the variables were estimated in each time period 
with analysis of variance I (one way) [13]. The correlations were made by the 
Fischer’s r [13]. The significance level used was 5%. The statistical study was 
conducted in a NEC-PC 980 1-F computer.
Results
The results of the variables studied in each period are shown in Table 1. 
The haematocrit was found very high in TO (61 ± 5.8), with a highly significant 
statistical difference (P < 0.001) as compared to haematocrits from the different 
periods. After the first six months this variable returned to normal and remained 
within the normal range in the follow-up period. Blood volume was very high 
in TO with highly significant differences (P < 0.001) compared to the blood volume 
found in the other periods. This variable was also found moderately high at 6, 12 
and 24 months, but the differences were not significant as compared to the first 6 
months. In TO the red cell volume was considerably high, during the first six months
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Table 1
Time 
in m on th s
H aem ato cr i t B lood  volume 
ml /kg wt
R ed  cell volume S e ru m  iron 
ml/kg wt ug/ %
Jl/2 59 p e *
min
Plasma iron 
mg/24 h
i tu rn o v e r  
m g/kg wt
0 61 +  0.58 94 + 19.8 87+ 15.5 65 +  23 23 53 1.00
(18)
1 -6
X X X
49+ 0.71
X X 
74 +
X
16.9
X X X
36+ 11.9
X X X
85 +  43 40 33 0.60
(18)
7 -1 2 47+ 0.78 70 + 16.9
X
32+ 11.1
X X
102+ 47 72 35 0.60
(18)
13-18 45+ 0.58 63 ± 13.8 28 +  7.6 86+  34 65 32 0.50
(17)
19-24 45 +  0.79 70 + 19.5 32+ 13.7
X X
113+49 61 34 0.50
(17)
25-30 47+ 0.72 63 + 17.2 29+ 10.3 113+49 50 50 0.70
(17)
Normal
values 40-50 66 + 15.3 26+ 2.1 6 0 -  180 60- 120 20-40 0.6-0.8
X X  
X
X P <  0.001 
X P <  0.01 
X P <  0.05
+
( ) *
=  SO 
=  n
=  x 50
it also increased but to a lesser degree. The statistical significance was 
P < 0.001 and P < 0.05, respectively. Within 12 months, this variable remained 
slightly above the normal value. The same alteration was found two years later.
Fig. 1
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Although within the normal range, the lowest serum iron value was found at the 
initial evaluation (TO). This parameter remained stable in the other periods.
Plasma °<JFe clearance was very fast (23 min) in TO. In the first 6
months it was still accelerated, but slower than in TO. It became normal between 
12 months and 2 years. Between 25 -30  months it accelerated again.
In TO, a marked increase was observed in PIT both in mg/24 h and mg/kg 
wt. These values were 53 and 1.0 mg, respectively. Later, it returned to normal, 
but it was increased again between 25 — 30 months. A significant positive correla­
tion was found between haematocrit and red cell volume in each period with the 
exception of the period from 13 to IB months (P < 0.001) (Fig. 1).
Discussion
it has been found that there is an abnormal population of erythroid colony 
forming units (CFUe) with the capacity of proliferation in the absence of erythro­
poietin in the bone marrow of PV patients [11, 14]. Some authors have considered 
that this abnormal population is more of a quantitative than a qualitative na­
ture [6].
It is likely that the degree of erythroid production in PV patients is related 
to the amount of abnormal CFUe present in the bone marrow. In addition, it has 
been observed that not all patients have the same degree of erythroid proliferation.
The follow-up of these patients in clinical practice in order to evaluate 
the disease severity is usually based on haematocrit measurements. There are, 
however, observations suggesting that the haematocrit value is not a good indicator 
of total red cell volume [7], although both variables are frequently correlated [1]. 
It has been observed that in cases when the haematocrit value is 60% or higher 
the red cell volume is also increased [1, 8]. In our work the haematocrit showed 
a correlation with red cell volume in each period except between 13—18 months. 
At the onset of the disease, when the haematocrit was over 60 %, the red cell volume 
was also very high. In the follow-up, however, the haematocrit was found to be 
normal, but the red cell volumes were still high. Our results suggest that in PV 
under adequate haematological control it is advisable to carry out, in addition 
to the regular determination of red cell volume, measurements indicative of the 
degree of erythrocytosis.
1It has been observed that there is no relationship between Fe T^ and
marrow iron turnover (MIT), the latter being an indicator of total erythropoiesis. 
However, under extreme conditions it is possible to find a linear relationship 
between both parameters [12].
In active PV there is erythroid hyperplasia and plasma jlJFe clearance is very
' 1
fast. In our investigation, the lowest Fe T^ values were observed in TO when
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the patients had not received any kind of treatment. This fast plasma 5UFe clearance 
does not seem to have been influenced by hyposideremia, since in this period serum 
iron values, although the lowest observed throughout the study, were within nor­
mal range. These observations suggest that ,>,JFe T 0 could be a good indicator of
erythroid hyperplasia in PV. Another aspect of interest was that this parameter 
was the second one to become normal within a period of 12 months following 
treatment. Between 25 — 30 months a new reduction was observed, even when the 
rest of the parameters studied at that time were normal, with the exception of PIT. 
1
This behaviour of FeT in PV may be useful in determining when the erythro­
poietic activity starts to become normal and when the increase just starts again.
It has been demonstrated that PIT and MIT correlate significantly, although 
the former is usually higher [2]. With MIT increased levels as in PV, this difference 
is relatively stable; hence PIT in PV could be useful to evaluate total erythropoiesis. 
We found that PIT, besides being the first variable to return to normal, displayed
1
alterations very similar to 0 Fe T^ but inversely. Thus, the highest value of PIT
was found prior to the treatment. Later, it was restored to normal and at 2.5 years 
it was increased again. From results obtained it could be stated that PIT followed 
1
by Fe T^ are the first parameters to become normal and the first to alter after
a prolonged period of normal status of ferrokinetics. Considering that precisely 
these two parameters, under erythroid hyperplasia conditions as in PV, could 
measure total erythropoiesis indirectly, they might be used as the most reliable 
indicators for the haematological control of this disease. This would enable one 
to apply therapeutic measures before the recurrence of symptoms and signs causing 
increased blood volume so these patients could maintain their normal activities.
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Evaluation of Preoperative Blood Tests 
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Determinations of the total calcium content and aggregability of the platelets 
as well as tests of coagulation and fibrinolysis were carried out on 93 patients before 
undergoing total hip replacement. All patients received low dose heparin, solely or 
combined with dihydroergotamine. Twenty-six patients developed deep vein throm­
bosis (DVT) detected by the labelled fibrinogen uptake test and confirmed by ascending 
phlebography. Only a few tests, among them the total calcium content of platelets, 
showed a statistical difference between the patients who subsequently developed DVT 
and those who did not. Combination of several tests by a multivariate statistical 
analysis programme proved to have more predictive value than the analysis of single 
tests.
Keywords: blood coagulation tests, calcium, fibrinolysis, hip prothesis, platelet 
function tests, venous thrombosis
Introduction
Deep vein thrombosis (DVT) occurs frequently after total hip replacement. 
It would be helpful in treating the condition if a means of identifying individuals 
at risk of developing DVT could be found. Some clinical studies have been made 
to establish relationships between preoperatively measured variables of the hae­
mostatic system and the incidence of postoperative DVT [1-13; for review of 
papers till 1979 see 14]. Although some variables were found to differ significantly 
between the groups of patients who did and did not develop DVT, it is still impos­
sible to identify the individuals at higher risk by means of a single test. Prognostic 
indices based on clinical and/or laboratory data produced a more reliable predic­
tion of DVT after gynaecological [1, 15, 16] or major abdominal [6, 7, 9, 13] 
operations. As far as we know such a prognostic index has not yet been derived 
for patients undergoing hip replacement.
According to our studies some preoperative coagulation and platelet par­
ameters, for example the total calcium content of platelets, differ significantly in 
patients who develop DVT following hip replacement as compared to those who 
do not. Further on, a multivariate discriminant function gives an improved dis­
crimination which is comparable to earlier published prognostic indices for post­
operative DVf.
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Patients and Methods
The patients (34 males, 59 females) were cases for elective total hip replace­
ment aged 40 to 80 years (mean age 61.6 years). The drugs taken by the patients 
were recorded. Patients who had taken acetylsalicylic acid were excluded from 
the study. Besides routine physiotherapy and walking exercises, all the patients 
received low dose heparin (5000 units twice per day) subcutaneously, solely or 
together with dihydroergotamine (0.5 mg), starting 2 hours before the operation.
The 125-I-fibrinogen uptake test was used to screen for DVT. The legs 
were scanned daily for a period of 8 to 10 days after surgery. The details of the 
procedure were described earlier [17]. An ascending phlebography was done in 
patients with positive leg scans or when thrombosis was suspected clinically. Ac­
cording to the phlébographie diagnosis two patients were classified into the DVT 
group despite a negative fibrinogen uptake test, and one patient was classified into 
the control group despite a positive leg scan.
Laboratory tests
Blood samples were taken 2 to 4 days before the operation and anticoagu­
lated with citrate (0.11 M, 9 : 1 v/v). The microthrombus index (ratio of circulating 
platelet aggregates, MTI) according to Wu and Hoak [18] was measured im­
mediately. All other platelet tests were performed using platelet rich plasma 
(PRP) prepared by centrifugation for 10 min at 200#.
Platelet aggregation was measured turbidimetrically according to Born using 
a non-commercial equipment. The platelet concentration was adjusted to approx­
imately 105//d using autologous platelet poor plasma as the diluent. The aggre­
gation protocol was rigorously standardized and the agents used included ADP 
(Reanal, Budapest; 1.5 and 15 #M) and epinephrine (Jenapharm, GDR; 30 #M) 
as inducers of aggregation and diamide (azodicarboxylic acid bis-dimethylamide, 
Sigma ; 225 #M) as an inhibitor of irreversible aggregation. The aggregation curves 
were analysed as follows:
AT maximal change of light transmission (reversible aggregation) or change of 
light transmission after a fixed time interval (1.5 #M ADP: 5 min; 15 #M 
ADP and 30 #M epinephrine: 13 min), expressed as per cent of the differ­
ence in light transmission between PRP and platelet poor plasma. 
dTrel AT as per cent of the maximal aggregation response obtained using 15 #M 
ADP.
Rd ratio of the maximal change of light transmission in the presence of diamide 
(added simultaneously with the inducer) to AT of the response to the same 
inducer alone, as per cent of AT.
The total calcium content of platelets was determined as described previously 
[19]. 2 ml of PRP was preincubated with acetylsalicylic acid (100 #M) and then 
centrifuged for 10 min at 1400#. The platelet pellet was washed twice with a 
calcium-free buffer, washed (HNCfj/PRC^), dissolved (HC1, LaCl3), and the cal­
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cium content was determined by atomic absorption spectrophotometry. The 
results are given as nmol Ca per 109 platelets. Platelets were counted by phase 
contrast microscopy.
The activated partial thromboplastin time (APTT), the one-stage prothrom­
bin time (Quick), and the bleeding time were determined by standard methods 
[20]. Quantitations of antithrombin III, a2-macroglobulin and «^antitrypsin anti­
genic concentrations were performed by the “rocket” technique according to 
Laurell [21] using commercial antisera (Behringwerke, FRG). The “rocket” 
electroimmunoassay (EID) was carried out in agarose gel (Indubiose A37, Indus­
trie Biologique Française, Gennevilliers, France).
Fibrin lysis was determined according to Halse [22] in a separate blood 
sample taken immediately after venous occlusion with a tourniquet (80 Torr, 10 
min).
Statistical methods
Wilcoxon’s rank test and the chi square test were used to calculate statistical 
significances. Furthermore, the data were processed by a computer programme to 
do a multivariate statistical analysis. The multivariate technique yields a linear 
combination of the observations — called a discriminant function — for the 
classification of an individual into one of two populations. It also yields a measure 
(Mahalanobis distance) reflecting the statistical “distance” between the two patient 
groups. A more theoretical approach based on the Bayes theorem allows to obtain 
two probabilities (one for each group) — called а-posteriori probabilities — that 
an individual belongs to these groups.
Results
Of the 93 patients investigated, 26 developed DVT in the postoperative 
period. With respect to the incidence of DVT there was no significant difference 
between the groups treated with heparin solely or in combination with dihydro­
ergotamine.
Table 1 shows the mean values of some tests for the groups of patients who 
did and who did not develop DVT. For practical reasons it was not possible to 
do all the tests on all the patients. This applies especially to induced aggregations 
and the calcium content of platelets because these tests are time consuming and 
had to be done without delay after venipuncture. Bleeding time (n = 90), Quick 
test (n =  90), antithrombin III (n =  88), a2-macroglobulin (n =  88), ^-anti­
trypsin (n =  89), fibrin lysis (n = 89) and the epinephrine induced platelet ag­
gregation (n = 43) did not provide statistically significant differences between the 
groups with and without DVT.
Some parameters were analysed by the multivariate technique. Using four 
variables a (microthrombus index, MTI), b (calcium content of platelets), c 
(APTT), and d (age), the discriminant function
V = 0.5 a -  0.035 b -  0.228 c + 0.120 d [1]
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was derived. The values of V calculated by this equation for the 42 patients of 
whom a, b, and c were measured preoperatively are shown in Fig. 1. With a cut­
off point of —2.7 the discriminant function correctly identifies 90% of the DVT 
patients (sensitivity 90%) and wrongly allocates 12.5% of the patients without 
DVT into the DVT group (specificity 87.5%).
Table 1
Mean values of selected preoperative tests
Test DVT Controls 2P
Microthrombus index 0.92 + 0.08 (24) 1.03 +  0.12 (50) a
Pit. calcium content 86+ 25 (13) 129+ 37 (44) b
(nmol/IOa cells) 
APTT (sec) 31.1 +5.6 (24) 33.4+ 4.8 (63) e
Aggregation (inducer,
mode of analysis)
1.5 /(M ADP, JT  (%) 14.4+ 8.8 (18) 10.6+ 7.5 (26) e
1.5 ADP, - ITrel ( % ) 22.0+ 9.3 (18) 16.6+ 9.1 (26) c
1.5/(M ADP, Rd ( % ) 66+  31 (18) 114+ 110 (26) c
15 fiM  ADP, /IT ( % ) 63.8+ 13.1 (18) 60.6+ 12.5 (26) f
15 pM  ADP, Rd (%) 23+11 (18) 34+ 18 (26) d
Fig. 1. Scatter diagram of values of the discriminant function V. Calculated for 42 patients 
on the basis of equation [1]. Solid and hollow circles represent patients who developed 
DVT and those who did not, respectively
Fig. 2A shows the а-posteriori probabilities (based on the Bayes theorem) of 
the individuals belonging to the thrombosis group. The Mahalanobis distance (D) 
between the two groups is also given. Fig. 2B shows the analogous results based 
on three variables only. The microthrombus index (MTI) was omitted first be­
cause this reduced D least. In the following steps APTT and age were omitted 
(Figs 2C and 2D, respectively). Regarding the statistical distance between the two
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Number of patients in parenthesis. Pit. =  Platelet
a: P <  0.0005 (one tailed test); b: 2 P <  0.001; c: 2P <  0.05; d: 2P <  0.1; e: 2P <  
< 0.2; f: not significant
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Fig. 2. Scatter diagram of the posterior probabilities (according to the theorem of Bayes) 
to belong to the thrombosis group, based on the indicated variables. Solid and hollow circles 
represent patients who developed DVT and those who did not, respectively
groups of patients, the combination of platelet calcium content with APTT and 
age is more effective than the combination of calcium content with age. Further­
more, this combination of variables is more effective than the evaluation of a 
single variable.
Although platelet aggregation induced by 1.5 /rM ADP together with 225 
/(M diamide also yielded a significant (2P < 0.05) difference between the groups 
of patients it was not included in a multivariate analysis together with the platelet 
calcium content and the microthrombus index in order to avoid a further drop­
out of patients on whom not all of these tests were performed. But other combina­
tions of variables including varicosis and smoking habits were also analysed by 
the multivariate technique. In most cases the combination of two or more variables 
resulted in an improvement, but in no case was there a distinct separation of the 
patients of both groups.
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Discussion
In the present study besides a number of established laboratory tests some 
recently developed tests were also used. To our knowledge this is the first evaluation 
of the platelet calcium content in connection with a thrombotic tendency. It 
appears that a predisposition to thrombosis may be associated with a continuous 
stimulation of some circulating platelets to undergo the release reaction thereby 
changing into so-called exhausted platelets [23]. During the release reaction plate­
lets lose 60 — 70 % of their total calcium content which is localized in dense gran­
ules [24]. Reimers et al. [25] found that when in-vitro exhausted platelets were 
returned to the rabbit they continued to circulate with a normal half-life. Thus 
the occurrence of exhausted platelets may result in a decreased average calcium 
content of the whole platelet population.
Were this concept true, a decreased total platelet calcium content in patients 
should correlate with an increased plasma level of ß-thromboglobulin (ß-TG). 
Preliminary experiments in normal subjects failed to reveal this correlation (un­
published results), probably because ß-TG is localized in а-granules whereas cal­
cium is mainly stored in dense bodies [24]. It is known that secretions from these 
two granule types are separate processes [26].
The mean microthrombus index of 0.92 in the DVT group reveals a weak 
tendency towards spontaneous formation of reversible platelet aggregates. This 
is in accordance with a greater extent of induced aggregation (1.5 /íM ADP, 
zlTrel) in this group. At low concentrations of ADP the aggregation is not ac­
companied by a release of granule constituents [26]. Therefore, an increased 
response to 1.5 pM  ADP is not contradictory to a decreased total calcium content 
of platelets.
Diamide, which was used in some aggregation tests as a modulator, is a 
thiol-oxidizing agent [27]. In platelets it alters proteins of the cell membrane [28] 
and the cytoskeleton [29], and changes the cellular thiol-disulfide status by a 
decrease of the reduced glutathione (GSH) level [for review see 30]. The thiol- 
disulfide status strongly influences the arachidonic acid metabolism [29 — 31] and 
this connection may be responsible for an altered aggregation response under 
pathological conditions [31].
Our intention was to check whether the susceptibility of platelets to a 
perturbation of the thiol-disulfide status could be discriminating with respect to 
a thrombotic tendency. We found that in platelets of the DVT group diamide 
partially inhibits the aggregation induced by ADP (resulting in RD < 100). This 
effect is more pronounced at 15 pM ADP. A better differentiation is found at
1.5 /(M ADP between the patient groups with and without DVT. At the concen­
tration of 1.5 /JM the platelets of the group without DVT showed a slightly larger 
extent of aggregation in the presence of diamide (RD > 100). These results indi­
cate that platelets of DVT patients on the average are more sensitive to a pertur­
bation of the cellular mechanisms underlying the aggregation response than are 
the platelets of patients without DVT.
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Despite the fact that a hereditary deficiency of antithrombin III (AT III) is 
strongly associated with thromboembolism [32] there are contradicting results 
in the literature regarding the predictive value of a lowered AT III level for postop­
erative DVT. Several studies did not reveal a statistically significant difference 
between the preoperative AT III level of patients with and without DVT after 
total hip replacement [8, 10] or after other operations [12, 33]. This applies both 
to patients who received specific prophylaxis [8, 12] and to patients who did not 
[10, 33]. This is in accordance with our results, but in contrast to some other re­
ports [4, 13, 34]. In studies on patients undergoing major abdominal surgery 
without specific prophylaxis [13] or total hip replacement with low dose heparin 
[4, 34] the authors found a significantly lower preoperative AT III level in those 
patients who subsequently developed DVT.
No difference was found in the plasma proteases a r antitrypsin and a2- 
macroglobulin levels of the two groups of patients. The former protease is pos­
sibly the major plasma inhibitor of factor Xa [35, 36] and the latter one contrib­
utes about 25% to the overall plasma antithrombin activity [37]. The study of 
Lowe et al. [9] also failed to show a difference between preoperative a2-macroglob- 
ulin levels of the patient groups with and without postoperative DVT.
To conclude, in our study beside the APTT only some tests of platelet func­
tion and chemistry showed a statistical difference between the patients who did 
and those who did not develop DVT. Although the multivariate analysis of two 
or more of these variables marginally improved the distinct separation of the 
groups, the values for sensitivity (90%) and specificity (87.5%) of the discriminant 
function derived in the present study are similar to those found by other workers 
in gynaecological or general surgical patients.
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Haemoglobin levels, total with blood cell counts and differential white blood 
cell counts were estimated for 512 Africans and 196 Caucasians who had been living 
in the same cosmopolitan Nigerian town for at least a year. Haemoglobin levels for 
African females differed significantly from those of Caucasians and many of the 
African females had values which indicated anaemia. Total white blood cell counts 
were similar, but an increased lymphocyte count was found in Africans and a higher 
neutrophil count in Caucasians. Eosinophil count was higher in Africans than in the 
Caucasians.
Keywords: Africans, anaemia, Caucasians, eosinophilia, haemoglobin
Introduction
In Nigeria, normal haematological values for Africans are still based on 
literary data established elsewhere in Caucasian subjects [1]. Several authors 
[2, 3, 4], however, have found values for Africans that persistently deviate from 
these. In the recent past several investigators [2, 5, 6, 7] have compared normal 
values between Africans and Caucasians. Except for the work of Ezeilo [5] most 
of these studies have been carried out on Africans in their African environment, 
without comparing the haematological values of Caucasians in the same environ­
ment. Data from such a concurrent comparative study similar to a recently pub­
lished report [8] comparing biochemical values would be more convincing in the 
establishment of differences between Africans and Caucasians. Such data is 
scanty.
In this paper we report the values obtained from studies carried out concur­
rently on Africans represented mainly by Nigerians, and Caucasians resident in the 
cosmopolitan town of Port Harcourt. This town has a considerable population 
of Caucasian workers especially in the numerous oil industries located in it. This 
investigation was conducted to obtain more data necessary for establishing the 
real haematological reference values for Africans. Such information is essential for 
the better understanding of clinical conditions in which some of these haematolog­
ical indices may be important in the management of patients.
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Materials and Methods
Blood samples were collected over a 9 month period at the University of 
Port Harcourt Teaching Hospital and at the several Industrial Clinics at Port 
Harcourt from subjects who attended clinics for routine checks or for medical 
examinations before proceeding for overseas vacation. All subjects were healthy 
and symptom-free for at least four weeks before the study, and all were completely 
normal on examination. Women who were menstruating at the time or who just 
finished it (less than a week) were excluded from the studies. 512 Africans and 196 
Caucasians aged 16 to 45 years were included in our study. Venous blood (about
2.5 ml) was collected from each subject into a sequestrene (EDTA) bottle with 
a plastic syringe and shaken gently to mix with the anticoagulant. Haemoglobin 
(Hb) concentration and total white blood cell (WBC) counts were estimated on 
Coultronics Model S7 Coulter Counter within 5 hours of collection of the speci­
men. White cell differential counts were done using Coultronics C4 cells standard.
The examined Caucasians were predominantly Europeans. Asians, Ameri­
cans and other whites, however, were also included. Caucasians who had not lived 
in Port Harcourt for at least a year were excluded from the studies.
The mean of the values of each group were calculated and the ± S. E. values 
indicated were appropriate. The significance of the results were calculated using 
Students’ I test.
Results
Table 1 shows the mean haemoglobin values and ranges for both Africans 
and Caucasians. A significantly lower mean value (P <  0.001) and range was 
observed for female Africans. The values for male Africans are not statistically 
different from those of Caucasians.
A histogram of the percentage distribution of the female subjects to various 
ranges of the haemoglobin values can be seen in Fig. 1. This figure indicates that
Table 1
Haemoglobin values (gm I)
Subjects M ean Ran g e
Africans (male) 13.6 +  0.9 12.9-16.0
Caucasians (male) 14.1 +  1.1 13.8-17.0
Africans (females) 12.3+0.7 10.5-14.8
Caucasians (females) 13.7 +  0.8 12.4 — 16.6
H aem ato lo g ia  21, 1988
N. Nduka et al.: Haematological indices: Africans, Caucasians 59
Fig. 1. Histogram of percentage of subjects against the various Hb ranges. Range of gm/1 
haemoglobin: A — 10.5—11.5; B — 11.6—12.5; C — 12.6—13.5; D — 13.6—14.5; E —
14.6 and above
values for many African females fall mainly in the 10.5 — 11.5 gm/1 (29%) and 
the 11.6—12.4 gm/1 (37%) ranges. On the other hand, that of Caucasian females 
fall mainly in the 12.6—13.5 gm/1 (37%) and 13.6—14.5 gm/1 (34%) ranges.
Table 2 shows the total WBC and differential counts for both Africans and
WBC for Africans: Mean total: 6.1 +  1.Ox 109/l
Range: 2.6 — 9.4x 109/l 
WBC for Caucasians: Mean total: 6.6 +  1.l x  109/1 
Range: 3.4-9.5X 109/1
Differentials
M e a n (%)
Africans Caucas ians
Neutrophil 39.5 +  5.0 54.0 +  7.1
Lymphocyte 48.8 +  6.3 35.5+4.2
Eosinophil 9.2+1.4 4.1+0.5
Monocyte 2.0+0.3 5.4+0.7
Basophil Less than 1 °/0 1.0+0.1
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Differentials ( %, not to scale)
Fig. 2. Comparative histogram of total WBC and differentials obtained from this study 
against mean of values obtained from other studies: A: values from this study; B: mean
values from other studies
Caucasians. The difference in the mean total WBC counts and range for the two 
groups is not statistically significant at the 5% level. There are, however, differ­
ences (statistically significant at the P < 0.05 level) in the differential counts of the 
two groups. The table indicates a predominance of lymphocytes in Africans and 
a predominance of neutrophils in Caucasians. The eosinophil level in Africans 
reaches a value that would usually be regarded in haematological literature as 
“eosinophilia”. A histogram (Fig. 2) of the mean total WBC and differentials 
for both groups of subjects as obtained from this study is compared to a working 
set of “normal values” obtained from a review of similar studies by previous 
authors [9]. Our study is in agreement with the reported predominance of neutro­
phils in Caucasians and of lymphocytes in Africans; further on the high eosinophil 
count for Africans.
Discussion
Results from this study show marked differences in the haemoglobin levels 
of Africans and Caucasians, the Caucasians having higher mean levels. This 
difference in the haemoglobin level is statistically significant only in the female 
subjects. The mean Hb values and ranges of African females were much lower
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than those reported in literature. These frequently observed low values were 
often associated with anaemia. The majority of the studied subjects (66%) fall 
within these lower ranges. These subjects, however, did not look anaemic and 
had no signs or symptoms indicating anaemia. Therefore their Hb values were 
well entitled to be considered “normal” . An implication of this condition may 
become obvious during surgery when the anaesthetist insists that the Hb level 
of the patient be brought up to a certain level before the patient is anaesthetized. 
An anaesthetist would normally be reluctant to anaesthetize a patient with Hb 
value lower than 11 gm/1. This study has shown that a large proportion of African 
female subjects (29%) have Hb values ranging from 10.5—11.5 gm/1. In fact, of 
these 29%, 50 subjects, have been monitored several times, over a 4 month 
period and found to have Hb values consistently less than 11 gm/1 (result not 
included). It is interesting to note that in this same environment, the Hb values 
found in Caucasian females are similar to values reported in literature.
The total WBC counts for Africans differ only slightly from those of Cauca­
sians in this study. Inspite of the fact that white blood cell counts are subject to 
certain physiological variations including pregnancy and menstrual cycle, this 
parameter has such a wide range of normality that we do not consider this differ­
ence significant. Also, no sex differences were apparent. The mean values and 
range obtained for Africans in this study are higher than a recently suggested 
“working set of normal values” for Africans (mean 5 .5xl0‘J/ l ;  range 2 —9x 
X 109/1 ) [9].
The differential WBC counts obtained in our study are consistent with the 
well documented differences between the Africans and Caucasians [2, 5, 9] es­
pecially regarding the predominance of lymphocytes in Africans in contrast to 
neutrophils which predominate in Caucasians. However, the neutrophil value for 
Caucasians in this study is 54% which is nearer to the 52% suggested by Ezeilo 
[9] than the 60 — 70% reported in some papers [9]. In this study like in that of 
Ezeilo, over 300 samples were examined and because of the wide range of normal­
ity of WBC counts a sample size of at least 250 was calculated necessary for ob­
taining reproducible results. Apparently racial factors rather than sex differences 
were responsible for the differences observed in this parameter. Inter and/or 
intra sex differences were not obvious.
A higher eosinophil count in Africans is observed. However, many factors 
— including environmental ones — can cause a rise in the eosinophil level. Our 
results are significant because they are based on studies of two groups living in 
the same tropical environment. Whatever the cause of high eosinophil count, it 
is obvious from this and earlier studies that a definite diagnosis of “eosinophilia” 
for an eosinophil count up to 10% in an African could be misleading. This is 
because the level of this white cell in Africans is consistently 9% (see review) [9]. 
There have been suggestions [10] as to the role of eosinophils in health and disease. 
It is noteworthy that the healthy Caucasians examined in this study, living in 
the tropics, with greater exposure to parasitic helminth infections did not neces­
sarily acquire eosinophil levels higher than that of their kins not living in the
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tropics. It is also noteworthy that sex differences were not observed for eosinophil 
counts, the counts for females being similar to those of males of the two groups. 
The reason for the lower incidence of eosinophilia among Caucasian residents 
could be hereditary or may be due to a lower incidence of infestation. This, 
however, cannot be established from the available data. The high eosinophil 
counts in Africans, which may be due to frequent parasitic helminth infestation, 
could result in disturbances of iron absorption. Inspite of the no-sex-differences 
observed, the low “anaemic” haemoglobin values found in the female Africans 
may be a consequence of iron deficiency. Females are, of course, more susceptible 
to iron deficiency anaemia. It is noteworthy that parity did not influence the 
distribution of the subjects to various Hb ranges in our study.
Data from comparative studies of haematological values in Africans and 
Caucasians living in the same African locality is scanty. Previous comparisons of 
these values have been based on the values established in the African environment 
against those reported in haematological literature [2, 6, 7]. The comparisons by 
Ezeilo [5] of these values in Africans, Europeans and Asians presumably in the 
same environment were performed on cord blood. This study compared values 
for the adult Africans and Caucasians living in the same environment.
Although there are genetic and cultural differences between Africans and 
Caucasians, differences in their haematological parameters due to dietary and 
environmental conditions as postulated by some investigators [9] are reduced to 
the minimum by the exclusion from our study of those Caucasians who had not 
lived in Nigeria for at least a year. The results obtained in this study showing differ­
ences in some of these parameters for the two groups of people are more direct 
and therefore correspond better to the real differences of haematological indices. 
We suggest that clinicians in Africa should recognize the differences and contri­
bute to the work of compiling the reliable “African haematological reference 
values” to be used in the future instead of the reference values obtained from the 
nvestigation of Caucasian populations.
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Abstracts
Effects o f inherited membrane abnormalities 
on the viscoelastic properties o f erythrocyte 
membrane. R. E. Waugh (Department of 
Biophysics, University of Rochester Medical 
Center, Rochester, N. Y., 14642, USA). 
Biophys. J. 51, 363-369 (1987).
Several workers have identified molecular 
abnormalities associated with inherited blood 
disorders. This work examines how these 
alterations in molecular structure affect the 
viscoelastic properties of the red blood cell 
membrane. Changes in the membrane shear 
modulus, the membrane viscosity, and the 
apparent membrane bending stiffness were 
observed in cells of eight patients having a 
variety of disorders.- Two had reductions in 
the number of high-affinity ankyrin binding 
sites, two had abnormalities associated with 
the protein band 4.1, and six were known to 
be deficient in spectrin. The data suggest 
that the membrane shear modulus is propor­
tional to the density of spectrin on the mem­
brane and support the view that spectrin is 
primarily responsible for membrane shear 
elasticity. Although membranes having ab­
normalities associated with the function of 
ankyrin or band 4.1 exhibited reduced elasti­
city, the degree of mechanical disfunction 
was quantitatively inconsistent with the ex­
tent of the molecular abnormality. This indi­
cates that these skeletal components do not 
play a primary role in determining membrane 
shear elasticity. The membrane viscosity was 
reduced in seven of the eight patients studied. 
The reduction in viscosity was usually greater 
than the reduction in shear modulus, but the 
degree of reduction in viscosity was variable 
and did not correlate well with the degree of 
molecular abnormality.
B. Sarkadi
The effect o f  denbufylline on the viscosity o f  
rat whole blood and on the deformability (fil- 
terability) o f  rat blood cell suspensions. J. J. 
Jukna, C. D. Nicholson (Beecham-Wülfing 
Research Laboratories, D-3212 Gronau, 
Leine, FRG). Naunyn-Schmiedeberg’s Arch. 
Pharmacol. 335, 445-448 (1987).
The novel alkylxanthine, denbufylline 
[l,3-di-n-butyl-7-(2-oxopropyl)-xanthine] has 
been examined, in vitro, for effects on the 
viscosity of rat whole blood and on the fil- 
terability of rat blood cell suspensions. For 
comparison, pentoxifylline was also exa­
mined for rheological activity. Denbufylline 
reduced the viscosity of whole blood at all 
shear rates utilised, up to 128.5 s-1. The 
effect was, however, more pronounced at a 
low (0.7 s_1) than at a high (94.5 s_1) shear 
rate indicating that the compound reduces 
blood cell deformability. Denbufylline also 
increased the filterability of blood cell sus­
pensions. This is further evidence that the 
compound increases the deformability of 
blood cells. Denbufylline elevated the filter- 
ability of both pure erythrocyte and mixed 
erythrocyte/leucocyte suspensions, the effect 
being greatest with the latter. This suggests 
that denbufylline may influence the deform­
ability of both red and white blood cells. 
However, the effect on white blood cells, 
under the experimental conditions employed, 
is apparently more marked. Pentoxifylline 
also reduced the viscosity of rat whole blood 
and increased the filterability of rat blood 
cell suspensions. However, denbufylline was 
10— 100-fold more potent in these tests than 
pentoxifylline.
B. Sarkadi
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Difference between human red blood cell 
Na+ — Li+ countertransport and renal 
Na+—H+ exchange. A. M. Kahn (Depart­
ment of Medicine, University of Texas 
Medical School, Houston, Texas 77025, 
USA). Hypertension 9, 7— 12 (1987).
Several laboratories have reported that 
the activities of sodium-lithium counter­
transport are increased in red blood cells 
from patients with essential hypertension. 
Based on the many similarities between this 
transport system and the renal sodium-proton 
exchanger, a hypothesis has been put forth 
in the literature that increased red blood cell 
sodium-lithium countertransport activity may 
be a marker for increased sodium-proton ex­
change activity in the renal proximal tubule. 
The present studies were designed to test the 
hypothesis that sodium-lithium counter­
transport in red blood cells from humans or 
rabbits is mediated by the same transport 
mechanism that mediates sodium-proton ex­
change in the renal brush border from those
species. Similar to what has been reported 
for the rabbit, the present studies show that 
an amiloride-sensitive sodium-proton ex­
changer is present in human renal brush 
border vesicles. However, Na+—Li+ coun­
tertransport in human and rabbit red blood 
cells, assayed under several different condi­
tions, was not inhibited by amiloride. In 
agreement with what has been reported for 
humans, the present studies show that extra­
cellular proton-stimulated sodium efflux is 
inhibited by amiloride in rabbit red blood 
cells. These data demonstrate a difference 
(amiloride sensitivity) between the red blood 
cell sodium-lithium countertransporter and 
the renal brush border sodium-proton ex­
changer in humans and rabbits. These experi­
ments detract from the hypothesis that in­
creased red blood cell sodium-lithium coun­
tertransport activity in patients with essen­
tial hypertension is a marker for increased 
sodium-proton exchange activity in the ren­
al brush border.
B. Sarkadi
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Joseph G. Sinkovics: Medical Oncology. An 
Advanced Course. A Self-Assessment Guide 
for Subspeciality Board Examinations and 
Practice. Second Edition, Revised and 
Expanded, Marcel Dekker Inc., New York 
and Basel, Two volumes, 2062 pages.
J. G. Sinkovics is Director of the Com­
munity Cancer Center of Saint Joseph’s 
Hospital and holds a clinical professionship 
in medicine at the University of South 
Florida College of Medicine in Tampa, 
Florida. His recent publication entitled 
Medical Oncology is not a textbook for 
leisure or causal reading. The main purpose 
of this book is to give help for residents in 
preparing for subspeciality board examina­
tion in medical oncology. The other, not 
less important goal of the book is to be a 
guide for all the physicians treating tumorous 
patients.
The publication introducing the author’s 
comprehensive experience perfectly corre­
sponds to the purpose. All the field of onco­
logy is presented and various types of 
malignomas are discussed in detail, but 
according to their importance. After the 
favourable reception of the first edition, the 
recent second edition, published in 1986, is 
completely updated and expanded to two 
volumes reflecting the enormous growth of 
clinical oncology. The work represents an 
unparalleled accomplishment in gathering 
together the hard-core advances from the 
vast amount of recent literature on malignant 
diseases.
Since the book is intended for physicians, 
the author does not deal with the determina­
tion of individual forms of diseases. These 
definitions can be obtained from other 
textbooks. Instead, the up-to-date informa­
tion and data on pathology, etiology,
immunology of malignomas are discussed, 
the recent developments in their diagnosis 
and treatment are presented. On the basis of 
several thousand publications, a great 
amount of information is collected and 
presented in a concise form.
The book is divided into six main parts 
which are composed of several chapters. 
The individual diseases are discussed con­
cerning their etiology, epidemiology, histo- 
pathology, diagnosis and staging, treatment 
and occasionally the supportive care.
In the first part the author deals with 
haematologic oncology; he introduces the 
changed concepts of the classification and 
therapy of lymphomas. The new achiev- 
ments of the leukaemia and AIDS research 
are also presented, including information on 
the role of oncogens in human tumors.
The second part deals with tumors 
originated from mesenchima, particularly 
with the soft tissue- and bone tumors. In 
the third part the neuroectodermal and 
neurogenic tumors are discussed. Classifica­
tion of the pigment-cell neoplasms and 
APUD-omas are also included in this 
chapter, indicating the author's modern 
concepts.
The carcinomas are described in part 
four. Obviously, the largest scope is devoted 
to this most frequent and most significant 
group of malignomas. Their incidence and 
their etiology are consistently discussed in 
connection with the epithelial tumors of 
different organs. Detailed information is 
given on the most important histological 
features, clinical signs, staging, about efficient 
diagnostic and therapeutic procedures.
The fifth part is a summary on the 
principles and practice of modern cancer 
therapy. Particular emphasis is laid on the 
presentation of the internationally accepted
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and successfully used new protocols in the 
treatment of malignant melanoma, breast-, 
lung cancers, gastrointestinal tumors and 
gynecological malignancies. Side effects, 
infectious complications and their treatment 
facilities are also discussed in detail.
Chapter six is an especially useful part of 
the book. According to the purpose of 
publication it is devoted to residents prepar­
ing to take board examination. This part 
contains self-assessing tests. A key to the 
questions is included, even giving references 
in some instances.
The book is well structured and balanced. 
Its style is concise, for the sake of brevity 
— according to the author’s words — it is 
almost telegraphic. In the presentation,
attached to the description of each individual 
disease, clear-cut tables can be found 
summarizing the most important characteris­
tics. This presentation assures a good 
orientation and the book can easily be used 
in the every-day practice.
This publication containing an enormous 
amount of information proves the author’s 
great experience in oncology. The book is an 
excellent manual in training for examina­
tions, but it is also a suitable work for 
practitioners, giving a versatile review about 
various types of malignancies. It can also be 
a useful reference-book for theoretical 
experts.
K. Lapis and K. Simon
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Announcement
GUIDELINES FOR MANUFACTURERS MANUALS 
FOR USE IN DEVELOPING COUNTRIES
The International Committee for Standardization in Haematology has recom­
mended that the following information should be provided by the manufacturers 
of instruments intended for customers in areas where service facilities and reagent 
supplies may be limited.
1. Ideally the manual should be provided in the language of the country 
and the translation checked by a native speaker; otherwise it should be available 
in an international language which is most commonly used in that country. 
It should be written at a level which is understandable to a technical worker who 
has had the equivalent of five years of high school education.
2. The manual should have 8 sections:
(a) Description of instrument and its component parts
(b) Unpacking and setting up for use
(c) Method of operation including daily maintenance by junior staff
(d) Method of calibration and quality control
(e) Service maintenance by senior staff
(f) Trouble shooting
(g) Description of ancillary materials (reagents etc.) used in the analytic 
procedure
(h) Performance characteristics, and limitations of the instrument.
3. The description of the instrument and its component parts should be 
amply and clearly illustrated so that each part can be readily identified. The 
principles of the function of the instrument should be described.
4. In unpacking, if there is more than one package, each package should be 
numbered, and the instruction should state how to loosen/unwrap the package. 
Setting-up instruction should include clear description of essential ambient loca­
tion, power requirement — e.g. what type of plug and how to connect it. It should 
be remembered that most medical equipment failures in developing countries are 
due to simple faults such as a blown fuse, a defective electrical connection, or 
simply the inability of the operator to install the equipment properly.
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5. Method of operation should be set out in numbered order. It is desirable 
to have, in addition, a summary of these numbered instructions on a separated 
plastic covered card and/or a wall chart.
6. There should be similar clear instructions in numbered order for
(a) Cleaning at end of each day
(b) Instrument shut-down at end of each day
(c) Any special precautions if instrument is not going to be used for a 
period of time
(d) Avoiding contamination, and dealing with a spill of specimen and/or 
reagent.
7. There should be clear instructions for the regular maintenance proce­
dures, listed in the correct order of procedure and indicating the time intervals 
between the maintenance schedules. The degrees of skill required for the different 
levels of maintenance should be indicated.
8. Adequate descriptions should be given for identifying likely cause of 
problems with well illustrated instructions on their correction in step by step 
detail. A circuit diagram should be provided. It might be desirable to advise how 
a temporary repair can be performed until the next opportunity for a visit by the 
manufacturer’s Service Engineer.
9. The composition of all reagents used in the system should be given with 
full details of their preparation. The possible use of locally available alternatives 
to the manufacturer’s disposable items should also be indicated. When a non­
disposable container is used in place of the disposable one, or a disposable one 
is to be reused, instructions should be given on how to clean and prepare it for use.
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Sérodiagnostic Profiles of HIV and HIV Pathogenesis In Vivo
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S. A. D anner2, R. A. Coutinho3
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Haematohgia 21 (2), pp. 71—81 (1988)
Different stages of HIV infection are marked by expression of HIV genes, 
production of HIV antibodies, formation of antigen/antibody complexes and clearance 
of such complexes. Transient HIV antigenemia appearing generally 6—8 weeks prior 
to HIV antibody (HIV-Ab) seroconversion and lasting 3—4 months is generally seen 
in acute infection. If IgG antibodies to both envelope and core protein persist in the 
absence of HIV-Ag the short-term prognosis is relatively good. However, HIV-Ag 
seroconversion may appear at any time after HIV-Ab seroconversion. Progression to 
AIDS is strongly associated with declining or absent levels of IgG antibodies to p24. 
Titers of antibodies to HIV p24 below 64 are strongly associated with the presence of 
HIV antigen and a poor clinical outcome.
HIV antigen may be less efficiently detected with the present assays in sera from 
regions where the prototype strains of HIV (HTLV-III and LAV) are less prevalent, 
like Central Africa. Levels of HIV-Ag in serum, and possibly in CSF, can be decreased 
by nucleoside analogues, like AZT. This indicates HIV-Ag and possibly antibody to 
HIV core protein p24 as suitable markers for selecting individuals for antiviral therapy 
as well as monitoring the efficacy of such therapy.
Keywords: HIV, serodiagnosis, HIV core antibody, HIV core antigen, prog­
nostic markers
Introduction
Human immunodeficiency virus (HIV) is the cause of AIDS as well as severe 
neurological diseases [1—4]. HIV infection may also result in progressive en­
cephalopathy (PE) even without severe immunodeficiency in both children and 
adults [5, 6]. Brain tissue of HIV infected individuals has transmitted HIV to 
chimpanzees [7], and HIV antigens and particles have been demonstrated in brain 
[8] as well as other tissues of AIDS patients. In vitro uninfected CD4+ cells fuse 
with cells expressing HIV glycoproteins on their membrane forming multinu- 
cleated giant cells [9, 10].
Synthesis of HIV envelope and core proteins is activated in vitro by the 
trans-activator protein tat3 [11]. Tat3 activity is crucial for replication of HIV. 
In vivo clinical and immunobiological abnormalities develop in a large propor­
tion of long-term HIV antibody seropositive persons [12].
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Recently we have been able to show that sérodiagnostic profiles in serum 
as well as cerebrospinal fluid are strongly associated not only with the present 
clinical status of the patient but may also be helpful in predicting the clinical 
outcome of asymptomatic НГѴ infected individuals [15]. These advances in diag­
nostics will help us to select individuals [13— 19] for antiviral therapy as well as 
to monitor the efficacy of such therapy. In this paper we will review the several 
markers that have appeared useful in studying the pathogenesis of HIV in vivo.
Materials and Methods
Subjects
Sera originated from several sources. The first group was comprised of 
homosexual men from Amsterdam. These men were participants in a prospective 
study on the prevalence and incidence of HIV infection or patients treated at the 
internal medicine department of the Academic Medical Center of the University 
of Amsterdam. The second group consisted of haemophiliacs from the Nether­
lands seroconverting for HIV antibody and followed for at least three years. The 
third group comprised of HIV-Ab seropositive intravenous drugusers partici­
pating in a prospective study in Amsterdam.
Immunoblot analysis o f HIV antibodies
Sucrose gradient purified, heat inactivated LAV/HTLV-III was fractionated 
by electrophoresis using a 12% polyacrylamide slab gel in the presence of sodium 
dodecylsulphate. The protein bands on the gel were transferred to a nitrocellulose 
sheet (0.45 /im Schleicher and Schuell, Dassel, W. Germany). Following transfer, 
the sheet was rinsed with PBS-Tween 0.05% and incubated for two hours in 
PBS (pH 7.4.) at room temperature. Next the sheet was rinsed with PBS-Tween, 
dried and stored at 4 °C until use. When used, the sheet was cut into strips and 
each strip was pre-incubated for one hour at 37 °C in 2.5 ml PBS-Tween, con­
taining 4% normal goat serum. Subsequently 25 /.il of heat inactivated test serum 
was added to each strip separately and incubation was continued for one hour at 
37 °C. Following washing with PBS-Tween, the strips were incubated at room 
temperature for one hour with biotinylated goat anti-human IgG (Vector, Bur­
lingame, California, USA), or with mouse monoclonal antibodies (Bio-Yeda, 
Israel) if human IgG subclasses were determined. After another washing the 
strips were incubated for one hour at room temperature with a preformed com­
plex of avidin and biotinylated horse-radish peroxydase (Amersham, Buckingham­
shire, UK) if goat antihuman IgG was used. When mouse monoclonals were 
used an additional step with biotinylated goat-anti mouse IgG was performed 
prior to incubation with the avidin-HRP complex. Following washing, colour was 
developed using 4-chloro-l-naphthol as substrate.
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Proteins p 18, p24 and p55 were considered to be encoded by the gag-gene 
and proteins gp41, and gpl20 by the env-gene.
Proteins p65/53 and p33 were considered to be encoded by pol-gene.
HIV antigen detection
Solid phase enzyme immunoassay (Abbott Laboratories, North Chicago, 111., 
USA) was used for assay of serum samples for HIV antigen. Two-hundred micro­
liters of sample were incubated overnight at room temperature with a bead coated 
with human antibody to HTLV-Ш. Beads were washed with distilled water; 
rabbit IgG antibody to HTLV-11I added and incubated for 4 hours at 40 °C. Beads 
were washed as before, then incubated for 2 hours at 40 °C with horseradish 
peroxidase-conjugated goat antibody to rabbit IgG. After a final wash, the beads 
were transferred to tubes and O-phenylenediamine was added. After 30 min at 
room temperature in the dark, 1 ml of 1 N H2S 04 was added to each tube. The 
A490 was read with a Quantum Dual Wavelength spectrophotometer (Abbott, 
North Chicago). A sample was considered positive if its OD was > 0.050 plus 
the mean of five replicates of normal human plasma. The assay is most sensitive 
for the core antigen of HIV and detected approximately 20 — 30 pg/ml in these 
assays.
Antibodies to HIV core and envelope proteins
Antibodies were measured by using commercially available, competitive 
enzyme immunoassays (Abbott Laboratories), referred to as CIA-RA. Briefly, in 
the first system, beads coated with recombinant HTLV-III core antigen (containing 
the entire p24 gag-gene product, as well as portions of the pi 5 and pi 8 gag-gene 
products) were incubated with 50 g\ of the serum samples and with 200 p\ of 
horseradish peroxidase-conjugated human antibody to HTLV-III for 16 — 22 
hours at room temperature. Beads were washed with distilled water, and colour 
was developed as described above for the antigen test. Because this is a competi­
tive enzyme immunoassay, intensity of the colour formed was inversely related 
to the amount of antibody to the HIV core antigen in the sample. The cutoff 
point was determined as the sum of the negative control mean (n =  3) and the 
positive control mean (n =  2) divided by two. The same procedure applied to the 
antibody to envelope antigen assay; however, beads were coated with recombi­
nant HTLV-III envelope antigen (containing the entire p41 env-gene product, 
as well as 45 amino acids from the gpl20 env-gene product). Labeled antibodies in 
the core and envelope CIA-RA were prepared from patients’ sera with high titers 
to core or envelope, respectively, on Western blot. Core antibodies were titrated 
using a standard curve.
H aem ato lo g ia  21, 1988
74 J Goudsmit et al.: Sérodiagnostic profiles o f H IV and H IV  pathogenesis in vivo
Detection o f HI У specific immune complexes
Two sets of 400 g\ of each serum sample were incubated overnight at 4 °C 
with an equal volume of 0.2 M EDTA (pH 7.5) and 200 g\ polyetylene glycol 
(PEG) 12%.
After centrifugation at 8400^ for 15 minutes, the supernatants were tested 
for HIV-Ag and antibodies to recombinant core and envelope antigens. Subse­
quently the pellet of one tube was dissolved in PBS, the pellet of the other in 6 M 
guanidine to disrupt the immune complexes. Samples with buffer only and 
with purified HIV lysate dissolved in PBS or 6 M guanidine were used as controls. 
The samples were used to coat beads for 6 hours at 40 °C. The coating solution 
was then washed away and beads were incubated with horseradish peroxidase- 
labeled human anti-HTLV-lll for 2 hours at 40 °C. Beads were again washed and 
colour was developed by using OPD as substrate similarly to the HIV-Ag assay.
Results
HIV antigen in serum in acute HIV infection
Transient HIV antigenemia has been observed around HIV-Ab seroconver­
sion in 19% of our series of acutely infected homosexual males and in 13% of 
HIV antibody seroconverted haemophiliacs (Table 1). HIV-Ag was observed in 
samples taken three months before the first HIV-Ab positive sample.
In all of these cases antibodies to both the HIV core and HIV envelope 
proteins appeared.
The short-term prognosis of this group was indistinguishable from the ma­
jority of HIV antibody seroconverters who never showed HIV-Ag in any serum 
sample and remained asymptomatic during the first two years of follow-up. 14% 
of the homosexual men seroconverting for HIV-Ab became HIV antigénémie 
approximately at or may be even before HIV antibody séroconversions, and
Table 1
Occurrence and persistence of HIV antigen in acute HIV infections
H IV  an tig en  status N u m b e r (% )
1. Homosexual men Negative 36/58 (62%)
Transient 11/58 (19%)
Persistent 8/58 (14%)
2. Haemophiliacs Negative 14/16(87%)
Transient 2/16(13%)
Persistent 0/16 ( -  )
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remained so during the follow-up period. This group had a poor short-term clinical 
outcome; 50% of these men developed ARC or AIDS within the first year of 
follow-up. Antibodies to HÍV env proteins became readily detectable in contrast 
to antibodies to HIV core proteins which had a low titer or were absent.
Figure 1 summarizes the sérodiagnostic profiles observed during acute HÍV 
infection. Profile I, showing transient HIV-Ag and IgM antibodies to HIV core 
and persistence of IgG antibodies to HIV-core and envelope proteins with oc­
casionally circulating HIV specific immune complexes, is the most frequent and 
has the best prognosis for the time being. Profile II, showing persistence of HIV- 
Ag in both free as well as complexed configuration and the occurrence and persist­
ence of IgG antibodies to envelope proteins, is far less frequent, and is associated 
with a grave clinical and immunological outcome.
Fig. 1. Sérodiagnostic profiles of acute HIV infection
“Flu-like” syndrome may occur in association with both profiles in the 
early antigénémie phase, prior to HIV-Ab seroconversion. HIV may pass the 
blood-brain barrier shortly after entrance into the body resulting in transient 
expression of HIV in the cerebrospinal fluid followed by intra-blood-brain-barrier 
synthesis of HIV antibody. Symptoms of acute meningitis or meningoencephalitis 
may accompany this phase occurring at, or shortly after HIV-Ab seroconversion. 
Generally these symptoms disappear within the first month after HIV-Ab serocon­
version.
Preferential decline o f antibodies to p24 associated with AIDS
Immunoblot analysis of sequential sera of individuals progressing to AIDS 
showed a decline of IgG recognition of core proteins, especially p24, while IgG 
recognition of the envelope proteins gp41 and gpl20, as well as of the pol-gene
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Fig. 2. Immunoblot analysis of sequential sera of patients with ARC, one with LAS and 
a healthy homosexual man (HSH). Patient 14 progressed to AIDS
products p65/53 and p33 remained constant (Fig. 2). This loss of fgG recognition 
of p24 was not seen in patients not progressing beyond ARC.
Relationship o f circulating HI V antigen, decline o f antibodies to H IV  core proteins 
and disease
HIV-Ag was seldom found in free configuration (8%) and somewhat more 
frequently in complexed form (29 %) in sera with detectable levels of antibodies to 
p24 (Table 2). HIV-Ag was frequently found in free configuration (70%) and less
S erum  an tibody  
s ta tus
H IV  antigen  (% )
N u m b er S eru m /su p e r- P E G  Serum
o f  sam ples n a ta n t  p rec ip ita te  and PEG
Ab to HIV corepresent 38 1 (3%) 11 (29%) 2 (5%)
Ab to HIV core absent 50 10 (20%) 8(16%) 25 (50%)
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Relationship between HIV antigen and HIV core antibody and the formation of HIV antigen-
antibody complexes in serum
J. Goudsmit et al.: Sérodiagnostic profiles o f HIV and H IV  pathogenesis in vivo I I
Fig. 3. Relationships between HIV antigen levels, titers of antibodies to HIV core and clinical
status
frequently (16%) in complexed form in sera without detectable levels of antibodies 
to p24.
HIV antigen was not detected in sera with reciprocal anti-p24 titers over 
64 (Fig. 3).
Severe clinical disease was strongly associated with low titers of anti-p24 
and high levels of HIV-Ag.
Table 3
HIV antigen in serum of HIV antibody positives according to age, geographic origin
and stage of infection
Clinical ca teg o ry G eo g rap h ic  origin P ercen tage  positive
1. AIDS (CDC IV C&D)
homosexual men Europe 86% (30/35)
slim disease Central Africa 10% ( 1/10)
2. Constitutional disease 
(CDC IV A) 
homosexual men Europe 32% ( 7/22)
3. Other (CDC 11 & 111)
homosexual men Europe 17% (24/145)
haemophiliacs Europe 0% (0/16)
IV drugusers Europe 3% (2/60)
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H IV antigen in serum according to age, geographic origin and stage o f infection
Among adults from Europe or the USA, HIV antigenemia was observed 
in 86 —91 % of the cases (Table 3). In contrast HIV antigenemia was seldom pres­
ent in sera of Central Africans with slim disease.
HIV antigenemia was less frequent among adults with constitutional disease 
or without symptoms.
Figure 4 illustrates the different sérodiagnostic profiles observed in our 
series and patients. Profile I and III with persistence of IgG antibodies to core 
and envelope proteins with or without core Ag/Ab complexes were the most 
frequent. These profiles are strongly associated with subclinical HIV infection. 
Profile IV represents the transitional state to persistent HIV antigenemia (Profile 
V). Generally antibodies to p24 disappear. Transition from profiles I —III to 
IV/V may occur at any time and places the person subsequently at increased risk 
for AIDS. Profiles IV and V are strongly associated with the progression to AIDS. 
Profile II (with persistence of antibodies to env proteins, but absent antibody to 
core) has been noted in several AIDS and ARC patients.
Fig. 4. Sérodiagnostic profiles of chronic HIV infection
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Discussion
ШѴ antigen in serum appears to be detectable in pictogram amounts gener­
ally six to eight weeks prior to HIV-Ab seroconversion without a window phase 
with both markers absent [16, 20]. Because of the sensitivity of the current HIV- 
Ag assays as well as sampling errors approximately 80% of sera taken 3 — 4 
months prior to HIV-Ab seroconversion escape HIV-Ag detection. IgM antibody 
assays do not appear to solve this problem.
To ascribe a “flu-like’ syndrome firmly to an acute HIV infection paired 
sera should be tested. In the absence of positive serology for a CMV, EBV, HBV, 
HAV or Toxoplasma infection the following serological pattern may be considered 
conclusive:
1) HIV-Ag in the absence of anti env/core Ab in the acute phase serum.
2) HIV-Ag + / — in the presence of anti env/core Ab in the recon­
valescence serum taken 3 months later.
The same philosophy is pertinent to needle stick injuries: HIV-Ab serocon­
version is obligatory to avoid problems with the interpretation of the results.
When HIV-Ag persists directly following НГѴ-АЬ seroconversion the clini­
cal prognosis appears to be worse than when HIV-Ag disappears. For screening 
purposes sensitive assays, including immunodominant epitopes of the viral enve­
lope glycoproteins are mandatory. Antigen testing in low risk groups has still to 
be evaluated.
For prognosis the most important markers to date are HIV antigen and 
HIV core antibodies. Two main aspects should be stressed. Both HIV-Ag and 
HIV core Ab should be quantitated and the consistency of the sérodiagnostic 
profile should be confirmed by testing the individual at least twice in 6 months.
Progression to AIDS is strongly associated with declining or absent levels 
of antibodies to the HIV core protein p24, as has been subsequently confirmed 
by Weber et al. [22]. Recently we have been able to show that these antibodies 
are trapped in immune complexes of core antibody and antigen [23].
The following tentative conclusions can be drawn: Declining or low titers 
(<  64) of antibodies to p24 in the presence or absence of free circulating HIV 
antigen bears a grave clinical prognosis when persisting over 6 months.
HIV antigen levels decline concomitant with clinical improvement when 
adequate doses of AZT are administered [24]. No data on changes in titers of 
antibodies to core proteins are available yet.
This indicates HIV-Ag and possible HIV core Ab as suitable markers for 
antiviral therapy as well as for monitoring such therapy.
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Incidence of HIV antibodies have been studied in 617 patients with congenital 
bleeding disorders. Screening was performed with the Organon ELISA test, repeatedly 
positive samples were tested with four different confirmatory assays. HIV antibodies 
were found in 3/356 patients with haemophilia A, 21/114 patients with haemophilia 
B, 3/123 patients with von Willebrand disease and in 1/24 patients with other types of 
congenital coagulation disorders. All the 28 seropositive patients were treated with 
imported coagulation factor, mostly with factor IX concentrates. No patient treated 
exclusively with nationally produced factor preparations between 1981 and 1985 was 
found to be anti-HIV positive.
Keywords: HIV, haemophilia, factor IX
Introduction
Haemophiliacs have to be treated with coagulation factor concentrates orig­
inating from hundreds to thousands of plasma donors. As a consequence, deter­
mination of the prevalence of anti-HIV antibodies in haemophiliacs treated with 
locally produced preparations can be considered as a good estimate for the pre­
valence of HIV-infected persons among blood donors and in the total population 
of a given country [6].
In the present study, anti-HIV antibodies have been measured in 617 pa­
tients with congenital bleeding disorders. This includes vast majority of congenital 
bleeders in our National Registry. Correlation of the prevalence of seropositivity 
to the type and intensity of the treatment was calculated. Confirmed anti-HIV 
positivity was found in 28 patients with haemophilia. All the 28 seropositive pa­
tients were treated with imported commercial coagulation factor, mostly with 
factor IX concentrates. No patient treated exclusively with nationally produced 
factor preparations was found to be anti-HIV positive.
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Materials and Methods
Patients
Blood samples from 356 patients with haemophilia A, 115 patients with 
haemophilia B, 123 patients with von Willebrand disease, as well as from 23 pa­
tients with other congenital coagulation disorders were collected in 25 Haemophi­
lia Care Centers. Sera were separated, heat-treated at 56 °C for 30 min, and stored 
at —20 °C for a maximum of 4 weeks. After that sera identified with code numbers 
were transported to the National Institute of Haematology and Blood Transfusion, 
Budapest for anti-HIV evaluation. After completion of the study, the centers 
were asked to give the following data: diagnosis, sex, age, use of imported factor 
concentrate in the last 4 years, type and amount of preparation used as well type 
and amount of the nationally produced coagulation factor preparations used in 
1984. Spouses or regular sexual partners of the anti-HIV positive haemophiliacs 
were also tested for the presence of HI V antibodies.
Measurement o f the anti-HIV antibodies by ELISA technique
Vironostika kit of the ORGANON TEKNIKA (Turnhout, Belgium) was 
used for the anti-HIV screening. Measurement was performed strictly according 
to the recommendations of the manufacturer.
Confirmatory investigations
Each repeatedly positive serum sample was tested with four types of confirm­
atory assays: 1. For revealing false-positivity due to anti-lymphocyte antibodies 
with a control ELISA plate coated with shed material from uninfected H9 cells 
(SORIN BIOMEDICA, Saluggia, Italy), 2. with a type 2 (competitive) enzyme 
immunoassay kit of Wellcome Diagnostics (Temple Hill, England) known to 
have an outstanding specificity [11], 3. with indirect immunofluorescence (IFA) 
test using th HIV producer cell line СЕМ/LAV as antigen (kindly provided by 
Prof. Chermann, Paris) and as a control, uninfected CEM cells [9], 4. with the 
Western blot kit of the Du Pont de Nemours firm.
Immunological studies
T cell subsets were determined in 9 confirmed anti-HIV positive children 
with haemophilia B, in a patient with factor VII deficiency and as control in 8 
seronegative children with haemophilia A. T cell subsets were measured in mono­
nuclear cell suspensions isolated from the peripheral blood of patients using 
indirect immunofluorescence microscopy and monoclonal antibodies from the 
OKT series (ORTHO, Raritan. USA).
H aem ato lo g ia  21, 1988
E. Újhelyi et a l : HI V antibodies in Hungarian haemophiliacs 85
Results
Incidence o f anti-HIV positivity among patients with congenital coagulation disorders
Anti-HiV measurements were performed in the sera of 617 patients with 
haemophilia A, B, von Willebrand disease or other type of congenital coagulation 
disorders (Table 1). Presence of anti-HIV antibodies were confirmed by all the 
4 methods applied in all of the 28 seropositive patients. Repeatedly positive ELISA 
result was obtained in the sera of an other patient which, however, could not be 
confirmed. Thus, the confirmation rate (number of confirmed positive samples/re- 
peatedly ELISA positive samples) was 28/29. Most patients (21/28) found to be 
anti-HIV positive had haemophilia B. Almost one-fifth of the patients with 
haemophilia B became seropositive, whereas only a minor percentage of the pa­
tients with other type of congenital coagulation abnormality tested had HTV anti­
bodies.
Type o f  haem o p h ilia
N u m b er o f  
p a tien ts  
te sted
P atients w ith  con firm ed  
an ti-H IV  p ositiv ity
n um ber %
Haemophilia A 356 3 0.8
Haemophilia B 114 21 18.3
von Willebrand disease 123 3 2.4
Other 24 1 4.3
Total 617 28 4.5
Only 2 of the 28 HIV antibody positives are females, one of them (who in 
the meantime, died of gastric cancer) had von Willebrand disease, the other pa­
tient, a 15 year old girl has factor VII deficiency. One half of the positives are 
children and 20/28 are under 20 years of age.
Results o f anti-HIV measurements in the regular sexual partners o f the seropositive 
heterosexual haemophiliacs
8 spouses and regular sexual partners of the seropositive adult patients with 
haemophilia were tested. Two of them were found to have HIV-antibodies.
Study o f the association between the treatment with imported coagulation factor 
concentrate and occurrence o f H IV  seropositivity
After completion of the study, the haemophilia centers had been asked to 
give information on the use of imported coagulation factor concentrates in the
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Table 2
Incidence of anti-HIV positivity in haemophiliacs treated or not treated with imported
coagulation factor concentrate
Patients
T ype o f  h aem oph ilia
trea ted non- t rea ted
w ith im p o rted  fa c to r  co ncen tra te  in  1981 — 1985
N u m b e r o f
A n ti-H IV  +  -ve 
p a tie n ts N u m b er o f
A n ti-H IV  +  
patien ts
tested n u m b e r % tested n u m b er %
Haemophilia A 3 0 4 13 .3 3 2 6 0 0.0
Haemophilia B 4 5 2 0 4 4 . 4 6 9 0 0.0
von Willebrand disease 9 3 3 3 .3 1 1 4 0 0.0
Other 1 1 — 2 3 0 0.0
Total 85 2 8 3 2 . 9 5 3 3 0 0.0
patients tested between 1981 and 1985. Data are shown in Table 2. Less than 10 
per cent of the patients with haemophilia A were treated with imported concen­
trates, and HIV antibodies developed only in a small percentage (13%) of these 
patients. By contrast, two-fifths of the patients with haemophilia B tested were 
given imported factor concentrates and 20/45 (44%) of them became seropositive. 
Only a few patients with von Willebrand disease or other congenital coagulation 
disorders were treated with imported factor preparations. 4/12 of these patients, 
however, were found to be seropositive. Altogether, 28/85, that is 33 per cent of 
the imported concentrate-treated patients became anti-HIV positive.
None o f the patients treated exclusively with coagulation factor concentrates 
produced in Hungary were found to have HIV-antibodies, although these patients 
were exposed, on the average to blood of 62 donors in 1984 and some of them 
received preparations made from several hundreds of Hungarian blood donors.
Association between the amount of imported factor IX concentrate used and the 
development o f HIV-antibodies
We have got exact data on the use of imported factor IX concentrate in 
1981 — 1985 in the case of 46 patients with haemophilia B (45 patients) and factor 
VII deficiency (1 patient). 19 of these patients became anti-HIV positive (Group 
1) while 27 patients remained seronegative (Group 2). There was a significant 
difference in the amount of factor IX concentrate administered to the two groups. 
The patients belonging to Group 1 received more than 6 times as much concentrate 
as the patients of Group 2 (Table 3).
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Table 3
Amounts of imported factor IX concentrate which had been administered in 1981—1985 
to haemophiliacs found to be anti-HIV positive and negative in 1986
P atients
N um ber o f  
patien ts  
tested
A m o u n t o f  im p o rted  
F a c to r  IX  co n c en tra te  
rece ived /patien t
m ean ±  S .D .
Anti-HIV
positives* 19 29 130 25 360
Anti-HIV
negatives** 27 4 550 6 230
* 18 haemophilia B, 1 factor VII deficiency 
** 27 haemophilia B
T cell subsets in HI V seropositive and seronegative children with haemophilia
The absolute number of lymphocytes, as well as the percentage and absolute 
number or T3 + , T4 + , and T8+ lymphocytes were determined in the blood of 
10 children with haemophilia (9 haemophilia B, 1 factor VII deficiency) found to 
be HIV seropositive, and as control, in 8 HIV-seronegative children with hae­
mophilia A of the same age as the seropositives (Table 4). In October, 1986 signif­
icant difference was found only in the absolute number of T4 + cells. In the 
group of seropositives this value was about one-half of that of the seronegative 
children. 3 seropositive patients, but none of the seronegative children, had an 
absolute T4+ cell number below 400 /Л.
Table 4
T-cell subsets in anti-HIV positive and negative children with haemophilia
(October, 1986)
G ro u p
N u m ­
ber o f  
p a ­
tien ts
Lym phocytes
ДІ
O K T 3 +
lym phocytes
O K T 4  +
lym phocy tes
O K T 8  +
lym phocy tes O K T 4  +
% r\ % dl % ДІ O K T 8 4-
te sted m ean S. D .
Anti-HIV
positives 10 2318 + 54.9 + 1280+ 24.7 + 576+ 31.9 + 738 + 0.85 +
804 9.7 486 9.4 315 10.0 324 0.40
Anti-HIV
negatives 8 3146+ 50.9 + 1680+ 30.3_± 1033 + 27.1 ± 942+ 1.12 +
1042 9.6 575 10.4 548 7.8 519 0.26
P - 0.05 <  p <0.1 n.s. n.s. n.s. <  0.05 n.s. n.s. n.s.
n.s. =  not significant
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Discussion
Near to or more than 50 per cent of the haemophiliacs are anti-HIV positives 
in West-European countries; and 80 — 95% in USA (in Australia 56%; in France 
48%; in Spain 67,7%) [7]. Very recently similar data were reported from the 
United Kingdom: 927 haemophiliacs out of the 1264 tested had antibodies to 
HIV [1].
Since most patients with haemophilia in Hungary are treated with nationally 
produced coagulation concentrate, it seemed very important to study the preva­
lence of anti-HIV positivity in Hungarian haemophiliacs. Determinations made 
in the majority of the registered haemophiliacs indicate that less than 5 per cent 
of these patients have HIV antibodies. Moreover, none of the 533 haemophiliacs 
tested who were treated exclusively with nationally produced coagulation factor 
concentrate or were not treated at all became HIV seropositive, although many 
patients were exposed to the blood of several hundreds of donors. This finding 
demonstrates that the vast majority of Hungarian blood donations could be consid­
ered safe between 1981 and 1985. This assumption was supported by the initial 
results of the donor screening. Regular screening of blood donors began in Hun­
gary in February, 1986 and since 1 July a compulsory anti-HIV antibody assay is 
made from the blood of each donor at each donation. Till 31st December 1986 
389000 units were tested. Confirmed positivity was found in 5 donors, all the five 
were males and admitted retrospectively to be homosexual. Infection of the first 
full-blown AIDS patient in Hungary (registered in late December, 1986) originated 
from a blood transfusion during cardiac surgery (coronary bypass) in January, 
1985. The patient belonged to no known risk group. Detailed investigation of 
blood donors revealed one HIV-antibody positive individual, one of the later 
detected five seropositive homosexual donors.
In the USA [5] and UK [1] the rate of seropositivity was considerably 
higher in patients with haemophilia A than in those with haemophilia B. In 
contrast to this 20 of the 28 HIV seropositive haemophiliacs in Hungary have 
haemophilia B. The explanation of this apparently paradoxical finding is simple: 
while the vast majority of patients with haemophilia A in Hungary have been 
treated with nationally produced concentrates, due to a temporary shortage of 
the national PCC (prothrombin complex concentrate) product, a number of pa­
tients with haemophilia B especially those treated in a Pediatric Haemophilia 
Centre received imported commercial factor IX concentrate. Our findings, in 
agreement with the results of Baselga et al. [3], demonstrate that risk of transmit­
ting HIV infection with factor IX concentrate is similar to that of factor VIII 
concentrate. When it became clear that these concentrates caused HIV infection, 
their import was immediately suspended. Seropositive patients were notified and 
educated on safe-sex practices. Unfortunately, in 2 cases this education was too 
late: the regular female sexual partners of these patients also became anti-HIV 
positive. There was a strong positive correlation between the amount of the con­
centrate used and the development of HIV antibodies: those patients who became
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seropositive had received more than 6 times more cencentrates than those who 
remained seronegative. This finding is in line with the results reported by several 
groups concerning factor VIII [2, 8] and factor IX [3] administration.
We have started a longitudinal immunological and clinical follow-up study 
in the patients with haemophilia found to be HIV seropositive. Until now none 
of these patients have developed full-blown AIDS, 2 children who had lymph- 
adenopathy and minor opportunistic infection can be classified in Group III or 
IVa of HIV infection according to the newest CDC classification system [4]. At 
the latest immunological evaluation performed in October, 1986, seropositive 
children had significantly less absolute T4+ cell number than the seronegative 
haemophiliacs of the same age and 3/10 seropositives had less than 400 T4 + 
cells//tl which is considered to be a critical value [10]. In the future we shall con­
tinue the longitudinal study of the HIV antibody positive haemophiliacs using 
several immunological tests in parallel.
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Equations for the Calculation of Factor VIII Potencies 
from the Results of Parallel-Line Clotting-Time Assays*
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An equation was derived: lnC01 =  InD, — (aj/aJlnD , +  (a2/a,)lnC02 +  
+  1 /a^b j— b2) which related the potency of a sample (C01) to the potency of a 
standard (C02) via the dilution factors (D, & D») that produced common clotting 
times for the sample and standard. This equation could not be used in practice since 
C01 and b, were both unknown. Derivation of a usable formula for calculating sample 
potencies was found to require the assumption that b! =  b2. It was found that b is not 
always a constant in Factor VIII assays and may vary with the nature of the clotting 
assay mixtures.
Keywords: assay variation, coagulation factor potencies, Factor VIII assays, 
parallel-line bioassays
Introduction
Early descriptions of clotting factor assays sometimes contained statements 
saying that linear graphs of clotting-time versus dilution could not be obtained 
even with logarithmic transformations [1,2]. However, later improvements led to 
the use of logarithmic standard curves with the thromboplastin generation test 
[3, 4] and the activated partial thromboplastin test (APTT) [5], although the 
original description of the APTT referred to the use of a semilogarithmic graph [6].
Despite these improvements, problems related to variations of slopes [7] 
and other parameters have continued to plague laboratories that assay clotting 
factors [8, 9]. Thus it became clear that additional variables may require definition 
and control before these clotting tests may be considered to be as accurate and 
precise as possible.
The study to be reported here arose from an attempt to define the mathema­
tical factors that were required for a valid coagulation factor assay when the 
parallel-line method and logarithmic transformations were employed. Rather 
than use an approach based on enzyme kinetics, the study was designed to con­
sider the assay from the point of view of the analyst who is presented with clotting- 
times and dilutions and must derive a potency by comparison with a similar set 
of data from a standard preparation.
* An abstract describing the results of this study was presented before the 69th Annual 
Meeting of the Federation of American Societies for Experimental Biology, Anaheim, CA, 
USA (Fed. Prcc. 44: 1845 (1985)).
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The results of the current study reinforced some of the assumptions and 
“rules of thumb” that are employed by those who routinely conduct clotting fac­
tor assays. However, it also revealed the requirement for an assumption that has 
not been previously considered. The results have shown that this is not always 
a valid assumption, and this condition may invalidate the use of dilution ratios for 
calculating clotting factor potencies from parallel line assays.
Materials and Methods
Definitions
a — Slope of a line generated by plotting a transformed clotting-time on 
the vertical axis versus a transformed dilution factor on the horizontal 
axis.
b — Constant introduced into the equation for a straight line. Initially it 
served a purpose similar to that of an integration constant and was 
not necessarily equal to the intercept.
C — Concentration of a clotting factor in units per ml.
C0 — Original concentration before starting a dilution series.
D — Dilution factor. Series of I : 4, 1 : 8, 1 : 16, 1 : 32 and 1 : 5, 1 : 10,
6 : 20, 1 : 40 were used after predilution of samples to approximately 
1 unit/ml.
I — The intercept along the vertical axis when D =  1 (1 :1  dilution).
r — The correlation coefficient obtained from the least squares fit to a
straight line. When the data points fall along a perfectly straight line, 
r equals 1.0.
T — A clotting-time corresponding to a particular value of D.
Subscripts: Terms related to samples have 1 as a subscript, while a subscript 
of 2 refers to a standard.
Calculations
Calculations were done with a Texas Instruments Tl-59 calculator using 
built-in linear regression functions [10] for calculating least squares fits to a 
straight line. The calculator was programmed to accept duplicate clotting-times 
and single dilution factors. Average clotting-times were calculated, and they and 
their corresponding dilution factors were transformed as appropriate. The paired 
data were then entered into the calculator’s linear regression subroutine. The 
parameters for the least squares fit to a straight line were calculated and stored 
for later retrieval.
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Clotting assays
The data for this study were obtained from two laboratories who used the 
Hyland Clotek and General Diagnostics Coag-A-Mate X2 as clot timers. These 
laboratories were engaged in the potency testing of factor VIII concentrates via 
APTT assays. The data were taken from routine test results on a variety of sam­
ples in various potency ranges. One of the laboratories used the General Diagnos­
tics Automated APTT reagent, containing micronized silica, and 25 mM C aC l2; 
while the second laboratory used a Hyland Diagnostics reagent, containing kaolin, 
and 30 mM CaCl2. Samples were prediluted to approximately 1.0 unit/ml. Di­
lutions were then made and incubated for 3 or 5 min with the activator and phos­
pholipid reagent in factor ѴПІ deficient plasma before CaCl2 was added to 
initiate clotting.
Results
Derivation o f an equation for calculating concentrations
In deriving the equation, the following general assumptions were employed.
1. The clotting-time is inversely proportional to the concentration of the coagula­
tion factor, i.e. Tal/C.
2. The sample and standard may be considered to be simple dilutions of each 
other. The result being that dilution series and their associated clotting-times 
from the sample and standard will generate a pair of parallel lines separated by 
a distance proportional only to the difference in concentration between the 
sample and the standard.
3. If two reaction mixtures each contain the same concentration of the coagulation 
factor, they will produce the same clotting-time, i. e. if Cj = C2, then Tt = T 2.
4. Within the range of the dilutions used, a straight line may be produced by 
plotting InT on the vertical axis and InD on the horizontal axis.
Each of these assumptions may become invalid under certain conditions, 
but the execution of a valid coagulation factor assay requires at least the first 
three to be valid. Assumption number 4 will be assumed to be valid for the pur­
poses of the following derivations. It will be seen later that the only critical part 
of assumption 4 is the use of a logarithm of D.
Assumptions 1 and 4 could be combined since:
C = C0/D
and substitution into assumption 1 gave:
T a D/C0
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Assumption 4 then gave:
InT a ln( D/C0)
or InT = aln(D/C0) + b
The equation could now be expanded for generating the dilution curve.
A. InT = alnD — alnC„ + b
The intercept (I) was evaluated by setting D = 1 (i.e. the sample had not 
yet entered the dilution series). At this point InD = 0 and I is related to a, b and C0.
Thus: I =  b — alnC„ = lnT(at D = 1)
or
B. b = I + alnC0 
as antilogs:
C. eb =  e'Cl z T Q  (at D = 1)
If b were a true constant such that b2 = b2 for a pair of parallel lines in a 
clotting assay, then from equation B:
D. lnC0] = (a2/a,)lnC0, +  —---- —
ai
If the lines were truly parallel so that a, =  a2 and if the concentrations were 
given in percentages so that C02 = 100%, then equation D would be identical 
with an equation derived by Margolis et al. [11 ], if D = 1 were taken as the com­
mon dilution factor.
Returning to equation A and choosing a common clotting-time for lines 
from a sample and standard so that InT, =  lnT2, it follows that:
a^nD, — ajlnCo! + b, = a 2lnD2 -  a2lnC02 + b2 
or
E. lnC01 = InD, -  (a2/a,)lnD2 + (aJa^InC,,, + 1 /a ,(b , -  b2)
Where D , and D2 were the dilutions giving T, = T2. Equation E could not be 
evaluated as b, needed to be known before C01 could be calculated.
If it were assumed that b, = b2, then :
lnC01 =  InD, — (a2/a,)lnD2 + (a2/a,)lnC02
or in antilogarithmic form:
F. C01 = D ,/D2(a2/a , )C „2(a2/aj)
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Imposing the parallel line assumption so that a t = a2, gave:
G. C01 = Co^DJD.,)
which was the usual dilution ratio equation for calculating the potency of an 
unknown from that of a standard.
Evaluation ofb
The assumption that b was a constant was crucial for the derivation of a 
formula for calculating concentrations of factor VIII relative to that of a standard. 
Therefore the numerical value of b was measured under various conditions to see 
if b could be established as a constant in factor VIII assays.
An in-house factor VIII control preparation was diluted to produce values 
of C0 in the range about 1.0 unit/ml. Dilution curves were then produced for each 
value of C0. The values of a and I were calculated for each line and, along with 
the corresponding value of C0, were entered into equation C. The calculated value 
of eb was then plotted against the corresponding value of C0. Figure 1 showed that 
the value of b differed between the two laboratories and varied with the value of 
C0; even though each laboratory did all of its testing during a single day, using 
the same reagents and substrate plasma for all assays.
Discussion
Equations
The reader should not conclude that equations D and F will allow one to 
ignore a lack of parallelism. Equations D and F will permit the calculation of a 
potency from a pair of intersecting lines, but the validity of the number will be 
questionable as the lack of parallelism will indicate that the sample and standard 
are not simple dilutions of each other and that the clotting-times are responding 
to different controlling factors. Margolis et al. [11] noted that the slope of a dilu­
tion curve should be characteristic of the factor being assayed. Therefore if the 
slopes are not equal the possibility that the clotting-times are being controlled by 
different limiting factors becomes real.
Equation E was derived without assuming that a t =  a 2 or bx = b2. Unfor­
tunately the calculation of C01 via equation E required prior knowledge of b,. The 
derivation of equations D and F required the assumption that bj = b2, and 
equation G, an often used formula, required the further assumption that 
Uj = a.2.
Note that when equation E was derived, the clotting-time ceased to be a 
factor as the condition that Tj = T2 eliminated T from the resulting equation. 
The result was the same whether T or a logarithm of T were used.
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The constant, b
Other equations exist for calculating the results of clotting factor assays. 
Elődi et al. [12] derived a semilogarithmic equation that was employed for stud­
ying sources of assay errors. Margolis et al. [11] derived a logarithmic equation 
that was carried through to a formula for calculating clotting factor concentrations 
by comparing clotting-times at a common dilution factor. Neither of these groups 
appear to have included the constant, b.
Hemker et al. [13] approached this derivation from basic enzyme kinetics 
and generated equations that did not require logarithmic transformations. With 
these equations a straight line could be obtained when the clotting-time was plotted 
as the ordinate with the dilution factor as the abscissa. When the dilution factor 
was set to zero in their equation, the intercept on the ordinate was found to be 
related to the reciprocal of the enzyme concentration times a constant. As their 
derivation and the present derivation were based upon different initial assumptions, 
it is difficult to say if their constant and b are the same. However there are simi­
larities between the terms and these constants may be related.
The derivations provided by Hemker et al. [13] were interesting and infor­
mative, as they were based on enzyme kinetic assumptions that were useful for 
describing the relationship between clotting-enzyme concentrations and clotting- 
times. However, the present work was based upon the assumptions for parallel 
line bioassays and the relationship between the present study and theirs was not 
pursued.
If equation A is taken and b omitted, 1, the intercept where D = 1, would 
be negative at values of C0 greater than 1.0 unit/ml. As InT at D =  1 equals 1 and 
is known to be positive at C0 values that are greater than 1.0 unit/ml, the existence 
of b as an additional term in the intercept is inferred.
Fig.l. Variation of b as a function of factor VIII concentration (C0). Equation C (see text) 
was used to calculate values for b from data obtained from Laboratory 
A ( •  ) and Laboratory B (X)
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From Fig. 1, it appears that b has a non-linear relationship to C0, and there 
are regions where b is fairly constant. These variations could cause problems 
when a sample is prediluted to several levels. In fact it is possible that the variation 
of b may contribute to the phenomenon known as the predilution effect. Aronson 
and Marder [14] described this anomaly, in which the back-calculated potency 
of a preparation varies with the predilution made before entry into the assay 
dilution series. Inspection of equation E and Fig. 1 will lead to the conclusion 
that this situation could arise in a series of assays where b varied with C0. From 
Fig. 1 it appears that the difference between bx and b2 may be minimized by having 
C01 and C„, very close to each other. This may be the reason for the laboratory 
technician’s rule that the best assay results are obtained when the sample and 
standard are very close to each other in potency.
Figure 1 showed that the value of b is dependent upon the composition of 
the clotting systems (difference between laboratories) and the initial concentration 
of factor VIII (variation of b with C0). The failure to eliminate inter-laboratory 
variations with a monographed assay for factor VIII [9] may have been the result 
of variations of b among and within the laboratories participating in the study.
If b is not constant or equal to zero, equation B shows that the intercept of 
an assay line will be dependent upon b as well as C„. Thus the distance separating 
a pair of parallel lines will be dependent upon another factor besides the difference 
between the concentrations of the sample and standard. The resulting violations 
of assumptions 2 and 3 would invalidate the use of a parallel line assay system.
It was concluded that the use of semilogarithmic or logarithmic systems led 
to an equation that could not be evaluated. Derivation of useful equations required 
the use of assumptions that were demonstrably incorrect under certain conditions. 
Consequently, the performance of valid coagulation assays was found to require 
the demonstration that the dilution curves for the samples and the standard were 
similar enough to minimize variations of the intercept term, b.
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Lectin-Induced Adhesion of Human Platelets to Glass. 
Comparison with the Lectin-Induced Aggregation
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Effects of Phytohaemagglutinin (PHA), Concanavalin A (Con A) and Lens 
culinaris (Lens) lectins on the adhesion of human platelets to glass surface were studied. 
All the three lectins tested enhanced platelet adhesion to glass.
Concentration-effect curves showed that maximum effect was reached at about 
25—30 |itg/ml. In the presence of autologous plasma both spontaneous and lectin- 
induced adhesion to glass were diminished. The inhibitory effect of K.CN, NaN3, cy- 
tochalasin B and partly of colchicin suggests that lectin-induced platelet adhesion to 
glass is a process depending on cell metabolism and the state of the cytoskeleton. Only 
PHA was observed to be a potent inducer of platelet aggregation similar to physiolog­
ical aggregants. Con A had no effect on platelet aggregation but caused shape change 
which was blocked by metabolic inhibitors. Neither shape change nor aggregation 
were induced by Lens up to a concentration of 400 /ig/ml. A comparison between the 
mechanisms of lectin-induced substrate adhesion and lectin-induced aggregation of 
platelets is described.
Keywords: platelets, lectins, substrate adhesion, glass surface, aggregation
Introduction
Studies on platelet adhesive properties are of interest because of the central 
role they play in the haemostatic processes and their pathological deviations. 
When the blood vessel wall is injured, platelets become activated and typical func­
tional alterations [1] can be observed: they begin to adhere to the exposed sub- 
endothelial connective tissue, which is rapidly followed by aggregation and release 
of some biologically active substances. In vitro platelets adhere to most surfaces 
and usually adhesion leads to ADP release. When the investigation is performed 
in a dynamic system, the formation of platelet aggregates can be observed [2]. 
These early steps of platelet activation have been a subject of intensive investiga­
tion during the past few years.
Plant lectins are a very convenient tool for studying the mechanisms of platelet 
activation. The effect of their binding to human platelets has been investigated 
earlier [3, 4, 5, 6, 7]. It has been found that lectins with specifities directed towards 
mannose and glucose, such as Concanavalin A (Con A), Lens culinaris (Lens) 
etc., do not induce platelet aggregation, whereas Con A itself can induce a release 
reaction [3] and some macromolecular events characteristic for platelet activation
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[4, 5, 6]. On the other hand, lectins with galactose directed specificity, such as 
Ricinus communis, as well as wheat germ agglutinin (N-acetylglucosamine de­
terminant) and Phaseolus vulgaris agglutinin or PHA (N-acetylgalactosamine de­
terminant) were found to be strong inducers of both aggregation and release 
reaction [3, 7]. There is no clear evidence, however, about the effect of lectins 
on platelet substrate adhesion, for example to glass or other artificial surfaces.
The aim of the present paper is to investigate the effect of some lectins: 
Phytohaemagglutinin (PHA), Con A and Lens on human platelet adhesion to 
glass and to compare it with the lectin-induced aggregation.
Materials and Methods
Materials: The experiments were performed with human venous blood from 
7 healthy volunteers who stated that they had had no medication for at least 
10 days prior to bleeding. 3.8% sodium citrate in 9 : 1 ratio was used as an anti­
coagulant. Con A, Lens, colchicin and cytochalasin B were purchased from Sigma; 
PHAp was purchased from Difco Lab.; KCN, NaN3 and formaldehyde were 
obtained from Merck. All other reagents were commercial preparations of analyt­
ical grade.
Isolation of platelets: Citrated blood was centrifuged at 120# for 15 min at 
room temperature. Platelet-rich plasma (PRP) was transferred to polypropylene 
tubes and diluted with autologous plasma to 10 cell/ml. Washed platelets were 
prepared from PRP by centrifugation at 750# for 20 min in the presence of 3 mM 
EDTA. The cell pellet was gently resuspended in HEPES-buffer (145 mM NaCl, 
5 mM KC1, 0.5 mM Na2HPO,, 1 mM MgCl2, 5 mM glucose and 10 mM HEPES, 
pH 7.3), and washed twice more with the same buffer. The final pellet was re­
suspended to a concentration of 1 x 108 cells/ml in HEPES-buffer without EDTA.
olCr labeling o f platelets: Platelet suspension in HEPES-buffer was incubated 
for 30 min with Na2(51C r)04 at a concentration sufficient to give approximately 
5x 104 c.p.m. per 0.2 ml platelet suspension. Cells were washed 3 times with 
HEPES/EDTA-buffer and resuspended to 1 x 108 cells/ml in buffer without EDTA.
In some experiments fixed platelets were prepared as follows: washed cells 
were resuspended in 2% formaldehyde in buffer saturated with 5% autologous 
plasma and incubated at 4 °C for 20 min. After two further washings in HEPES- 
buffer the cells were adjusted to 1 x 10s cells/ml.
Measurement o f platelet adhesion: Flat bottomed glass scintillation vials 
were used for the adhesion test. They were processed as follows: the vials were 
washed with non-ionic detergent (Triton X-100), rinsed with tap and distilled 
water followed by soaking in 10% H20 2 for 6 hours. After further thorough 
washing with bidestilled water, the vials were dried at 120 °C for 1 hour. Processed 
glass vials were filled with 0.2 x 108 51Cr-labeled platelets and resuspended in a 
final volume of 2 ml HEPES-buffer. The vials were incubated for 60 min at 37 °C 
and counted in a у-counter (LKB) The solution was then decanted, the vials
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rinsed 5 times with buffer and counted again. The percentage of adhesion was 
calculated according to the formula:
C.P.M. before washing — C.P.M. background
% ADHESION = ------------------------ --------------------------5------- X 100
C.P.M. after washing — C.P.M. background
The experiments were considered correct if no aggregation was found in the 
decanted solution by microscopic investigation. In some experiments the platelets 
were preincubated for 1 hour at 37 °C with 2 mM KCN, 10 mM NaN3, 1 mM 
colchicin or 20 /íg/ml cytochalasin B.
Measurement o f platelet aggregation: The aggregation was measured by 
recording the light transmission through a stirred platelet suspension, according 
to the method of Born [2]. The increase of optical transmission at 400 nm was 
registered with an aggregometer, adjusted to produce full-scale deflection for 
platelet count difference of 0.8 x 108 cells/ml.
The platelet shape change was measured under the same optical conditions 
and defined as a decrease of optical density (caused by changes in the form of 
platelets from disc to sphere) within 3 minutes after addition of an aggregant.
Data presentation: Each point is the mean + S.E.M. of 4 different platelet 
preparations. Each measurement was carried out in triplicate. Statistical signif­
icance between comparable points was determined using Student’s t test.
Results
Effect o f lectins on platelet adhesion to glass
Preliminary experiments showed that the lectins used did not induce detect­
able release of olCr at the concentration tested for at least four hours (data not 
shown).
PHA was found to increase sharply the adhesion of washed platelets to 
glass surface (Fig. 1). The maximum effect was reached at a lectin concentration 
of 30 /ig/ml: 27.8 ± 2 % .  This is about 4 times higher than spontaneous adhesion 
to glass: 6.9 +  0.7 (p < 0.05). At higher concentrations of lectin, a decrease of 
the PHA-induced adhesion was observed (19.5 ± 1.5% at 100 pg/ml PHA). At 
the same time microscopic investigation revealed single aggregates .
Con A and Lens also amplified the adhesion of platelets to glass to an 
approximately equal extent (Fig. 1). Maximum adhesion was reached at a con­
centration of about 25 — 30 /<g/ml which was 19.8 ± 1.8% for Con A and 18.4 + 
±  2.1% for Lens (p < 0.05), which is much lower than the PHA-induced one. 
The concentration-dependent curves for Con A and Lens were flatter.
In a preliminary experiment we found that unwashed platelets (platelet- 
rich plasma) showed lower adhesion to glass than washed cells. The influence of 
added autologous plasma on spontaneous and lectin-induced platelet adhesion
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Fig. 1. Effect of PHA, Con A and Lens on human platelet adhesion to glass. Concentration- 
dependent curves. 0.2x 108 51Cr-labeled platelets were incubated ina final volume of 1 ml for 
60 min at 37 °C in scintillation glass vials. The percentage of adhesion was calculated as de­
scribed in Materials and Methods. Each point is mean +  S. E. M. of four different experiments. 
The measurements were done in triplicate
to glass was tested (Table 1). The results showed that increased plasma concentra­
tion diminished spontaneous, as well as Con A and Lens-induced adhesion of 
platelets to glass surface. The results with PHA (not presented) were considered 
inaccurate because of the formed aggregates.
Effect o f lectins on platelet aggregation
Of the three lectins tested, only PHA induced both change of shape and 
aggregation (Fig. 2). The degree of aggregation depended on PHA concentration.
Table 1
Spontaneous and lectin-induced adhesion of platelets to glass in the presence of autologous
plasma
A uto logous plasm a 0% 1 % 5% 10% 20%
Spontaneous 7.8 7.4 4.8 4.1
+  Lens 20 /ig/ml 15.3 11.1 9.9 8.7 8.1
+  Con A 20 /«g/ml 15.1 9.8 9.3 7.8 7.4
The percentage of platelet adhesion to glass was measured. Cells at a concentration 
of 0.2x 108 cells/ml were incubated at 37° C for 60 min in glass vials with HEPES-buffer, 
pEl 7.3, to which autologous plasma was added in the indicated percentages. The final assay 
volume was 1 ml. Each value is a mean calculated from three experiments.
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Fig. 2. PHA-induced aggregation of washed platelets (a) and platelets suspended in autolog­
ous plasms (b). Platelets were suspended in HEPES-buffer pH 7.3 or in autologous plasma 
(PRP) at a concentration of 108 cells/ml. Aggregation was assayed at 37 °C in the presence
of different PHA concentrations
Fig. 3. Con А-induced shape change of washed platelets. The experimental conditions were
as described in Fig. 2
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Washed platelets showed maximal aggregation at 50 ^g/ml (Fig. 2-a), while 
in the presence of plasma (PRP) a similar effect was reached at 200 /tg/ml (Fig. 
2-b).
As shown in Fig. 3, Con A produced a well expressed change of platelet 
shape, but no aggregation. This phenomenon was also concentration-dependent 
and was “optimal” at about 50 /tg/ml. At higher concentrations the effect was 
irreversible.
Lens culinaris did not produce any effect on either platelet aggregation or 
shape change up to 400 /tg/ml (data not shown).
Influence of different “ inhibitors''’ on lectin-induced adhesion and aggregation
The effects of cytochalasin B, colchicin, KCN and NaN3 on Con-A-induced 
platelet adhesion were tested. Each compound except colchicin showed statisti­
cally significant inhibitory effects (Fig. 4). Similar results were obtained with Lens- 
induced adhesion (data not shown).
The effect of indomethacin (10 /(M), KCN, NaN3 and chemical fixation of 
cells with formaldehyde on PFfA-induced aggregation is shown on Fig. 5-a. 
Indomethacin inhibited the aggregation by about 30%, while KCN, NaN3 and 
formaldehyde fixation — by about 50%. Fig. 5-b shows the temperature depend­
ence of PFIA-induced aggregation of platelets. Neither aggregation nor shape 
change was observed at temperatures below 10 °C.
Con-A-induced platelet shape change was totally blocked by KCN, NaN3 
and low temperature (Fig. 6).
Fig. 4. Effects of some inhibitors on Con А-induced platelet adhesion to glass. Platelets were 
suspended in HEPES-buffer pH 7.3 at a concentration of 1 X 10s celis/ml. To each vial 0.2. ml 
cell suspension, 50 /<g/ml Con A and one of the following inhibitors were added: cytochalasin 
B (b), colchicin (c), KCN (d) and NaN3 (e). The control is signed (a). Each value is mean +
S. E. M. of four experiments
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Fig. 5. Effects of inhibitors (a) and temperature (b) on PHA-induced aggregation of platelets. 
The washed platelets were preincubated with the inhibitors indicated and after two more 
washings the cells were resuspended in HEPES-buffer pH 7.3. Other experimental conditions
were as described in Fig. 2
Fig. 6. Effects of temperature and some metabolic inhibitors on Con А-induced shape change 
of washed platelets. The washed platelets were preincubated with the inhibitors indicated 
and after two more washings the cells were resuspended in HEPES-buffer pH 7.3. Other 
experimental conditions were as described in Fig. 2
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Discussion
Our results show that the lectins PHA (N-acetylgalactosamine determinant), 
Con A and Lens culinaris (glucose-manose determinants) have the ability to 
amplify adhesion of platelets to glass. PHA had the strongest effect with a maxi­
mum at about 30 /ig/ml, where the adhesion was nearly 4 fold higher than the 
spontaneous one (Fig. 1). The decrease of adhesion at a concentration of 100 /xg/ 
/ml (or higher) was due to a parallel PHA-induced aggregation which was con­
firmed by microscopic investigations. It is known [2] that rotation is necessary 
for aggregate formation, but evidently single aggregates may also be formed under 
static conditions. The disadvantage of our adhesion system is that it does not 
differentiate between platelet adhesion and eventual lectin-induced aggregation. 
That is why experiments on the effect of some inhibitors on lectin-induced ad­
hesion to glass were performed with Con A and Lens only. As shown in Fig. 1, 
these lectins which did not induce aggregation showed typical saturation-con­
centration curves.
As far as the mechanism of lectin-induced adhesion to glass is concerned, 
similarly to lectin-induced agglutination mechanism [8], it could be assumed that 
lectins as polyvalent ligands bind simultaneously to platelet membrane and glass 
surface, e.g. the adhesion is carried out by a “bridging action” of the lectin 
molecule. Such a mechanism, however, is not in agreement with our observations 
on the effects of different inhibitors. Depression of the lectin-induced adhesion 
to glass by KCN and NaN3 (Fig. 4) shows that the level of intracellular ATP is 
important. Furthermore the inhibitory effect of cytochalasin B (and partly of 
colchicin) suggests an involvement of the cytoskeletal system in the adhesive 
process. The low effect of colchicin might be due to the short-term preincuba­
tion of platelets with this inhibitor (1 hour). Longer periods (the recommended 
4 hours) [9] were not suitable for our non-sterile experimental conditions.
Recently it has been shown that polymerisation of platelet cytoskeletal 
elements and association of specific platelet surface proteins with the cytoskeleton 
might be key elements in the process of platelet activation [5, 6]. As the latter 
is dependent on the metabolic state of the cells and the function of the cytoskeleton, 
we suggest their participation in the mechanism of lectin-induced adhesion of 
platelets to glass.
Previous investigations by other authors indicated that Con A can induce 
platelet activation and membrane glycoprotein phosphorilation, association of 
membrane proteins with the cytoskeleton [5, 6], rearrangement and capping of 
the platelet membrane receptors [10] and release reaction [3]. All these data 
suggest that the effect of lectin-induced adhesion to glass — observed in our 
laboratory — may be of physiological importance and is dependent on the initial 
functional state of the platelets.
The presence of autologous plasma significantly decreased both sponta­
neous and lectin-induced platelet adhesion to glass (Table 1), which may be due 
to the screening action of plasma proteins. Our preliminary results have shown
H aem ato log ia  21, 1988
G. AUankov, M. Setchcn.ska: Lecthi-induced adhesion o f  human platelets to glass 107
that some plasma glycoproteins have similar effect, but further investigations are 
required for solving this problem.
Our studies show that of the three lectins tested only PHA was a potent 
inducer of platelet aggregation. This is in agreement with the data of Majerus 
and Brodie [7]. In the presence of autologous plasma the PHA-induced aggrega­
tion was significantly reduced (Fig. 2-b). A ten-fold higher PHA concentration 
was necessary for inducing the typical platelet aggregation effect in the presence 
of PRP. We assume a similar screening action of plasma proteins, as that involved 
in the adhesion process.
The metabolic inhibitors KCN and NaN3 reduce the aggregation, but not 
completely (by about 30 — 35%), while temperatures below 10 °C totally block 
the process. This suggests that lectin-induced aggregation is also dependent on 
cell metabolism, but probably a “physical-chemical” cell-lectin interaction takes 
place during the aggregation. Our findings related to chemically fixed cells are in 
agreement with this theory (Fig. 2-a).
Indomethacin causes an inhibitory effect of about 30 — 35%, which suggests 
an involvement of arachidonic acid metabolic products in the mechanism of 
lectin-induced aggregation (similar to physiological aggregation).
Our finding that Con A and Lens do not cause platelet aggregation actually 
confirmed the results of Greenberg and Jamieson [3]. However, Con A induces 
a well expressed platelet shape change, which is also dependent on the metabolic 
state of the cells, as shown by its inhibition by KCN and NaN3 or low temperature 
(Fig. 6). This effect was described in detail in our previous work [11].
The data reported herein show that the tested lectins have different effects 
on platelets. While PHA is a potent inducer of aggregation (similarly to the physio­
logical one) Con A causes only platelet shape change, and Lens has no effect 
on either shape change or aggregation. However, all three of them induce platelet 
adhesion to glass. This indicates that lectin-induced adhesion is a less specific 
process than lectin-induced aggregation, and apparently there are differences in 
the underlying mechanisms. On the other hand, both processes are dependent on 
cell metabolism, the cytoskeleton and probably the initial state of membranes, 
which suggests that this might be a possible approach to the functional assess­
ment of platelets in vitro.
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The oxygen consumption, subcellular distribution of hexokinase were studied 
in normal and leukemic spleen cells of AKR mice. High mitochondrial-bound hexo­
kinase activity and 0 2-consumption were detected in fetal state, in leukemic or BPV- 
induced lymphoproliférative conditions and after spermine incubation of normal 
spleen cells. After ConA-treatment, however, all of the hexokinase was found in 
cytoplasmic fraction and 0 2-uptake was strongly decreased. Studies on respiration of 
mitochondria isolated from normal and leukemic cells supported the role of mito­
chondrial-bound hexokinase in elevated 0 2-consumption of leukemic cells.
Keywords: mitochondrial-bound hexokinase, oxygen consumption, leukemic 
and stimulated lymphoid cells, age dependency
Introduction
Previously, we found increased total hexokinase activity and altered subcel­
lular distribution in leukemic cells. Large amount of hexokinase activity was 
bound to the mitochondria and elevated 0 2-consumption was observed in leu­
kemic cells. We assumed a possible relationship between mitochondrial-bound 
hexokinase and elevated leukemic cell respiration [1].
Our aim was to reveal the correlation between mitochondrial hexokinase 
binding and 0 2-uptake in normal and leukemic cells.
Materials and Methods
18-day-old fetal, newborn and 6 —8-week old adult AKR female mice were 
used. In adult AKR animals the AKR leukemia (AKRL) was maintained by serial 
passages from mouse to mouse with a leukemic spleen suspension containing 10e 
viable cells [1, 2]. In addition, the following procedures were carried out:
— one group of the animals was treated with Bordetella pertussis vaccine (BPV, 
9 X 10‘J germ/animal), and the spleen cells were prepared on the 3rd day after 
the treatment
V SP , U trecht, T o kyo  
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— another group of the animals was treated with Concanavalin A (ConA, 2,4 
mg/animal). The speen cells were prepared on the 6th day after i.p. inoculation
— 10' viable spleen cells of normal AKR mice were incubated in the presence of 
1 mM spermine for 30 min, at 37 °C.
The subcellular distribution of hexokinase was determined as previously 
described [1], according to Hommes and Everts [4], and Salotra and Singh [10]. 
Mitochondria were prepared by the method of Viyayakumar and Weidemann 
[14]. The respiratory control ratio of all preparations was better than 4 in the 
presence of 10 mM succinate plus rotenone. 0 2-consumption of intact cells and 
mitochondria was determined at 37 °C using a Clark-type electrode [1, 3]. The 
standard incubation medium for mitochondria contained: 110 mM sucrose, 60 
mM KC1, 10 mM KH2PO,, 5 mM MgCl2 and 0.5 mM EDTA [7]. The pH was 
adjusted to 7.4 with HC1. Further additions are given on the appropriate table.
Results
In our first set of experiments the subcellular distribution of hexokinase 
activity was determined in normal and leukemic spleen cells. The data of Table 1 
indicate that most of the hexokinase activity was found in the mitochondrial 
(8.500 g pellet) and the cytoplasmic (18.000 g supernatant) fractions. Normal and 
leukemic cells showed significant differences in the hexokinase activity of these 
fractions. Increased hexokinase activity of the whole homogenate of leukemic cells 
and altered subcellular distribution were found. In leukemia, a subcellular trans-
Table 1
Distribution of hexokinase activity between the subfractions of normal and leukemic AKR 
spleen cell homogenate (mU/rng protein +  SE)
N orm al cells recoveryc Leukem ic cells recoveryc
850 g pellet 0.9+ 0.05 6.6 1.0+ 0.1 2.8
8500 g pellet“ 2.1 ±  0.1 15.5 18.3+ 1.2** 51.9
18 000 g pellet 0.5+ 0.01 3.7 1.2+ 0.1 3.4
18 000 g supernatant 9.1 ±  1.1 67.4 12.4+ 1.1 35.2
Total activity1 13.5+ 1.3 93.2 35.2+ 1.6** 93.3
“ treated with 0.5% Triton X 100
b total activity was measured in whole homogenate, treated with 0.5 % Triton X 100 
c the values are given as percentage of recovery in each fraction compared to homo­
genate
** p <  0.001 compared to the normal value
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Table 2
Hexokinase activity and oxygen consumption in spleen cells of AKR mice in different ages
and leukemic conditions
H exok inase  activ ity3
O . consum p-
8500 g 18 000 g tion»
pelletc s u p e rn a ta n t to ta
a mU/nig protein +  SE (n =  6 — 6) 
b nmoles O2/min/107 cells +  SE (n =  6 — 6) 
'treated with 0.5% Triton X 100 
* p <  0.01 compared to the 
** p <  0.001 normal adults
18 day old foetus 
Newborn
6—8 week old adult 
Adult, leukemic
14.5 ±  1.0** 2 .0+  0.6**
10.5+1.2** 3.4+0.4**
2.1 ±  0.1 9.1 ±  1.1
18.3+1.2** 12.4+1.1
location of hexokinase activity from the cytoplasmic (18.000 g supernatant) to 
the mitochondrial (8.500 g pellet) fractions was observed.
The influence of age (compared to the leukemic conditions) on subcellular 
distribution of hexokinase activity and its relation to the 0 2-consumption is shown 
in Table 2. It was observed that the age of the animals plays an important role 
in total hexokinase activity and its subcellular distribution. The highest total and 
mitochondrial-bound hexokinase activity was found in fetuses. The 0.2-uptake 
of spleen cells changed similarly to that of the mitochondrial hexokinase activity.
Table 3
Effect of different treatment on subcellular hexokinase distribution and oxygen consumption
in spleen cells of AKR mice
H exokinase  ac tiv ity3
0 2 co n su m p ­
t io n 158500 g 
pellet
18 000 g
su p e rn a tan t to ta l
Control, adult, untreated 
Adult, leukemic'
BPV treated'
Spermine inc.'
ConA treated'
2.1 ±  0.1 
18.3+ 1.2** 
28.5+ 1.7** 
8.9+ 1.0**
9.1 ±  1.1 
12.4+ 1.1 
0 .0+  1.0 
2.6+ 0.2** 
33.6+ 1.8**
13.5+ 1.3 
35.2+ 1.6** 
40.2+ 2.1** 
12.6+ 1.4 
34.4+ 2.0**
13+ 1 
18+ 1* 
19+ 1.5* 
21 +  1.3** 
4 +  0.8**
a mU/mg protein +  SE (n =  6—6) 
b nmoles O2/min/10‘ cells ±  SE (n =  6—6)
'fo r  more details see: “ Materials and Methods” 
* p <  0.01 compared to the adult 
** p <  0.001 controls
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We investigated the effect of different factors on subcellular distribution of 
hexokinase and 0 2-consumption. Table 3 indicates that in leukemic as well as 
in BPV-induced lymphoproliférative conditions the hexokinase activity is shifted 
from the cytoplasma to the mitochondria, in spite of an elevated total hexokinase 
activity.
Incubation of normal spleen cells in the presence of spermine can shift the 
hexokinase equilibrium towards the mitochondria without any changes in total 
activity. In all cases the elevated mitochondrial bound hexokinase activity was 
accompanied by a higher 0 2 uptake. In ConA induced “normal” lymphoproliféra­
tive conditions we observed an increased total hexokinase activity without extended 
mitochondrial binding and a strongly decreased 0 2-consumption.
Table 4
Effect of hexokinase on oxygen consumption of mitochondria isolated from normal and
leukemic cells3
no add ition f- 50 m U  hexok i­
nase
Normal 7.43 ±  0.68 13.4+ 0.95**
Leukaemic 8.35+ 0.73 15.8+ 0.93**
“ nmoles 0 2/min/mg mitochondrial protein +  SE (n =  6—6)
Incubation of mitochondria was carried out (1—1 mgs) in standard medium 
(see: Materials and Methods) with 1 mM ATP and 10 mM glucose. The respiratory 
substrate was 2 mM succinate plus 1 pm rotenone.
** p <  0.001 compared to the value measured in absence of hexokinase
These data indicated a possible stimulatory effect of mitochondrial-bound 
hexokinase on cell respiration. To support this hypothesis, we investigated the
0.2-consumption of mitochondria isolated from normal and leukemic cells. Table 
4 shows that there is no difference in 0 2-consumption of normal and leukemic 
mitochondria. At the same time the 0 2-uptake of both normal and leukemic 
mitochondria were stimulated to the same extent by adding hexokinase (glucose 
phosphorylation system).
Discussion
Hexokinase has been considered as a typical example of “ambiquitous” 
enzyme the intracellular distribution of which may vary rapidly and reversibly 
between soluble and membrane-bound forms reflecting the change in concentra­
tions of regulating metabolites [6, 8]. High aerobic glycolysis in rapidly growing 
tumor cells has been reported to be correlated with the increased mitochondrial- 
bound hexokinase activity [8]. On the other hand, because of direct utilization of
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mitochondrially formed ATP the mitochondrial-bound hexokinase can regulate 
and stimulate the mitochondrial respiration [5, 12, 13].
Our data suggest:
— the mitochondrial-bound hexokinase activity is high in fetal state, in leukemic 
or BPV-induced lymphoproliférative conditions (this latter resembles leukemic 
conditions in some aspects [11]), but not in adult state or “normal” prolifera­
tive conditions (ConA treatment). High mitochondrial hexokinase activity 
was observed after spermine incubation of normal spleen cells. Polyamines 
are known to support the translocation of hexokinase from cytoplasma to the 
mitochondria [6].
— the changes in subcellular distribution of hexokinase are reversible and rapid 
(see spermine incubation), although we have no data concerning ConA treat­
ment.
— the observed high mitochondrial-bound hexokinase activity is always accom­
panied with higher cell respiration.
— in spite of the elevated energy requirement only an elevated cytoplasmic and 
no mitochondrial-bound HK activity was observed after ConA treatment. As 
increased cellular activities following lectin stimulation are dependent on gly­
colysis rather than on respiration [9], our observations sopport this phenom­
enon.
— studies on Oä-consumption of both normal and leukemic mitochondria sug­
gested that the increased 0 2-uptake of leukemic cells was due rather to the 
altered subcellular distribution of hexokinase (i.e.: increased mitochondrial 
binding) than to the different respiratory rates of normal and leukemic mito­
chondria. Although, both normal and leukemic mitochondria may bind hexo­
kinase, the increased mitochondrial hexokinase activity and the subsequent 
high 0,-consumption are characteristic for leukemic cells.
The observed findings may reflect the different energy requirements of normal 
and leukemic states and/or the altered concentrations of metabolites affecting 
hexokinase equilibrium.
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The importance of the adherent layer in long-term mouse bone marrow cultures 
as a reservoir of the most primitive stem cells is known. The role of the adherent cell 
layer in long-term human cultures (LTC) is examined from this point of view. Confluent 
adherent layers developed after about 3 weeks of culture. At that time and weekly there­
after the cellularity and granulocytic-macrophage progenitor (CFU-GM) content of 
the adherent fraction were determined after tripsinisation. We have documented that 
CFU-GM were present in the adherent layer of human cultures for at least 8 weeks. 
These findings emphasize the importance of assessing the progenitor cell content of 
the adherent layer in long-term human cultures.
Keywords: adherent layer, long-term human cultures, progenitor cells
Introduction
The development of long-term bone marrow cultures is an important advance 
in our ability to study stem cell proliferation and differentiation, the role of inter­
actions between stromal cells and haemopoietic cells [1]. An adherent layer devel­
ops after the inoculation of bone marrow cells which was found to be composed 
of phagocytic mononuclear cells, lipid-containing, spindle-shaped cells. This layer 
is essential for the survival of progenitor cells in most species [2], but the role of 
the single cells types is uncertain yet. In mouse cultures, when all of the non­
adherent cells are removed, the conditions are suitable for stem cell maintenance 
and proliferation [3]. It is assumed that the adherent layer serves as the primary 
stem cell reservoir. In human bone marrow cultures the evaluation of the non­
adherent fractions of LTC shows that primitive progenitors are detectable for 
periods of 1 — 3 months [4, 5, 6]. It appears that the adherent fraction of human 
cultures, similarly to mouse cultures, contains important populations of progenitor 
cells.
In this report we have assessed granulocytic progenitor cell maintenance 
in human long-term cultures, and have compared the CFU-GM content of non­
adherent and adherent fractions.
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Materials and Methods
Patients
The bone marrow samples of 9 haematologically normal individuals were 
investigated. Samples of normal bone marrows were obtained by aspirating cells 
from a rib removed from patients undergoing cardiothoracic surgery. The bone 
marrow samples were transferred to heparinized blood collection vials containing 
Iscove’s medium.
Bone marrow cultures
Long-term cultures (LTC) were established as previously described [1]. 
Briefly, 2 X 10' nucleated cells were seeded into 25 cm2 tissue culture flasks contain­
ing 10 ml Iscove’s medium (Gibco) supplemented with 10% preselected fetal calf 
serum (FCS), (Flow), 10% horse serum, antibiotics and 5 x 10-7 M hydrocortison 
in final concentration. Cultures were incubated at 37 °C in 5% C 0 2 atmosphere. 
At weekly intervals half of the medium and the non-adherent cells were removed 
and replaced with an equal volume of fresh medium.
Confluent adherent layers developed after about 3 weeks of culture. At that 
time and weekly thereafter, the cellularity and the number of progenitor cells of 
adherent fraction and non-adherent compartment were determined. The adherent 
cells were removed by tripsinization [7]: all the growth medium with the non­
adherent cells was removed from culture dishes and 5 ml of 0.1 % trypsin solution 
was added to the flasks, and cultures were incubated for 10 min at 37 °C. One milli­
liter of FCS was then added to stop further trypsin action, and adherent cells were 
easily detached by pipetting.
CFU-GM assay
Bone marrow cells were plated at 1 x lO’/ml in Iscove’s medium containing 
15% FCS and 20% supernatant of bladder carcinoma cell line 5637 as the source 
of colony stimulating factor (CSF) in 0.3% agar. The plates were scored on day 11. 
Groups of more than 50 cells were counted as colonies [11].
Results
Nonadherent cel! compartment
Cellularity. The cell content of the non-adherent layer declined gradually. 
After the third week the cell number of supernatant decreased to 3.7 x 106 from 
the initial 2 x 107/flask. After the sixth week the cell counts declined to 4.5 x 105. 
In the cultures non-adherent cells were detectable until the eighth week (Fig. 1).
Composition. The cellular composition of the supernatant changed during 
the life of the culture as shown in Table 1. The relative numbers of monocytes and
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macrophages increased to 30% by the fourth week, and at the same time there was 
a decline in the proportion of blasts, promyelocytes, myelocytes and metamyelo­
cytes. The relative number of granulocytes remained constant by the fourth week.
Table 1
Composition of non-adherent compartment in long-term cultures
W eeks % B last and  % M yelo- and  % B ands an d  % M onocy tes and  % L ym phocy tes
prom yelocytes m etam yelocytes segm en ts  m acrophages  and  no rm o b las ts
1. 2 ±  0.81 2 6 .2 2 +  3.9 4 0 .7 7 +  2.77 9 .6 6 +  2.94 2 1 .4 4 +  2.67
2 . 0 .7 7 +  0.77 15 .8 8 +  3.17 4 9 .2 2 +  3.32 3 0 .4 4 +  4.00 4 .2 2 +  2.14
The proportion of lymphocytes and normoblasts was 21 % in the first week, it de­
clined to 10% by the fourth week.
CFU-GM content. The initial CFU-GM number was 1 x 104/flask, in the 
first week it was 5.8 x 103/flask. During the first six weeks of culture there was 
a steady decline in the numbers of CFU-GM. Granulocyte-macrophage progeni­
tors were detectable until the eighth week (Fig. 2).
The adherent layer
Cellularity. The cell count of adherent fractions in the same experiments 
remained almost constant between the third and fifth weeks: (3.7— 1.5 x 10e/flask) 
and thereafter declined gradually. In the eighth week the cell number of the ad-
4 H aem ato log ia  21, 1988
Fig. 1. The cellularity of the nonadherent and adherent layer in long-term cultures
118 Zita Borbényi et a i : CFU-GM in adherent layer
Fig. 2. The CFU-GM content of the long-term cultures
herent layer was 5 x 105, ten times more than the cell content of the supernatant 
(Fig. 1).
Composition. By the end of the third week there was a confluent adherent 
layer with small round cells in association with adherent cells in the areas where 
the spindle-shaped cells first attached. Hereafter, increasing numbers of lipid con­
taining cells appeared. Wright’s-Giemsa staining of adherent cells showed fibro- 
blast-like cells, monocytes and macrophages.
CFU-GM content of cultures declined gradually with time. After 4 weeks 
of cultures, however, the CFU-GM content of the adherent layer was higher com­
pared to that of the supernatant. The difference in CFU-GM concentrations of 
the two fractions was highest in the fifth and eighth weeks (10 — 25 fold).
Discussion
The application of Dexter type murine base marrow cultures for human 
specimens resulted in CFU-GM maintenance of 6 —9 weeks [7, 8, 9].
Improvement of long-term human cultures by combination of fetal calf 
serum and horse serum and use of intraoperative marrow specimens has been 
reported [4]. This ensures a prolonged maintenance of granulocytic progenitors. 
In our experiments we were able to maintain CFU-GM in long-term cultures for 
at least 8 weeks without recharging. Some data [12] suggest that there are two 
phases in the life of the cultures. During the initial 3 — 4 weeks there are several 
simultaneous changes: the decline in the non-adherent cell count explained by 
feeding depopulation, attachment of cells to the flask, cell death and maturation.
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Determination of the number of progenitor cells present in the adherent 
fraction necessitated the development of a suitable method for detaching the ad­
herent cells. Trypsination was used based on the observation that satisfactory cell 
suspension could be obtained by using either trypsin or collagenase [10]. Neither 
of these agents have significant adverse effects on progenitor cell plating efficiency.
The studies of long-term bone marrow cultures have established two impor­
tant functions of the cells in the adherent layer. One is the modulation of stem cell 
proliferation [13] and the other is to provide the initial reservoir of stem cells [3]. 
Our experiments similarly to others suggest a flow of haemopoietic cells from the 
adherent to the non-adherent fraction. We have confirmed that CFU-GM in the 
supernatant arise from the adherent compartment. By the third week there are 
at least as many CFU-GM in the adherent layer as in the non-adherent fraction. 
Coulombel [10] reported that the most primitive progenitor cells identified by 
their high proliferative capacity were found in the adherent layer, and progenitor 
cells with lower proliferative capacity were found in the non-adherent fraction.
These findings implicate that if only the non-adherent fraction is evaluated 
the progenitor content of the culture may be underestimated. Changes in the num­
ber of total cells and progenitors in the supernatant are influenced by the release 
of cells from the adherent layer.
The retention of the most primitive progenitor cells in the adherent layer 
appears to be a feature of long-term human cultures in which haemopoiesis from 
normal progenitors is maintained. We suggest that assessment of the adherent 
fraction may be important when analyzing marrow cultures of patients with leu­
kaemia, as primitive normal stem cells, even if present, might not appear in the 
supernatant.
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Case Reports
Juvenile Chronic Myelogenous Leukaemia 
and Cleidocranial Dysostosis
E. Svarch, A. M enéndez, M. M orales, A. G onzalez 
Instituto de Hématologie e Inmunologia, Habana 8, Apartado 8070, Cuba
A 6 year-old Caucasian girl was admitted in May 4, 1982 with a 1-month 
history of haemorrhagic manifestations.
The mother, a maternal aunt and the maternal grandmother had cleidocra­
nial dysostosis.
Physical examination revealed cranial enlargement and prominent frontal 
bossing, the sagittal suture was depressed and the palate was high and narrow. 
The right clavicle was hypoplastic and the fingers were long and thin, clinodactyly 
of the fourth and fifth fingers was also observed. Other significant clinical findings 
included hepatomegaly of 4 cm, splenomegaly of 6 cm, strabismus and otitis.
Haematological data: Hb 10.9 g/dl, reticulocytes 1.2%, platelet count 
5 X 109/1, WBC count 30 X 109/1 with 3% blasts, 1 % promyelocytes, 58% neutro­
phils, 17% lymphocytes and 21 % monocytes. There were also 2 normoblasts/100 
leukocytes. The bone marrow aspirate demonstrated increased cellularity with 
predominance of granulocytic cells at all stages of maturation with a M : E ratio 
of 5.6 : 1, mégacaryocytes were very reduced in number, lymphocytes 8%. 
The karyotype was normal. All laboratory values were normal except fetal haemo­
globin 65%, Hb A2 0% and Hb A 35%, y globulin 1.82 g/dl and serum murami- 
dase: 22.5 pg/ml (normal values: 8—13). The leukocyte alkaline phosphatase was 
54 (normal value 35 — 50).
Roentgenograms confirmed the clinical finding.
Although the age of onset of the disease was unusual, the clinical and labo­
ratory data indicated juvenile chronic myelogenous leukaemia (JCML), and treat­
ment with 6 mercaptopurine was started on May 19, 1982. Within 1 month there 
was a decrease of hepatosplenomegaly and of leukocyte count, but the platelet 
count remained low. On November 29, 1982 the bone marrow was replaced by 
myeloblasts. The patient failed to respond to chemotherapy with COAP and died 
13 months after the diagnosis. Postmortem examination was not performed.
JCML is an uncommon childhood leukaemia characterized by hepatospleno­
megaly, leukocytosis, thrombocytopenia, the absence of the Philadelphia chromo­
some and an increased fetal haemoglobin [1]. Increased levels of y-globulin have 
also been observed [2].
JCML has been reported to be associated with congenital malformations,
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Von Recklinhausen’s neurofibromatosis, hypospadias, cleft palate, craniotabes, 
dysmorphic facies, cataracts, strabismus, nistagmus [2] and trysomy 8 [3]. Other 
defects involving skeletal system have been described in leukaemia [4].
Cleidocranial dysostosis is a rare disturbance of bone development of auto­
somal dominant inheritance [5].
To our knowledge this is the first report of association between cleidocranial 
dysostosis and JCML.
The occurrence of JCML together with cleidocranial dysostosis may be only 
coincidental or this congenital disease may be associated with a genetic predis­
position to leukaemia like other skeletal malformations.
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Duchenne Muscular Dystrophy and 
Acute Lymphoblastic Leukaemia
E. Svarch, A. Menéndez, A. Gonzalez 
Institute) de Hematologia e Inmunologia, Apartado 8070, Habana 8, Cuba
Duchenne muscular dystrophy is a sex-linked trait which so far has not been 
reported to be associated with other malignant diseases.
An 8 year old boy was admitted to our Institute due to anaemia. Physical 
examination revealed lumbar lordosis, weakness of the shoulder and pelvic girdles. 
The patient had a waddling gait, difficulty in climbing stairs and increased size of 
calf muscles (pseudo-hypertrophies). Gower’s sign was positive.
When the boy was 3 years old, Duchenne muscular dystrophy was diagnosed. 
An elevated creatine phosphokinase (CPK) : 95 /í/ і (Normal : 50 fiß) and muscular 
biopsy confirmed the clinical diagnosis. Haematological data at the time of admis­
sion were: Hb 9.6 g/dl, reticulocytes 1 %, platelet count 150 x 109/1, WBC count 
3.7 x 109/1 with 3% myelocytes, 45 % neutrophils, 46% lymphocytes and 6% mono­
cytes.
Bone marrow aspiration revealed ALL, Lx type according to the FAB clas­
sification. No immunological markers were detected. The treatment included 
the use of prednisone and vincristine for induction, prophylactic CNS therapy 
with methotrexate and dexamethasone, maintenance chemotherapy with 6 mercap- 
topurine and methotrexate and reinforcement therapy every 3 months of 1 dose 
vincristine and prednisone for 1 week. Just after the completion of induction ther­
apy, CNS leukaemia appeared, and therefore he received cranio-spinal irradiation. 
He remained in remission for 48 months and died of pneumonia in another 
hospital.
Although the etiology of ALL is not known, a pathogenic role of genetic 
factors is suggested based on the high incidence in identical twins [1].
The only cases when an association between a neoplasm of the haemato­
poietic system and a neuromuscular disease was found are the 3 subjects with 
progressive muscular dystrophy with multiple myeloma [2] reported by Kissling 
et al. No data are available on a possible linkage between the inheritance of genetic 
factors in ALL and the x chromosome. To our knowledge this is the first report 
of an association between Duchenne muscular dystrophy and ALL.
Although this association may be purely coincidental, we cannot exclude 
the existence of a higher prevalence of ALL in Duchenne muscular dystrophy. 
In view of this possibility, we thought this case interesting and that it may stimulate 
further studies to clarify this problem.
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Modulation o f erythrocyte vésiculation by 
amphiphilic drugs. P. Bütikofer, U. Brodbeck 
and P. Ou (Institut für Biochemie und Mole­
kularbiologie der Universität Bern, Bern, 
Switzerland). Biochim. Biophys. Acta 901, 
291 (1987).
Release of acetylcholinesterase-contain­
ing vesicles from human erythrocyte memb­
ranes induced by dimyristoylphosphatidyl- 
choline (DMPC) was inhibited by exposure 
of red cells to cationic amphiphilic drugs 
like tetracaine, chlorpromazine and prima­
quine which all are known to induce stoma- 
tocyte formation. On the other hand, the 
process was facilitated when red cells were 
exposed to crenators like the anionic drugs 
indomethacine and phenylbutazone or when 
DMPC was added to calcium-loaded red 
cells. The results suggest that agents which 
are known to modulate red cell shape do also 
influence the vésiculation behavior of the 
cells.
G. G ár dos
Inhibition o f calmodulin stimulation o f 
phosphodiesterase and Cdi+, Mg2+-ATPase 
activities and shape change o f erythrocyte 
ghosts by chloroquine. F. Nagai, K. Ushiya- 
ma, I. Kano, A. Nakagawa, T. Nakao and 
A. Nakajima (Department of Toxicology, 
Tokyo Metropolitan Research Laboratory of 
Public Health, Tokyo 160, Japan). Biochem. 
Pharmacol. 36, 3433 (1987).
The effects of chloroquine on calmodulin 
(CaM)-related enzyme activities and the 
shape of human erythrocytes have been 
studied. It was found that the CaM activa­
tion of rat brain phosphodiesterase was 
abolished by the addition of chloroquine. 
CaM was included in the assay of phospho­
diesterase activity at the concentration that 
gave half-maximal activation. The concentra­
tion of chloroquine that caused 50% in­
hibition of CaM stimulation of phospho­
diesterase was 7x 10~5 M. The type of 
inhibition was competitive with respect to 
CaM. The CaM-stimulated Ca2+, Mg2+- 
ATPase in erythrocyte membrane was also 
inhibited by chloroquine, the 50% inhibi­
tory concentration of which was about 
2x 10-4 M. Its mode of action was also 
competitive with respect to CaM. The shapes 
of erythrocyte ghosts prepared by hypotonic 
hemolysis were examined in a solution 
consisting of 2 mM MgCL, 154 mM NaCl 
and 10 mM Tris-HCl (pH 7.4); they were 
discocytic in the presence of 2 mM ATP and 
in its absence. They were converted to the 
invaginated form by the addition of chloro­
quine in the concentration range of 1 x 10-4 
— 5 X 10-4 M. This concentration is similar 
to that which caused the inhibition of CaM 
activation of Ca2+, Mg2+-ATPase.
G. G ár dos
Identification and purification o f a novel 
Mr 43,000 tropomyosin-binding protein from  
human erythrocyte membranes. V. M. Fowler 
(Department of Anatomy and Cellular 
Biology, Harvard Medical School, Boston, 
Massachusetts 02115, USA). / . Biol. Chem. 
262, 12792 (1987).
A new Mr 43,000 tropomyosin-binding 
protein (TMBP) has been identified in eryth­
rocyte membranes by binding of 125I-label- 
led Bolton-Hunter tropomyosin to nitrocellu­
lose blots of membrane proteins separated 
by sodium dodecyl sulfate-gel electropho­
resis. This protein is not actin, because 125I- 
tropomyosin does not bind to purified actin 
on blots. Binding of 125I-tropomyosin to this 
protein is specific because it is inhibited by 
excess unlabeled tropomyosin but not by
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F-actin or muscle troponins. This protein 
has been purified to 95 % homogeneity 
from a 1 M Tris extract of tropomyosin- 
depleted erythrocyte membranes by DEAE- 
cellulose and hydroxylapatite chromatog­
raphy, followed by gel filtration on Ultrogel 
AcA 44. The purified protein has a Stokes 
radius of 3.9 nm and a sedimentation coeffi­
cient of 2.8 S, corresponding to a native 
molecular weight of 43,000. Binding of 
12-T-tropomyosin to the purified TMBP 
saturates at one tropomyosin molecule 
(Mr 60,000) to two Mr 43,000 TMBPs, 
with an affinity of about 5x 10- , M. The 
TMBP is associated with the membrane 
skeleton after extraction of membranes with 
the non-ionic detergent, Triton X-100, and 
is present with respect to tropomyosin at a 
ratio of about one for every two tropomyo­
sin molecules. Because there is enough 
tropomyosin for two tropomyosin molecules 
to be associated with each of the short actin 
filaments in the membrane skeleton, the 
erythrocyte membrane TMBP, together 
with tropomyosin, could function to restrict 
the number of spectrin molecules attached 
to each of the short actin filaments and 
thus specify the hexagonal symmetry of 
the spectrin-actin lattice. Alternatively, this 
TMBP could be homologous to one of the 
muscle troponins and might function with 
tropomyosin to regulate erythrocyte acto- 
myosin-ATPase activity and influence eryth­
rocyte shape.
B. Sarkadi
Specific deposition o f complement protein 
C3b on abnormal PNH erythrocytes permits 
their separation by partitioning. Possible 
general approach for isolation o f specific cell 
populations. M. K. Pangburn and H. Walter 
(Department of Biochemistry, University 
of Texas Health Center, Tyler, TX 75710, 
USA). Biochim. Biophys. Acta 902, 278 
(1987).
The deposition of complement proteins 
on a cell surface has previously been shown 
to reduce the cell’s partition ratio in a two- 
polymer aqueous phase system. This phenom­
enon has now been extended to segregate,
by partitioning, subpopulations of erythrocy­
tes from patients with paroxysmal nocturnal 
hemoglobinuria (PNH). Purified components 
of the complement system were employed 
to deposit the protein C3b specifically on 
abnormal erythrocytes which lacked the 
membrane-associated complement regula­
tory protein DAF. As few as 2100 C3b/cell 
reduced the partition ratio and 24000 
C3b/cell resulted in resolution of the C3b- 
bearing and non-bearing human red cells. 
It was found that the proportion of cells 
separated did not equal the proportion of 
cells lysed by complement in the acidified 
serum lysis test when blood from three of 
the five patients was examined. The results 
indicate that the defect giving rise to DAF-  
cells may be, but is not necessarily, coexpres­
sed with defects affecting other membrane- 
associated regulatory factors. A broader 
application of the method using monoclonal 
antibodies to direct purified complement 
components to specific cell populations 
should permit their isolation in large quanti­
ties.
B. Sarkadi
Alterations o f electrolytes in serum and 
erythrocytes after myocardial infarction. 
H. Ising, T. Günther, F. Bertschat, K. Ibe, 
V. Stoboy and E. Heldman (Institute for 
Water, Air, and Soil Hygiene of the Federal 
Health Office, Berlin-West). Magnesium 6, 
192 (1987).
Electrolyte concentrations in serum and 
erythrocytes of 56 myocardial infarction 
(MI) patients and 50 patients having had an 
orthopedic operation or an accident were 
measured up to 2 weeks after the event. 
Several hours after the MI, considerable 
percentages of patients had had pathologi­
cally low serum concentrations of either K, 
Ca or Mg. In the erythrocytes of the MI 
group, K was decreased and Ca increased 
during the entire period of investigation, 
whereas, the serum electrolytes IC and Ca 
had normalized by day 15, at which time only 
half of the patients with pathologically low 
serum Mg had reached the normal Mg range. 
By correlation analysis it was shown that
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the more the Ca concentration in the serum 
was decreased after MI, the less was the 
concentration of brain muscle creatine 
kinase.
Ilma Szász
Diamide stimulates calcium-sodium exchange 
in dog red blood cells. J. C. Parker (Depart­
ment of Medicine, University of North 
Carolina, Chapel Hill, North Carolina 27514, 
USA). Am. J. Physiol. 253, C580 (1987).
Calcium influx can be stimulated in dog 
red blood cells by preexposure to diamide 
under certain conditions. Diamide-activated 
calcium influx resembles swelling-induced 
Ca2+—Na+ exchange in several respects. 
These include saturation of calcium influx 
at external calcium levels >  0.5 mM, 
suppression of calcium influx by external 
sodium, and inhibition by quinidine. The 
ability of diamide to stimulate this transport 
pathway depends critically on the ionic 
composition of the medium in which the 
cells are bathed at the time of diamide 
exposure. The effect is greatest if the diamide 
preincubation is conducted in a hypotonic 
lithium chloride medium containing at least 
1 ,«M calcium. Stimulation of Ca2+-Na+ 
exchange is seen at diamide concentrations 
(0.10—0.33 mM) that are lower than those 
reported to cause major spectrin cross- 
linking, glutathione depletion, Ca2+-ATPase 
inhibition, or ion channel formation. The 
results suggest that dog red cells have a 
large latent capacity for Ca2+—Na+ ex­
change.
G. Gárdos
Action o f erythropoietin in vitro on rabbit 
reticulocyte membrane Ca-+-ATPase activity. 
W. D. Lawrence, P. J. Davis and S. D. Bias 
(Hematology and Endocrinology Divisions, 
Department of Medicine, State University 
of New York, Buffalo, N. Y. 14215, USA). 
J. d in . Invest. 80, 586 (1987).
The mechanism of action of erythropoie­
tin is thought to require specific interaction 
with the target cell surface and involve 
alteration of cellular calcium metabolism.
Using the rabbit reticulocyte membrane as a 
model of the immature red cell membrane, 
the in vitro the effects of human recombinant 
erythropoietin on membrane Ca2+-ATPase 
(calcium pump) activity were investigated. 
Erythropoietin in a concentration range of 
0.025 to 3.0 U/ml progressively decreased 
membrane Ca2+-ATPase activity by up to 
64% (P <  0.01). These concentrations have 
been shown by others to stimulate in vitro 
erythroid growth. The action of erythropoie­
tin on reticulocyte Ca2+-ATPase required an 
incubation time of 1 h before enzyme assay 
for maximum effect and was neutralized by 
antierythropoietin antiserum. Other nonhe- 
mopoietic growth factors (epidermal growth 
factor, insulin) had no effect in this assay. 
Ca2+-ATPase activity of membranes prepar­
ed from rabbit mature red blood cells was 
not inhibited by erythropoietin. The novel 
effect of erythropoietin on reticulocyte 
membrane Ca2+-ATPase activity is a mecha­
nism by which erythropoietin can influence 
cellular Ca2+ metabolism.
Ilma Szász
Conformational differences between the /., 
and E., states o f the calcium adenosinetri- 
phosphatase o f the erythrocyte plasma mem­
brane as revealed by circular dichroism and 
fluorescence spectroscopy. J. Krebs, M. Vasak, 
A. Scarpa and E. Carafoli (Laboratory of 
Biochemistry, Swiss Federal Institute of 
Technology, Zurich, Switzerland). Biochem­
istry 26, 3921 (1987).
Different conformational states of the 
purified plasma membrane Ca2+-ATPase 
from pig erythrocytes have been detected by 
circular dichroism (CD) and fluorescence 
spectroscopy. The helical content of the 
enzyme decreased by about 10% in the 
transition from the Ca2+ high-affinity form 
(10/(M free Ca2+ =  E L state) to the V043-- 
inhibited state (20 /iM V043_ =  E2 state). 
The changes in the CD spectra did not show 
full reversibility upon reversing the Et— E, 
transition, whereas those in the fluorescence 
spectra did. A temperature-dependent loss 
of «-helical content in the presence of Ca2+ 
was also observed. Intrinsic fluorescence 
measurements revealed an increase in
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fluorescence intensity upon addition of 
Ca2+. The change was fully reversed by 
ethylene glycol bis (/5-aminoethyl ether)- 
N,N,N’,N’-tetraacetic acid. The increase in 
fluorescence intensity was partly reversed by 
adding ATP, an effect which is suggested 
to correspond to the “Ca2+-occluded” form 
of the ATPase. The steady-state level of the 
fluorescence intensity was stable for several 
minutes in the presence of 100 ATP. 
By contrast, the decrease of fluorescence 
intensity induced by limiting concentrations 
of ATP(= I ,uM) was only transient, indicat­
ing the decomposition of the phosphorylated 
intermediate of the ATPase and the reestab­
lishment of the Ca2+ high-affinity form of 
the enzyme.
B. Sarkadi
Inhibitors o f inositol trisphosphate-induced 
Ca2+ release from isolated platelet membrane 
vesicles. S. M. Seiler, A. J. Arnold and H. C. 
Stanton (Department of Cardiovascular 
Biology, Bristol-Myers Pharmaceutical Di­
vision, Evansville, IN 47721, USA). Biochem. 
Pharmacol. 36, 3331 (1987).
Platelet membrane vesicles accumulated 
Ca2+ in an ATP-dependent fashion, and
25—50% of the accumulated Ca2+ was 
released by the addition of 10 inositol 
1,4,5-trisphosphate (IP3). The concentration 
of IP3 required for half-maximal Ca2+ 
release was approximately 0.5 /tM. The 
inhibition of lP3-induced Ca2+ release from 
these membrane vesicles by various agents 
was examined. On the plasma membrane 
Ca2+ channel blockers, cinnarizine and 
flunarizine were found to be potenti nhibitors 
of IP3-induced Ca2+ release while having 
no effect on ATP-dependent Ca2+ uptake. 
The IC50 value for both cinnarizine and 
flunarizine as inhibitors of IP3-induced Ca2+ 
release was below 10_6M. Nifedipine, 
verapamil, bepridil, and diltiazem did not 
significantly inhibit IP3-induced Ca2+ release 
at the highest concentration tested (50 /гМ). 
The “intracellular Ca2+ antagonists” ryano­
dine, TMB-8 (8-N,N-diethylamino)octyl-3,4,- 
5-trimethoxybenzoate), dantroline, trifluo­
perazine and chlorpromazine were not 
inhibitors of lP3-induced Ca2+ release at 
50 /íM. The local anesthetics benzocaine and 
lidocaine weakly inhibited the lP3-induced 
Ca2+-release with IC60 values of approxi­
mately 5 and 50 /(M, respectively, whereas 
other local anesthetics tested were less 
potent inhibitors. The potent inhibitors 
described may prove useful as probes of the 
IP3-induced Ca2+ release channels.
lima Szász
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Morphometry of Human Blood Leukocyte Ultrastructure: 
Its Potential Value in Haematology
R. J. Sokol,1* G. H udson,1 J. W ales,1 N. T. J ames2
Departments of 1 Haematology, and of 2 Anatomy and Cell Biology,
University of Sheffield, England
(Received 14 May, 1987; accepted 5 August, 1987)
A review of the literature on ultrastructural morphometry of human blood 
leukocytes has been carried out. It is concluded that: (1) Blood leukocytes are partic­
ularly suitable for morphometric study. (2) Morphometric methods have proved 
valuable in defining differing cytological features of cells in various lymphoid malig­
nancies, and in demonstrating ultrastructural differences (which could not otherwise 
have been detected) in monocytes and eosinophils corresponding to known functional 
changes. (3) Appropriate and valid numerical procedures are essential for determining 
morphometric equations and statistical probabilities; both morphometric measure­
ment and statistical analysis are made easier by the use of computers. (4) Ultrastructural 
morphometry should ultimately find an important place in clinical haematology.
Keywords: granulocytes, leukocytes, lymphocytes, monocytes, morphometry, 
stereology, ultrastructure
Introduction
Blood leukocytes are particularly suitable for morphometric study, as many 
of the normal limitations of these methods are minimized. A sample of blood 
cells is likely to be representative of the whole population and leukocytes are 
presented in random orientation; it is relatively easy to identify the cells to be 
studied and they are usually at a similar stage of maturity. It is therefore not 
surprising that in recent years there have been increasing numbers of morpho­
metric studies of human leukocyte ultrastructure in health and disease. However, 
the references are scattered throughout the literature. The extent of study of the 
different types of leukocyte varies widely and the minimal conditions for numerical 
validity have rarely been considered. It seemed important to review this work 
and to consider the use of appropriate numerical procedures, in order to highlight 
the potential value of the method in providing the haematologist with information 
not available from subjective assessment.
*To whom correspondence should be addressed: Regional Blood Transfusion Centre, 
Longley Lane, Sheffield, S5 7JN, England
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Lymphocytes
Considerable attention has been given to the ultrastructural morphometry 
of normal blood lymphocytes. In earlier studies, quantitative measurements on 
separated lymphocytes of normal subjects were obtained as a basis of comparison 
with those of lymphoid cells in malignant states [1] together with the changes 
they undergo in culture after phytohaemagglutinin (PHA) stimulation [2]. It has 
subsequently proved profitable to consider different lymphocyte subsets separately. 
A stereological model cell was described in relation to small T lymphocytes 
obtained after passing mononuclear blood cells through a nylon-wool column [3] 
and this enabled changes associated with their activation with PHA to be defined 
[4]. Differences between T and non-T lymphocytes have also been quantitated 
using cells separated by E-rosetting techniques. In a series of 6 healthy volunteers, 
the average T cell had a smaller cell volume and cell surface area, a lower nuclear 
euchromatin-heterochromatin volume ratio and a smaller volume and surface 
area of rough endoplasmic reticulum (RER) [5]. Statistically significant differences 
were reported between T and B cells (identified by Fab-peroxidase labelling) [6] 
but cells from only a single donor were studied. Morphometric studies of T cell 
subsets using monoclonal antibodies and fluorescent activated cell sorting [7] 
have shown that the T8+ suppressor/cytotoxic lymphocytes have larger cell 
volumes and surface areas, and a smaller nuclear : cytoplasmic (N: C) ratio than 
the T4+ helper/inducer cells. They also have a larger Golgi zone, a more extensive 
RER and mitochondrial component and a greater amount of heterogeneous 
granules. These differences may be the morphological counterpart of the differing 
functions of the two subsets.
In studies of patients with chronic lymphocytic leukaemia (CLL) [1, 8—11], 
the size of the circulating lymphocytes has been of particular interest. In these 
studies the mean volume of CLL cells was within the normal range [11] although 
a bimodal distribution into small and large cell types with mean sizes outside this 
range has been suggested [1] and mitogen-transformed CLL cells have been 
reported to be smaller than expected [12]. B cell types of CLL, as anticipated 
from the studies of normal cells, appear to have a more irregular plasma membrane 
(shown by relating the cell surface area to that of a sphere of equivalent volume) 
and a larger volume of RER than their T cell counterparts [11]. In hairy cell 
leukaemia, the cells have been shown to have volumes significantly greater than 
normal [1 ] and have the largest surface areas, the most irregular plasma membranes 
and the lowest N : C ratios amongst the chronic leukaemias and malignant lym­
phomas [11].
In prolymphocytic leukaemia, the cells may be distinguished from CLL cells 
by their larger volume, lower N  : C ratio and proportionately less heterochromatin 
[11]. They have also been reported to have a lower nuclear contour index (perim­
eter/ ]/ area) than normal [lymphocytes, with an increased number of mito­
chondrial profiles per section [13].
In B cell non-Hodgkin’s lymphomas (NHL), the circulating centrocytes
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may be distinguished from the cells of other B type malignancies by the high 
N :C  ratio, the high degree of nuclear irregularity and the lower amount of RER 
[11]. In Sézary syndrome, morphometric assessment of nuclear shape expressed 
as the nuclear contour index may be helpful in establishing the diagnosis [14].
Ultrastructural morphometry has also provided quantitative data on the 
circulating blasts of patients with acute lymphoblastic leukaemia (ALL) [15— 19], 
but here morphometry appears to be of less value as an aid to diagnosis and 
classification than in the more chronic states. When immunologically-defined sub­
sets of lymphocytes have been compared, no differences were found in respect of 
the volumes of the cell, nucleus, nucleolus or hetero- and eu-chromatin or in the 
surface areas of the cell and nucleus, although there was a greater volume of RER 
in the B-derived cells and a greater volume of dense granules in the T-cell types [19].
It may be noted here that morphometric analysis has also been applied to 
the study of lymphoid cells in other sites, and some of the ideas would be valid 
for application to blood cells. For example, assessments of nuclear contour index 
or nuclear “form factor” (4л x area/perimeter2) have been found useful in the 
diagnosis of T cell lymphomas involving lymph nodes [20] or skin [21, 22], 
especially when combined with immunohistochemistry [23]. Techniques for 
stereological study of RER were developed and applied to marrow myeloma 
cells in different immunological types of myelomatosis [24] while ultrastructural 
analysis of the RER of jejunal plasma cells showed increased RER length in 
coeliac patients [25]. Light microscopy preparations have sometimes proved ad­
equate for morphometric studies of lymphoid cells in the tissues. This has been 
particularly the case where changes in nuclear size and contour are helpful in 
diagnosis or classification. For example in sections of lymph node biopsies in 
non-FIodgkin’s lymphomas, good correlation has been reported between morpho­
metric findings and histopathological categories [26, 27], while in CLL, morpho­
metric analysis of nuclear area distribution curves by skewness coefficient was 
found to be useful in identifying patients with a poorer prognosis [28]. However, 
using imprint preparations of lymph nodes and other tissues, morphometry proved 
less valuable in classifying the cell type in individual cases of non-Hodgkin’s 
lymphoma, although significant differences were present between the centroblastic 
and B immunoblastic groups [29]. Smears of bone marrow cells have also been 
studied by these techniques in an effort to develop a computer-assisted method for 
classification of cells in ALL of childhood [30]. Such techniques seem both rapid 
and standardized and might give a meaningful prediction of survival.
Monocytes
While there is considerable evidence of dysfunction of mononuclear phago­
cytes in disease states [31], there has been no work until recently on the morpho­
metry of blood monocytes, although some basic morphometric data has been 
reported for leukaemic monoblasts [16, 17, 32]. In morphometric studies of blood
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monocytes carried out by us on 20 healthy subjects, 23 patients with Hodgkin’s 
disease and 12 with non-Hodgkin’s lymphoma [33, 34], 24 different measure­
ments were made. The results were examined by statistical procedures which 
included multivariate analysis and showed that the mitochondrial contribution to 
the cellular ultrastructure was significantly less in Hodgkin’s disease than in the 
other two groups, where a smaller total volume and surface area were found. 
This change appeared to be due to a reduction in the number of mitochondria 
(rather than their size). This finding, suggesting a reduced energy potential [35], 
would be consistent with previous studies which have shown decreased monocyte 
function in Hodgkin’s disease [36-38]. In the above morphometric studies [33, 
34], there were also significant changes in non-Hodgkin’s lymphoma, which 
implied the presence of larger, more leptochromatic nuclei. This would be con­
sistent with the nuclear changes present in skin window inflammatory macro­
phages in this condition [39]. The findings recall the diversity of functional 
changes which have been reported in monocytes in malignant disease presumably 
reflecting an interaction of factors of host and tumour origin [31]. The use of 
morphometric techniques should have an important place in detecting the presence 
of structural changes in monocytes in disease states.
Morphometric studies of macrophage development may also have important 
applications. Quantitative methods were recently used to measure changes taking 
place in normal human blood monocytes during suspension culture [40], and 
similar methods are currently being employed to see whether the pattern of 
differentiation is disturbed in malignant lymphoma. In a semiquantitative investi­
gation of cultured blood monocytes in childhood ALL [41 ], an arbitrarily defined 
cellular differentiation index suggested that there was impairment of morpho­
logical differentiation.
Granulocytes
A particular advantage of blood granulocytes is that they can be readily 
identified by their specific granules, thus permitting the use of sections where the 
nucleus is not present, and avoiding the need for correction for nuclear-biased 
sampling. Some basic morphometric data for neutrophils and eosinophils in 
healthy subjects have been reported [42-44]. In a recent morphometric study of 
circulating eosinophils in 18 healthy individuals, 24 different ultrastructural param­
eters were examined. No significant differences were found between the male 
and female subjects [45]. In unpublished observations, the same methods have 
been used to study the blood eosinophils of a patient with idiopathic hyper- 
eosinophilic syndrome and, applying appropriate multiple comparison procedures, 
some significant differences were found which could not have been determined 
on subjective analysis of the micrographs alone. The most important findings are 
summarized in Table 1. The cells in hyperéosinophilie syndrome were significantly 
larger and had a bigger surface area, the increase in surface area being much 
greater than would be expected from the increased cell volume. Increased numbers
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Table 1
Morphometric characteristics (mean values) of blood eosinophils
N o rm al
(45)
H yper-
eo s inoph ilic
S yndrom e
Whole cell
Volume (fl) 255 370*
Surface area (pm2) 228 330*
Excess surface membrane
(pm2) 34 81*
Nucleus
Volume (fl) 51 62
Surface area (ши2) 116 120
Mitochondria
Volume (fl) 4.4 6.9*
Surface area (шп2) 57 84*
Profiles/section 5.2 6.3*
Individual profile area (pm2) 0.11 0.13
Granules
Volume (fl) 43 30*
Surface area (ши2) 408 331*
Profiles/section 27 22*
Individual profile area (pm2) 0.20 0.16*
* Significant difference from normal.
of mitochondrial profiles were present whereas there were fewer granule profiles 
and these were of smaller size. The changes suggested premature activation of 
circulating eosinophils in hyperéosinophilie syndrome. The larger cell size and the 
excess surface membrane (evidence of enhanced surface membrane activity) would 
be consistent with this concept, while an increase in mitochondrial numbers is 
known to be a concomitant of enhanced metabolic activity [35]. These findings 
may be related to the presence of abnormal proportions of light density eosino­
phils with enhanced function which has previously been reported in hyper- 
eosinophilic syndrome [46, 47]. The presence of fewer granule profiles (Table 1) 
would be consistent with inappropriate degranulation. A morphometric analysis 
of human granulocyte degranulation in vitro [48] has shown that there is a selec­
tive loss of larger granules and this may account for the smaller size of the pro­
files here.
A few quantitative measurements have been made of granulocyte precursor 
cells (myeloblasts and promyelocytes) in acute leukaemias. There were significantly 
more granules and long endoplasmic reticulum in leukaemic myeloblasts when 
compared with normal myeloblasts [17] but the mitochondria were approximately 
equal in number and profile area [49]. Differences were also shown in the pattern
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of ultrastructural features in different “paraleukoblasts” in four forms of acute 
leukaemia [16]. In a recent study of six patients with acute myeloid leukaemia 
[50], planimetry was used to demonstrate differences in myeloperoxidase-deficient 
polymorphs in blood smears.
It is surprising that so few studies of granulocyte morphometry have been 
made in clinical states. Changes in cell size, nuclear segmentation and granule 
morphology are known to occur in both inherited and acquired conditions e.g. 
in Pelger — Huët anomaly, vitamin B12 deficiency, chronic granulocytic leukaemia 
and toxic states, and it seems likely that morphometry would provide valuable 
additional information in these conditions.
Numerical procedures
For quantitative studies, appropriate and valid procedures are required 
both to determine morphometric equations and to assess statistical probabilities. 
It is apparent from the literature reviewed above, that these requirements have 
not always been met. Textbooks of morphometry tend to concentrate on the 
morphometric equations and some discussion may therefore be useful in relation 
to the valid analysis of results and probabilities.
The validity of the analysis rests upon the use of unbiased estimators, and 
procedures theoretically derived for this purpose only yield unbiased results if all 
the statistical test assumptions have been fulfilled. Prior to statistical analysis, 
results expressed as percentages (e.g. mitochondrial volume fractions) may need 
to be transformed to ensure independence of variance to the mean ; the normality 
of distribution and homogeneity of variances should also be tested where appro­
priate; and ratios where numerator and denominator both vary as normal distribu­
tions should be excluded (as these generate Cauchy distributions which do not 
have finite means and variances, thus invalidating common sampling assumptions).
Statistical tests such as the Student-? test are only valid provided certain 
a priori conditions are met (as mentioned above) and single comparisons are to 
be made. Where more than one comparison is to be carried out, multiple com­
parison procedures are essential to avoid false conclusions regarding significant 
changes. Such procedures include the Dunn —Sidak procedure [51] and Multi­
variate Analysis [52 — 54]. The Dunn—Sidak procedure makes use of the fact 
that the overall significance level (S) for comparing a number of parameters (K), 
at the individual significance level of a, is given by the Bonferroni relation:
S = 1 -  (1 -  a)K
The individual significance levels (a) are determined from this relation, after 
setting the desired overall significance level (S). For example in a recent study of 
eosinophil granulocytes [45] where 13 independent parameters were being com­
pared in 9 male and 9 female subjects, individual significance levels (a) had to
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be set at 0.002 to give an overall significance level (S) of <0.05. Similarly when 
adequate sample size is being calculated for a morphometric study where multiple 
comparisons are to be made, the Bonferroni relation should be used to determine 
the individual significance levels in the calculations.
Both Univariate and Multivariate Analysis of Variance (ANOVA and 
MANOVA) are applicable when comparing several parameters in the presence 
of a number of other variables. Each has a different role. For example, ANOVA 
was suitable for a morphometric study of human macrophage development in 
vitro where 9 cell measurements were individually studied at 4 time intervals [40] 
while MANOVA was required for a morphometric study of blood monocytes 
where properties of the cell, cytoplasm, nucleus, intranuclear chromatin and 
mitochondria were simultaneously analysed for three data sets, i.e. normal, 
Hodgkin’s disease and non-Hodgkin’s lymphoma, allowing full comparisons to 
be made between the sets (normal v Hodgkin’s disease; normal v non-Hodgkin’s 
lymphoma; and Hodgkin’s v non-Hodgkin’s lymphoma) [34].
The increasing availability of modern computers upon which sophisticated 
statistical packages can be implemented, has made the application of valid numeri­
cal procedures much easier. However, it must be emphasized that all the test 
assumptions pertinent to the particular package must be met if valid conclusions 
are to be drawn.
Summary and Conclusions
Morphometry of peripheral blood leucocytes has led to clearer definition of 
the characteristics of different cell types and hence a greater understanding of the 
ultrastructural changes associated with disease states. In particular, the distinctive 
features of different types of circulating lymphocyte and the T cell subsets have 
been quantitated, and it has been possible to define the differing cytological 
features of cells in chronic lymphocytic, hairy cell and prolymphocytic leukaemias, 
and in Sézary syndrome and non-Hodgkin’s lymphoma. With regard to blood 
monocytes, subtle ultrastructural changes have been demonstrated which cor­
respond to known functional defects in malignant lymphoma, and the study of 
defective monocyte differentiation in vitro appears promising. Surprisingly few 
morphometric studies of granulocytes have been made, but cellular changes have 
been defined in the circulating eosinophils of hyperéosinophilie syndrome and in 
the blast cells of acute myeloid leukaemia.
The importance of using valid statistical procedures for the analysis of 
results has been emphasised. Population variances and normality of distribution 
must be taken into account and multiple comparison procedures are often essential.
Blood leukocytes are particularly well-suited to morphometric study and 
the increasing use of computers makes both morphometric measurement and the 
analysis of results much easier. While the application of quantitative methods is 
still mostly at the research stage in characterising leukocyte changes in disease, 
they will ultimately find a place in everyday haematological practice.
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Appendix
iStandard evaluation procedures and statistical methods used 
in the authors’ work
All studies are made on cells in random orientation, samples being collected 
and processed for electron microscopy by identical methods. Cells are selected 
for examination in an independent uniform random manner, the magnification of 
each micrograph being obtained by reference to a test graticule. For morphometric 
analysis, micrographs are covered by a transparent test grid bearing a rectangular 
lattice of known spacing, and point and intersect counting made on the features 
to be studied. Areal fractions (numerical equivalent to volume fractions) and 
surface-to-volume ratios are calculated from conventional formulae, compensating 
for non-equatorial sectioning and (where appropriate) for nuclear-biased sampling 
[33]. Adequacy of sample size is verified by ensuring that relative standard errors 
do not exceed 0.05 [45]. (In particular circumstances, pattern analysis is also used 
to estimate the distribution and relathe amounts of nuclear heterochromatin and 
euchromatin [33, 34]). The raw data are tested for normality and equality of 
variances and when these are not shown, the data are logarithmically transformed 
for the subsequent analysis [40]. Statistical analysis is only carried out on the 
measurements which are considered to be independent of one another [40]. The 
method used depends on the design of the particular investigation. We are cur­
rently using a SPSS-X statistical package run on a main-frame computer to carry 
out both multivariate and univariate analysis of variance in an investigation of 
macrophage development in malignant lymphoma where data for 9 parameters 
are being analysed at 5 culture intervals in 3 subject groups and the effects of 
age, sex, cellular immune status, histological type and disease stage taken into 
account. Other examples of less complexity are given in the section on ‘numerical 
procedures’ above.
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This article reviews the progress achieved in the field of inducing differentiation 
in human myeloid leukaemia in vitro and the need for applying this model in leukaemia 
therapy in vivo. The pre-clinical evaluation of differentiating agents in human myeloid 
leukaemia is analysed. The clinical experience with differentiation induction therapy 
in acute myeloid leukaemia is reviewed. This review examines the prospective applica­
tion of this new form of therapy in patients with acute myeloid leukaemia.
Keywords: chemotherapy, differentiation, monoblastic leukaemia, myeloblastic 
leukaemia
Introduction
The prevailing dogma of the 1950s and 1960s was “once a cancer cell, always 
a cancer cell” [1]. Studies of differentiation of cancer cells were not particularly 
encouraged at that time [2]. In the mid 1960s, an intensive study began of peptide 
growth factors (colony stimulating) and small effectors that could induce differen­
tiation of myeloid and erythroid leukaemia cells [3]. This approach has had a 
major impact in leukaemia research [4]. The important discovery in 1971 that 
dimethilsulfoxide (DMSO) induced erythroid differentiation in the Friend murine 
erythroleukaemia cells (FMEL) led to a decade of intense research on the small 
effector molecules [5 — 9]. This research has been directed towards identifying 
new inducers and helping to understand the biological and biochemical mechan­
isms involved in the induction of differentiation in leukaemic cells. Since then, 
the list of inducing agents has been greatly extended (Table 1). Human acute 
myeloid leukaemia (AML) arises from a neoplastic transformation at the pluri­
potent stem cell level, leading to a block in cell maturation at the recognizable 
stage of myeloblast or promyelocyte [10, 11]. The leukaemic blasts are unable 
to mature to functional end cells, they remain in the proliferative pool and rapidly 
accumulate [12]. It seems likely that leukaemic cells fail to differentiate because 
of an alteration of specific genes or their products that are obligatory for differ­
entiation. Another possibility may be a disturbed cellular mechanism that is 
normally required for a response to exogenous differentiating factors. Extensive
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Table 1
Inducers of human myeloid leukaemic cells differentiation in culture
D ifferen ta tion  in d u c e r C o n ce n tra tio n T a rg e t cells M a tu re  cells R eferences
I-Polar-Plarter Compounds
Dimethylsulphoxide (DMSO) 1.25% HL-60 & 
fresh AML
Granulocytes 21-25
Dimethylformamide (DMF) 6 0 - 100 mM HL-60 Granulocytes 22, 25, 26
N-methylacetamide 20 mM HL-60 Granulocytes 22, 25, 26
N-methylformamide 150-180 mM HL-60 Granulocytes 22, 25, 26
l-methyl-2-piperidone 4 mM HL-60 Granulocytes 22, 25, 26
Piperidone 37.5 mM HL-60 Granulocytes 22, 25, 26
Butyric acid
Hexamethylene bisacetamide
0.06 mM HL-60 & 
fresh AML
Granulocytes 21, 23, 
26, 27
(HMBA) 2 -  5 mM HL-60 Granulocytes 21, 22, 
24, 26
Diethylacetamide 10 mM HL-60 Granulocytes 26
N-ethylformamide 100 mM HL-60 Granulocytes 26
II-Vitamins Analogues :
Retinoic acid 1 /(M HL-60 & 
fresh AML
Granulocytes 23, 24, 
28, 29, 
30, 31
1,25-dihydroxyvitamin D3 
Ill-Cytotoxic Drugs :
1 /<M HL-60 & 
fresh AML
Macrophages 32-36
Nucleosides
Cytosine arabinoside (Ara-C) 2 /<M HL-60 & 
fresh AML
Monocytes 22, 24, 
37, 38, 
39, 40, 
41
5-azacytidine 1 fiM HL-60 & 
fresh AML
Both 38, 42, 43
2-deoxy-5-azacytidine
2-B-D-ribofuranosyl-selen-
1 pM HL-60 & 
fresh AML
Both 38, 42, 43
azole-4-carboxamide 2 pM HL-60 Both 39, 44
Anthracyclines
Daunomycin
I
25 ng/ml HL-60 Granulocytes 21, 32, 
39, 45, 
46
Mitomycin C 2 0 - 40 nM HL-60 Granulocytes 31, 45, 46
Aclacinomycin A 8 M HL-60 Granulocytes 24, 46
Actinomycin D 5 ng/ml HL-60 & 
fresh AML
Granulocytes 24, 39, 46
Methotrexate 10 nM HL-60 Granulocytes 31, 38
6-thioguanine 1.5 /4M HL-60 Granulocytes 21
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Table I (continued)
D if ferent ia t ion  inducer C o n ce n tra t io n T arg e t  cells M a tu r e  cells References
Homo-harringtonine 0.01 jUg/ml HL-60 & 
fresh AML
Monocytes 47
Hydroxyurea 8 jug/ml HL-60 Granulocytes 2 1 ,  2 2
Vincrinstine 5 ng/ml HL-60 Granulocytes 2 1 ,  2 2
Bromodeoxy-uridine 
V-Phorbol Esters & 
Teleocidin :
3 fig/ml HL-60 Granulocytes 45, 48
Phortol myristate acetate
(PMA) 16 nM HL-60 &
fresh AML
Macrophages 21, 23, 
24, 30, 
49, 50, 
51, 52, 
53
Teleocidin 50 nM HL-60 Macrophages 51, 53
V-Lymphokines & Cytokines:
Alpha-A-interferon 5.000 U/ml HL-60 Monocytes 54, 55
Alpha-D-interferon 1,000 U/ml HL-60 Monocytes 54 ,  55
Gamma interferon 
VI-Others
1,000 U/ml HL-60 Macrophages 36, 54, 
55, 56, 
57
Alkyllysophospholipids 1 fig/ml HL-60 Both 23, 58
Glycosphingolipid (GM3) 50 nmol/ml HL-60 Monocytes 59
Tunicamycin 0.5 pg/ml HL-60 Granulocytes 60
Calmodulin antagonists 1 -5  mM HL-60 Granulocytes 61
Azobenzene carboxylic acids 5 fiM HL-60 Granulocytes 62
Stilbenecarboxylic acids 5 /(M HL-60 Granulocytes 2
Phenylcarbamoylbenzoic acid NR* HL-60 Granulocytes 63
Polyeneamides NR HL-60 Granulocytes 63
Arphamenine A 100 /rg/ml HL-60 Granulocytes 64
Forphenicine 10 /rg/ml HL-60 Granulocytes 64
* N R=not reported
reports of inducing differentiation in leukaemic cells clearly demonstrate that the 
maturation block is reversible [13]. The arrest of cell proliferation by induction 
of differentiation to mature cells bypasses the genetic changes which cause malig­
nancy, thus, by inducing differentiation, the multiplication of cells is stopped. 
This phenomenon has changed our ideas on the treatment of acute leukaemias 
[14—17]. An alternative approach to the conventional cytotoxic therapy would 
be to use differentiating agents capable of inducing a terminal differentiation of 
leukaemic cells to mature forms with no further proliferative potential [18]. It is 
anticipated that this differentiation induction therapy could be applied using drug
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doses lower than those required for successful cytotoxic therapy. Therefore, the 
induction of differentiation would be of therapeutic value both in reducing the 
body burden of leukaemic cells and in minimizing the major toxicities caused by 
conventional cytotoxic therapy [19].
The management of acute myeloid leukaemia (AML), in spite of the appreci­
able progress since the early 1960s, has failed to achieve results similar to those 
in childhood acute lymphoblastic leukaemia. Although the medium survival time 
for those who achieve a remission is now about 2 years, the majority of patients 
with AML still die within 18 months of diagnosis [20]. This supports the applica­
tion of a new differentiation induction therapy in AML, which at the very least 
may represent a way to achieve the same limited results of our current cytotoxic 
therapies with much less distress to the patient.
Pre-Clinieal Evaluation of Myeloid Leukaemia Differentiation Inducers
Two leukaemic cell lines: the Friend murine erythroleukaemia virus-induced 
cell line (FMEL) and the human acute promyelocytic leukaemia cell line (HL-60) 
were extensively studied. When exposed to many differentiating agents in vitro, 
both (FMEL) and (F1L-60) cell lines lose their proliferative capacity and develop 
the morphological, biochemical and functional characteristics of their mature 
counterparts. Both cell lines are at a more mature developmental stage than the 
typical acute leukaemia cells and may, in fact, be primed to differentiation. There­
fore caution is necessary when extrapolating results from these models for possible 
future clinical trials with differentiating agents. Also, these cell lines represent a 
single population of leukaemic cells, while fresh myeloid leukaemic cells from 
patients are a heterogenous group of malignant cells [65]. Thus, a pre-clinical 
screening of the response of fresh human leukaemic cells in primary culture from 
patients with AML towards various differentiating agents might provide a basis 
for an in vivo clinical application. Only few studies with fresh human myeloid 
leukaemic cells from patients in primary culture have been reported.
In the proposed clinical trials with differentiating agents, a terminal differ­
entiation of the leukaemic cells should be achieved, i.e. almost all leukaemic 
cells mature with no residual blasts. In order to overcome the maturation arrest, 
treatment of the leukaemic cells with a selective combination of differentiating 
agents is one of the possibilities. Recently some reports suggested the usefulness 
of this method [66, 67, 68]. A pre-clinical screening of the response of fresh human 
leukaemic cells from patients with AML in primary culture using several combina­
tions of chemotherapeutic agents would be of great interest in supporting the 
use of maturation induction as an alternative to current anti-leukaemic therapy.
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Clinical Trials: Experience and Prospects
Many clinical studies applying the differentiation induction therapy in 
patients with acute myeloid leukaemia have been published either as anecdotal 
case reports, or as an abstract and/or small clinical trial. These patients were in 
relapse, either refractory to the conventional cytotoxic treatment or very old 
(age >  70), or cytotoxic therapy was contraindicated (e.g. hypoplastic bone 
marrow) [69 — 98].
Cytosine arabinoside (Ara-C), the drug of choice in the treatment of AML 
has been used in a subcytotoxic low doses. 60% of patients achieved a complete 
remission. The attractiveness of low doses of Ara-C in terms of minimal toxic 
side effects and potential use as an outpatient form of treatment guarantees 
continued drug trials. Two patients with acute promyelocytic leukaemia (APL) 
were treated with 13-cis retinoic acid: one achieved complete remission and one 
showed partial remission. Daily and intermittent administration of aclacino- 
mycin-A in low noncytotoxic doses achieved a complete remission in a patient 
with AML. On the other hand, sodium butyrate failed to achieve any remission 
in 8 patients and showed only a partial remission in a child with refractory AML. 
This disappointing result of butyrate therapy is due to the fact that the concen­
trations known to be effective in vitro (600 juM) cannot be given in vivo because 
of their toxicity. The same problem arises with other polar-planar compounds 
such as dimethylsulphoxide (DMSO) and dimethylformamide (DMF). It is obvious 
that these compounds are in the early stage of de\elcpment as drugs and caution 
is needed when using them in clinical trials.
In two studies, 6 patients were treated with a differentiating agent in com­
bination with chemotherapeutic agents, biological response modifiers and/or other 
inducers. Alpha-interferon in combination with cimetidine resulted in a complete 
remission in an elderly female patient with AML. Five patients were treated with 
a combination of 13-cis retinoic acid and 1,25 dihydroxy-vitamin D3 in addition 
to alpha-interferon and/or low dose cytosine arabinoside (Ara-C). 60% of patients 
achieved a complete remission. The evaluation of this form of combination therapy 
should be performed in larger randomized clinical trials.
Results from these limited clinical studies showed a complete remission in 
60% of patients. The patients with AML who seem most likely to benefit from 
this differentiation induction therapy are:
a) those aged 60 or more
b) those in a relapse and refractory to conventional cytotoxic therapy
c) those in whom cytotoxic therapy is contraindicated, e.g. hypoplastic.
Further larger, controlled clinical trials based on differentiation induction
therapy for the above listed AML patients are necessary for introducing this 
type of therapy.
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Role of Actin Polymerization in 
Monocyte Phagocytosis of Yeast Cells 
Effect of Cytochalasin B
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The role of the cortical actomyosin-like contractile system in monocyte phago­
cytosis was studied by means of inhibition with cytochalasin B. Monocyte phagocytosis 
of yeast cells was assayed with a fluorescence extinction technique of surface-located 
phagocytosis which distinguishes between adherence and ingestion phases of total 
phagocytosis. Cytochalasin B, 10 ,itg/ml, inhibited monocyte phagocytosis by 20-30%. 
The cytochalasin inhibition was significant and restricted to the ingestion phase. The 
finding supported the hypothesis that the contractile structures of the cell have a 
contributory role in IgG-mediated monocyte phagocytosis on a surface. It is suggested 
that the cytochalasin effect reflected the role of chemotaxis in monocyte phagocytosis 
assayed by the present technique.
Keywords: monocyte, phagocytosis, motility, cytochalasin B
Leucocyte phagocytosis as a part of the host defence against infections is 
a complex process comprising leucocyte adherence to the vascular endothelium, 
locomotion through tissues, attachment (adherence) to invading microorganisms, 
followed by engulfment and lysis of the microorganisms. It should be emphasized 
that a supporting surface appears to be essential for the mentioned activities of the 
leucocyte [1, 2].
Most tests of leucocyte phagocytosis elucidate only one or a few of the 
partial processes occurring in vivo. A comparatively complete and simple method 
was introduced by Hed [3] for the study of neutrophil phagocytosis. He confined 
phagocytosis to a glass surface with scattered neutrophils and an excess of yeast 
cells. The initial gripping of yeast cells (adherence) was discriminated from com­
pleted engulfment of yeast cells by a fluorescence quenching technique. This 
technique measures a combination of neutrophil chemotaxis, adherence and 
engulfment of target cells. Unfortunately, only the adherence step and the engulf­
ment step can be assessed directly.
We have adopted the Hed technique for the study of monocyte phagocytosis 
[4]. To our knowledge, the role of chemotaxis in monocyte phagocytosis measured 
by this technique has hitherto not been analysed quantitatively. The aim of the
* To whom correspondence should be addressed
VSP U trecht, T okyo  
A kadém iai K iadó, Budapest
152 L. Athlin et al.: Cytochalasin B and monocyte phagocytosis
present study was to quantitate this role by inhibition of the contractile structures 
of the monocytes with cytochalasin B (CB). The experiment was thus designed 
with one CB concentration subinhibitory for leucocyte locomotion, 1 //g/ml, and 
one CB concentration completely inhibitory, 10 pg/ml [5, 6, 7].
Material and Methods
Preparation o f yeast cell suspension
Baker’s >east (Saccharomyces cerevisiae) was suspended in saline, washed 
twice, boiled 30 min, washed twice, and labelled with FITC in a carbonate buffer, 
pH 10.2, 108 cells per ml of FITC buffer with a FITC concentration of 0.1 mg/ml 
for 60 min at +37 °C. The cells were washed three times with saline, re-diluted 
to 108 cells per ml, and frozen at —17 °C in 0.5 ml aliquots. Before the experi­
ment, the FITC-labelled yeast cells were opsonized with heat-inactivated human 
serum which had been stored at —70 °C for less than two weeks. Serum, 0.5 ml, 
was mixed with 0.5 ml of the FITC-labelled yeast cells, and the mixture was 
incubated at +37 °C for 30 min. The cell suspension was then washed twice and 
resuspended in 2 ml of saline.
Complete medium
The complete medium consisted of human serum, 165 ml, L-glutamine 
20 mM, 7 ml, Ham’s F 10 medium 500 ml (Flow Laboratories, Irvine, Ayershire, 
Scotland), amphotericin B 1.7 //g/ml, streptomycin 4 //g/ml, and benzylpenicillin 
2.4 //g/ml.
General experimental conditions
The monocyte migration (chemotaxis) over the glass surface toward the 
yeast cell could not be measured separately in the assay. Yeast cell adherence to 
the monocyte was defined as visible membrane contact between a brown yeast 
cell and a monocyte. Yeast cell engulfment by a monocyte was defined as the 
presence of a fluorescent yeast cell within a monocyte. Adherence and engulfment 
together made up the total phagocytosis. The distance between the yeast cells on 
the slide was estimated to be 20 — 50 pm, but the yeast cells often lay in clusters. 
The distance between monocytes was estimated to be 100 — 500 //m. The number 
of ingested yeast cells per monocyte ranged from 0 -  12. An excess of non-phago- 
cytosed yeast cells remained in the preparation after stopping phagocytosis.
Blood sampling
Heparinized blood, 16 IU/ml, was obtained from healthy blood donors 
from the Blood Transfusion Centre of the hospital.
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Isolation o f mononuclear leucocytes
Mononuclear leucocytes(L-MNs) were isolated from peripheral blood by 
the one-step metrizoate-Ficoll procedure described by Boyurn 1968 [8], using 
Lymphoprep® (Nyegaard, Oslo, Norway). The L-MNs were then washed twice 
in “complete medium” and resuspended to a concentration of 5 x 106 cells per ml.
Incubation for monocyte adherence to the glass surface
L-MNs, I x 106 cells in 200 //1 complete medium, were then seeded on 
sterile slides in Petri dishes and incubated in a humidified chamber with 5 % C 0 2 
at 37 °C for 30 min to allow the monocytes to adhere to the glass surface. For the 
removal of lymphocytes from the preparation, the slides were then rinsed with 
pre-warmed complete medium at 37 °C.
Table 1
The effect of cytochalasin B on adherence, engulfment, and total phagocytosis of yeast cells 
by monocytes. D: cell donor. S: sex. Cl : control cells without DMSO. C2: control cells with 
DMSO 0.25% v/v. T1 : test cells with cytochalasin B1 /tg/ml. T2: test cells with cytochalasin 
BIO /Ig/ml. x: arithmetic mean. Q, — Q3: interquartile range. Figures denote number of yeast
cells associated with 50 monocytes
A dherence
D s
C l C2 T1 T2
i f 39 15 12 12 27
2 f 43 27 15 27 14
3 f 26 14 32 17 13
4 f 43 11 33 11 12
5 m 33 18 7 13 15
6 m 33 16 14 7 8
7 m 25 15 12 24 28
8 m 54 18 15 12 8
9 m 60 15 17 6 21
10 m 25 19 21 9 17
11 m 64 29 6 11 15
12 m 59 44 26 36 36
13 f 40 8 12 20 15
14 m 39 9 24 17 17
15 m 32 12 36 29 24
16 m 50 31 12 9 17
17 m 52 26 7 11 2
18 f 21 42 19 40 25
X 41 21 18 17 17
Median 40 17 15 13 16
Q i- Q;j 31-53 14-28 12-25 11-25 13-25
Range 21 — 64 8 -44 6-36 6-40 2 -3 6
Significance p =  0.478
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Table 1 (continued)
D s Engulfmen t
C l C2 T1 T2
l f 39 125 141 95 87
2 f 43 63 8 6 118 83
3 f 26 91 113 46 99
4 f 43 85 8 8 85 79
5 m 33 84 82 63 59
6 m 33 85 79 64 91
7 m 25 115 112 95 43
8 m 54 67 96 95 6 6
9 m 60 90 72 100 60
10 m 25 121 109 99 39
11 m 64 100 106 131 122
12 m 59 67 57 99 49
13 t 40 117 127 94 68
14 m 39 144 141 103 111
15 m 32 89 60 94 55
16 m 50 97 115 115 59
17 m 52 43 43 65 36
18 f 21 70 123 126 79
X 41 92 97 94 71
Median 40 90 101 95 67
Q, - Q3 31-53 69-116 7 7 - 117 80-106 54-88
Range 21-64 4 3 - 144 4 3 - 141 46-131 36-122
Significance p =  0.003
p =  0.840
Cytochalasin B and DMSO
Cytochalasin B (Sigma, St. Louis, Mo., USA) was dissolved in dimethyl- 
sulphoxide (DMSO, Sigma), 4 mg/ml and stored at -2 0  °C. Prior to the experi­
ment, cytochalasin B was diluted in phosphate buffer, pH 7.4, and added to the 
test solutions to final concentrations of 1 and 10 /ig/ml (2 and 20 x 10-6 M). The 
corresponding DMSO concentrations were 0.025 and 0.25% v/v. Thus, a control 
of the DMSO effect was introduced (C2, DMSO 0.25%, Table 1).
Pre-incubation with cytochalasin B
Control slides were again incubated in complete medium for 30 min at 
+ 37 °C in 5% C 0 2 in humidified chambers. Test slides were incubated likewise 
with cytochalasin B, 1 or 10 /rg/ml.
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Table 1 (continued)
D s Phagocytosis
Cl C2 T1 T2
l f 39 140 153 107 114
2 f 43 90 101 145 97
3 f 26 105 145 63 112
4 f 43 96 121 96 91
5 m 33 102 89 76 74
6 m 33 101 93 71 99
7 m 25 130 124 119 71
8 m 54 85 121 107 74
9 m 60 105 89 106 81
10 m 25 140 130 108 56
11 m 64 129 112 142 137
12 m 59 111 83 135 85
13 f 40 125 139 114 83
14 m 39 153 165 120 128
15 m 32 101 96 123 79
16 m 50 128 127 124 76
17 m 52 69 50 76 38
18 t 21 112 142 166 104
X 41 112 1 16 111 89
Median 40 108 121 1 1 1 84
Q, - 0:, 31-53 100-129 92-140 91-127 74-106
Range 21-64 69- 153 50-165 6 3 - 166 38-137
Significance p =  0.004
P =  0.765
Phagocytosis experiments
Yeast cells labelled with fluorescein isothiocyanate, FITC (Merck, Darm­
stadt, FRG), and opsonized with human serum were added to control slides and 
test slides, 2.5 x 107 yeast cells in 200 g\ saline. The yeast cell suspension added 
to the test slides contained cytochalasin B, 1 or 10 /ig/ml. Incubation was per­
formed for 30 min at + 37 °C in 5 % C 0 2. The phagocytosis was stopped by dipping 
the slides in ice-cold saline. The fluorescence of non-ingested yeast cells was then 
quenched by dripping crystal violet in saline (Merck, Darmstadt, FRG), 0.5 mg/ml, 
onto the slides. The staining time was 10 s. The stain was decanted and the prep­
aration was sealed with a coverslip. Monocyte-adherent yeast cells (brown) and 
ingested yeast cells (fluorescent) were then counted in 50 consecutive monocytes 
at 320 x magnification with a Zeiss incident-light microscope. Control and test 
samples from a cell donor (N = 18) were run simultaneously (Table 1, Fig. 1).
Glassware
The glassware was thoroughly washed, rinsed in demineralized water and 
70% ethanol, and autoclaved at + 120°C for 20 min.
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Fig. 1. Cytochalasin B influence on yeast cell adherence to monocytes, monocyte enguifment 
of yeast cells, and total phagocytosis (the sum of adherence and enguifment). Data from 
18 cell donors (Table 1). Median (O), interquartiles (—) and extreme values (arrows). Cl: 
control without DMSO. C2: control with DMSO 0.25%. T1 : cytochalasin B 1 /tg/ml, T2:
cytochalasin B lO^g/ml
Statistics
The Friedman two-way analysis of variance was calculated according to 
Siegel 1956 [9]. The basic figures were provided by the numbers of yeast cells 
associated with 50 monocytes.
Results
The basic data are shown in Table 1 with a graphical representation of 
central tendencies and dispersion of individual values in Fig. 1.
Cytochalasin B, which has low water solubility, had to be dissolved in 
DMSO, maximum final concentration 0.25% v/v. This DMSO concentration did 
not affect monocyte phagocytosis significantly (Fig. 1, Table 1).
The data of Table 1 suggest that cytochalasin B, 10 /rg/ml, inhibited mono­
cyte phagocytosis of yeast cells significantly to 20 — 30%. The cytochalasin B 
inhibition of monocyte phagocytosis was confined to the enguifment process. 
Adherence was unaffected. Cytochalasin B, 1 /rg/'ml, had no effect on the different 
steps of total monocyte phagocytosis.
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Discussion
The main finding of the present study was that cytochalasin B, 10 /tg/ml, 
inhibited the ingestion phase of monocyte phagocytosis by 20 — 30% (Table 1, 
Fig. 1). It is reasonable to assume that this inhibition reflects the relative impor­
tance of cell locomotion in monocyte phagocytosis measured by the present assay, 
since leucocyte locomotion was reported to be arrested by such CB concentra­
tions [5, 6, 7].
The present findings are in agreement with previous results on neutrophil 
phagocytosis using the same technique [10] and on monocyte phagocytosis using 
other techniques [6, 11 ]. However, methods are reported in which cytochalasin B 
appeared not to inhibit macrophage phagocytosis [12].
Cytochalasin B is used extensively as a probe for actin polymerization due 
to its ability to cap the fast-growing barbed end of the fibrous actin molecule [13]. 
The various cytochalasins (from Greek chalasis, relaxation) were initially thought 
to interfere with cell locomotion and the cytoplasmic cleavage of cell division by 
paralysis of contractile processes [14]. Further investigations showed, however, 
that the presence of cytochalasin B in the cell medium induced a cell contraction 
[5, 6, 7, 15], which was reversible only after CB removal.
In addition to interference with the “relaxation” phase of contractile pro­
cesses by actin capping, cytochalasin B is reported to be a potent inhibitor of 
hexose influx into the cells [5, 6]. Control experiments suggested, however, that 
the CB inhibition of leucocyte phagocytosis could not be explained by CB inhibi­
tion of hexose uptake [5, 6].
The above-mentioned observations are compatible with the view that the 
variable CB effects on leucocyte phagocytosis, reports range from 0 — 99% [6, 12], 
reflect the relative importance of leucocyte locomotion in different experimental 
settings.
Like cytochalasin B, the main microtubule antagonists suppress monocyte 
phagocytosis by 20 — 30% when measured by the present technique [4, 16, 17]. 
The observed effect of cytochalasin B and microtubule antagonists is consistent 
with the hypothesis that actin kinetics and microtubule kinetics play a contrib­
utory role in the contractile events of IgG-mediated phagocytosis (cf. 10, 18).
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Changes of Contact Phase Proteins 
During Haemodialysis
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Functional and immunological activities of factors XII and XI, Prekallikrein, 
high molecular weight kininogen and C-l-esterase inhibitor were studied in eight 
patients before, during and after haemodialysis. During and after dialysis sessions 
a significant decrease in the functional activities of Prekallikrein and high molecular 
weight kininogen (p <  0.05) could be detected, whereas their immunological levels 
did not change. Furthermore C-l-esterase inhibitor increased after dialysis (p <  0.05). 
These results indicate activation of the kinin system during haemodialysis.
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Haematologia 21 (3), pp. 159— 162 ( 1988)
Introduction
The contact of blood with certain surfaces is the triggering mechanism of a 
set of enzymatic reactions involving different systems such as blood coagulation, 
complement, the fibrinolytic pathway and the kinin system [1 ]. During haemodial­
ysis, blood is in contact with foreign surfaces, and the data regarding a possible 
activation of the kallikrein-kinin system in such circumstances are contradictory 
[2, 3, 4]. Kinins are generated through the enzymatic cleavage of kininogens by 
kallikrein, and the activity is induced by its precursor, prekallikrein (PK) by the 
action of activated Hageman factor (FXII) [5].
The present study was undertaken to investigate the potential changes in 
the functional and immunologic activities of plasma proteins, such as factors XII 
and XI, PK, high molecular weight kininogen (HMWKg) and C-l-esterase inhibi­
tor (C-1-1NH), all of them involved in the plasma contact activation system, in 
patients submitted to haemodialysis.
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Materials and methods
Patients and haemodialysis sessions
Our study included eight patients (females and males: age range 19-78 
years, mean 58) who were attending the renal unit of the University Hospital. 
According to conventional clinical, radiological and histological criteria, chronic 
glomerulonephritis was diagnosed in all patients. The coagulation screening test 
(prothrombin time, activated partial thromboplastin time and thrombin time) 
were normal before the onset of our study (data not shown). The patients were 
on regular haemodialysis (12 hours per square meter per week over three sessions 
per week). Each dialysis session lasted approximately 4 hours. Dialyses were per­
formed using hollow fiber cartridges. The blood flow rate was over 300 ml per 
minute, and the water flow rate was 500 ml per minute. Intravenous heparin was 
given at a loading dose of 2500 U followed by 1000 U hourly to maintain an 
adequate anticoagulation status throughout dialysis. This dose of heparin was 
sufficient to obtain a recalcification time between 2.5 and 3.5 fold the control 
value throughout the dialysis session. None of these patients had hypotension or 
any other complications during dialysis. All patients were aware of the nature and 
purpose of the study, and all gave informed consent according to the Declaration 
of Helsinki.
Blood samples
Whole blood samples were taken before the onset of haemodialysis, 2 hours 
after and immediately after termination of the sessions. The blood samples were 
mixed with 0.13 M sodium citrate at a 9:1 volume ratio and platelet-poor plasma 
was obtained as previously reported [6]. The samples were stored at —80 °C until 
use. Pooled normal plasma was similarly prepared from 20 normal donors.
Coagulation assays
Procoagulant activities of factors XI, XII and HMWKg were assayed in a 
one-stage test using platelet-poor plasma as substrate obtained from patients 
congenitally deficient in the respective factors (supplied by Behringwerke, Marburg 
A. G., FRG) as reported previously [6]. HMWKg-deficient plasma was obtained 
from a patient with a congenital Fitzgerald trait previously reported [6]. 
The enzymatic activity of PK was measured using the synthetic chromogenic 
substrate S-2302 (Kabi Vitrum, Stockholm, Sweden) as described [7].
Quantitative immunological determinations of HMWKg, Pk and C-l-INH 
were determined by electroimmunoassay as previously reported [6]. Antisera 
were obtained from Nordic Faboratories (Tilburg, The Netherlands) except the 
C-l-INH antibody which was purchased from Behringwerke (Marburg A. G., 
FRG).
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Statistical analysis
Results are expressed tas mean values ± SEM. The plasma parameters 
obtained before, during and after dialysis were compared by Student’s /-test for 
paired data.
Results
Table 1 shows the mean values (±  SEM) of the different parameters studied 
before, during and immediately after the termination of the dialysis session. 
Haemodialysis did not modify the functional and immunological activity of FX1I. 
However, during and immediately after dialysis a significant decrease in PK and 
HMWKg activities (p < 0.05) was observed. The immunological levels of both 
proteins were not modified significantly. The functional activity of FXI only 
decreased during dialysis (p < 0.05) and returned to normal values thereafter. 
At the end of the procedure C-l-INH showed a significant increase compared 
to pre-dialysis levels.
Discussion
Data regarding the role of haemodialysis in the activation of contact phase 
proteins are contradictory [2 -4 ]. Wardle and Piercy [2] reported an increase in 
plasma kallikrein activity together with a decrease in PK and FXH levels in patients 
after haemodialysis. On the other hand, Deutsch et al. [3] found differences in 
the plasma levels of some proteins involved in the contact phase in patients with
H M W K g PK
Coag .  Antigen. Coag .  Antigen.
Before dialysis 
During dialysis 
After dialysis
111+4 
64+13* 
78 +  13*
102 +  3 
113+6 
96 +  5
97 +  7
75+11*
71+6*
97+4 
89 +  8 
89 +  7
FXI1 FXI C - l - I N H
Coag . Antigen. Coag . Antigen .
Before dialysis 
During dialysis 
After dialysis
84 +  6 
72 +  7 
96 +  10
90 +  2 
81+6 
85+4
93 +  5 
60+9* 
74 +  3
92 +  6 
128+7* 
139+9*
* p <  0.05 compared to pre-dialysis values
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Table I
Values (Mean +  SEM) obtained for the different proteins studied before, 
during and immediately after dialysis
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chronic renal impairments who were on haemodialysis and who were not. How­
ever, they did not find alterations in the contact phase after dialysis. Recently 
Vaziri et al. [4] suggested that dialysis does not induce alterations in the proteins 
of this system. In our opinion the discrepancies in the results of different authors 
may be due to the fact that different methods were applied, further on that func­
tional or immunological assays were not uniformly used.
In our study, if PK and HMWKg had been evaluated only by immunological 
techniques, no abnormalities would have been detected. However, according to 
functional assays there was a marked decrease in both proteins, with a significant 
increase in C-1-1NH after dialysis. It is unlikely that the decrease in the activities 
but not in the antigen concentrations of these proteins could be accounted for 
by the presence of heparin during dialysis since this discrepancy could not be 
observed in the properties of FXII. Moreover, no change was observed in the 
functional and antigenic activities of other coagulation proteins investigated, such 
as factor II and IX (data not shown). Like Vaziri et al. [4], we observed that 
functional and immunological activities of FXII remained unaltered during dial­
ysis. In other situations where an evident activation of the contact phase has 
been observed, no changes are reported in FXII levels; the finding has been inter­
preted as a lack of sensitivity of the method used in the study, which was unable 
to distinguish the various activated and inactivated forms of this protein [8].
In spite of the alterations found during and after haemodialysis, in the 
contact phase no clinical anomalies were observed in our series. In view of these 
results, we feel that the study of the contact phase is of great importance in patients 
undergoing dialysis, who display severe haemodynamic complications — such as 
hypotension — in which the genesis of kinins by activation of the prekallikrein- 
kinin system may play an important role in the pathogenesis of this complication.
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A 57 year old patient in whom Hodgkin’s disease (HD) and Chronic Lympho­
cytic Leukemia (CLL) was simultaneously diagnosed is described. The infiltration of 
peripheral blood and bone marrow by mature lymphocytes, with special immunological 
phenotype (SIg negative, mouse rosette positive and monoclonal antibodies B1 +  , 
B4 +  ) consistent with B-CLL and histological findings of lymphnode and axillary mass 
biopsies were typical of HD. The immunological study of the cell suspension from the 
axillary mass displayed a phenotype similartothat of the peripheral blood lymphocytes. 
Whether HD and CLL are two processes of fortuitous association, or a single clinical en­
tity remains to be elucidated. The immunological findings in our patient suggest a com­
mon origin for both disorders and that HD could sometimes be the result of a B cell 
proliferation.
Keywords: Hodgkin’s disease, Chronic Lymphocytic Leukemia, immunological 
markers
Introduction
The finding of Hodgkin’s disease and Chronic Lymphocytic Leukemia 
simultaneously in the same patient has been occasionally described [10, 11]. 
Hodgkin’s disease appears commonly in the late course of CLL, perhaps as a 
secondary effect of long term chemotherapy. However, the concurrent diagnosis 
of both diseases is extremely rare [11]. The characterization of tumour cells by 
immunological markers may be a useful tool in the study of these cases.
Case Report
A 57 year old male (occupation ; wood-carver) was admitted because of the 
progressive growth of a mass in the left axilla over the previous two months. The 
patient complained of episodes of nocturnal sweating, but of no other systemic 
symptoms. Physical examination revealed a diffuse infiltration of the soft tissue 
in the left arm by a mass of 15 x 15 cm. Adhering to the outer part of the axilla, and 
extending to the lower third of the arm, the mass showed signs of inflammation.
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Further on, a palpable left axillary lymphadenopathy (2 cm) and two unmovable 
tender epitrochlears (2 cm) were detected. No other lymphadenopathies were 
found. The patient had splenomegaly and hepatomegaly of 8 and 6 cm, respec­
tively. A blood count showed : Hb 14.5 g/dl, platelets 188 x 109/L, WBC 33.2 x 109/L 
with 11 granulocytes, 2 monocytes and 87 morphologically mature lymphocytes 
with abundant smudge cells. Other investigations showed hypogammaglobulinemia 
with IgG of 605 mg/dl, IgA of 55.6 mg/dl and IgM of 45.5 mg/dl. The immun­
ological study of peripheral blood cells using classical markers and McAbs [6, 
24] demonstrated an immature Blymphoid phenotype : EAET rosettes 3 %, mouse­
cell rosettes 44%, surface Igs negative, Cris-1 (CD 5) 13%, Han-PCl (anti­
plasma cell) negative, B1 (CD 20) 65%, B4 (CD 19) 58% and GRB1 (HLA-DR) 
87% [27]. The bone marrow biopsy showed a lymphocytic infiltration of a nodulo- 
interstitial pattern [23], Reed-Sternberg(RS) cells were not observed. The hepatic bi­
opsy revealed lymphoid infiltration by small lymphocytes, no eosinophils or RS cells 
were observed. A diagnosis of B-CLL in stage II according to Rai’s classification [21 ] 
was made. The axillary lymphadenopathy was removed. Infiltration by lacunar cells 
and — to a lesser extent — typical RS cells with large and biréfringent bands of scle­
rotic tissue surrounding lymphoid nodules were found. A diagnosis of Nodular 
Sclerosis (NS) type HD was established.
A biopsy was also performed on the axillary mass; on examination an in­
filtration of the soft tissues by mononuclear Hodgkin cells and to a lesser extent 
by RS cells, with abundant eosinophils and scarce plasma cells was found. Im­
munological analysis of the cell suspension of the axillary mass revealed predomi­
nantly B markers: E rosettes 3%, mouse rosettes 6%, surface Ig negative, Ki-1 
(CD 30) 2%, B1 (CD 20) 70%, B4 (CD 19) 60%, and GRB1 (HLA-DR) 55% 
[27]. A diagnosis of NS-type HD in stage Ile-B (Ann-Arbor) was established [2]. 
The patient was given a dose of 600 mg/day cyclophosphamide for three days 
and subsequently six courses of ABVD chemotherapy (Adriamycine, Beomycine, 
Vincristine and Daunoblastine) was administered with an excellent response.
Discussion
A patient suffering simultaneously from Hodgkin’s disease (HD) and Chronic 
Lymphocytic Leukemia (CLL) is described. The finding of HD in long term 
survival CLL patients has been occasionally described and a possible role of alkyl­
ating agents has been claimed [10, 11]. However, the concurrent diagnosis of 
both diseases is extremely rare and to our knowledge only two other cases have 
been reported [11].
Immunological markers, however, have not been studied in any of the 
previous cases. The differential diagnosis between HD and CLL or Well Differenti­
ated Lymphocytic Lymphoma (WDLL) is sometimes difficult since RS-like cells 
have been reported in the latter two diseases [16]. A further difficulty arises when
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the histological type of HD is of lymphocytic predominance. In our patient the 
diagnosis of HD is unquestionable because a typical nodular sclerosis (NS) was 
established. This histological pattern has only been found in one other case of 
HD appearing in the course of a CLL [10]. The infiltration of peripheral blood 
and bone marrow by morphologically mature lymphocytes with a special immuno­
logical phenotype (positive for B-cell markers Bl, B4, and mouse rosettes) is 
consistent with B-CLL. The absence of STg may be accounted for by its weak ex­
pression observed in some cases of B-CLL (10% B-CLL are SIgs negative) [3]. 
However, as mentioned above, biopsy of both the adenopathy and of the axillary 
mass was typical for nodular sclerosis seen in Hodgkin’s disease; an unexpected 
finding was that most of the cells obtained from the axillary mass had B-lympho- 
cyte markers.
Our studies and those of others [1, 9, 19], however, showed that lymph nodes 
affected by HD usually consist of T-lymphocytes. Furthermore, our observation 
that axillary mass lymphocytes showed the same aberrant phenotype as the peri­
pheral lymphocytes (SIg negative in contrast to the normal SIg+ B lymphocytes 
[28]) seems to support the hypothesis of a common progenitor B-cell. A second 
possibility is that B-CLL cells contaminated or infiltrated the Hodgkin's tissues, 
and we were dealing with a case of composite lymphoma — HD and non-Hodg­
kin’s lymphoma in the same tissue — a rare finding, though occasionally described 
[15]. However, this hypothesis was not confirmed by the histological findings 
which showed a single type of tumoral infiltration: NS Hodgkin’s disease. The 
difference in the mouse rosette receptors might be explained in terms of the vari­
ability of this marker depending on the tissue studied [4].
These results also involve the origin of RS cells, a controversial topic 
hitherto unsolved. Studies by Stein et al. [26] indicate that they are derived from 
activated lymphocytes of T or B origin. Recently Poppema et al. [20] suggested 
a B origin for RS cells. Although our studies have been performed on suspension 
cells, it seems that immunohistological analysis may be useful to assess the 
phenotype of the Reed-Sternberg cells.
Although the former possibility is attractive, other studies — including 
chromosomal analysis and gene rearrangement techniques — seem necessary for 
determining whether we are dealing with two related diseases arising from a com­
mon progenitor B cell, or with a fortuitous association of B-CLL with HD.
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The Interaction between Fibrinogen and 3H-L-arginine 
Cationic Peptides Derived from Fibrosarcoma in the Presence
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It has been found that cationic protein breakdown product — 3H-L-arginine 
labelled peptide fraction — interacts with fibrinogen in the presence of thrombin. The 
formation of the fibrin clot under these conditions makes the clot resistant to the 
fibrinolytic action of plasmin.
Keywords: fibrosarcoma induced by methylcholanthrene, fibrinogen, interac­
tion with 3H-L-arginine labelled peptide, proteolytic degradation of cationic protein
Introduction
In soluble cytoplasmic proteins of various tumor cells cationic protein mix­
ture with a heterogeneous arginine content has been observed [4, 6, 7]. Proteins 
containing arginine residues have been observed in tumor ascitic fluid as well [9]. 
Their amount in ascitic fluid is less than in cytoplasmic fraction.
Cationic proteins labelled with 14C-arginine, derived from cytosol of Ehrlich 
ascites tumor cells are occluded by fibrin clots under the influence of thrombin 
[8]. In vitro, in the presence of thrombin fibrinogen is bound strongly by cationic 
proteins rich in 3H-L-arginine isolated from fibrosarcoma, induced by methyl­
cholanthrene [15]. The effect of this reaction depends on the concentration of ca­
tionic proteins built into the fibrin clots and showing antifibrinolytic action [5].
Our work was aimed at studying in vitro the effect of proteolytic degradation 
products of SH-L—arginine labelled cationic protein, isolated from fibrosarcoma, 
on the thrombin-induced fibrin clot.
Materials and Methods
Bovine fibrinogen (fibrin-stabilizing factor-free) was purified by the method 
of Kekwick et al. [12]. Thrombin was produced by the Warsaw Serum and Vac­
cine Plant, Poland, and is expressed in NIH units.
3H-L-arginine-rich cationic proteins were isolated from cytosol of fibrosar­
coma induced by methylcholanthrene in rats using a method described in detail
V SP  U trecht, T o k y o  
A kadém ia i Kiadó, Budapest
170 R. Farbiszewski, A. Sokol : Fibrinogen and 3FI-L-arginine cationic peptides
elsewhere [6]. The purification of cationic protein mixture was carried out on 
SP-Sephadex column rechromatography. The chromatographic fractions were 
eluted with a linear NaCl gradient. The peak with the highest amount of 3H-L-ar- 
ginine and the highest specific radioactivity (2150 cpm/mg) was used for proteo­
lytic degradation. This protein had an isoelectric point at basic range pH(pI — 8.6) 
and a molecular weight of about 50 KD.
The enzymatic degradation of cationic protein was performed at pH 7.6. 
The incubation mixture contained two volumes of protein (2 mg/ml) and one 
volume of trypsin (0.5 mg/ml) both dissolved in 0.1 M phosphate buffer. The 
incubation at 37 °C was stopped after 60 min by addition of 0.8 pg of trypsin 
inhibitor IP-315.
Protein degradation products (PDP) were fractionated on CM-cellulose 
column equilibrated previously with 0.01 M phosphate buffer at pH 7.6. PDP 
were eluted with a linear NaCl gradient from 0.1 M to 0.6 M. 3 ml fractions were 
collected at flow rate of 30 ml per hour. Three peaks were obtained: first a peak of 
low radioactivity (430 cpm/mg) with about 20% of total protein content calculated 
from total 3H-arginine radioactivity of cationic protein. The second peak was of 
medium radioactivity (640 cpm/mg) with 30% of total protein content. The third 
showed the highest radioactivity (1070 cpm/mg) with a 50% of total protein 
content. The latter peak migrated to the catode during electrophoresis at pH 2.7; 
this indicated a cationic nature. During electrophoresis at pH 2.7 the first and 
second peaks remained on the start line. In all peaks a-amino nitrogen was measur­
ed [3]. 3H-L-arginine labelled fractions of the single peaks were pooled, and 
concentrated by lyophilization.
Interaction of all 3H-L-arginine labelled peptide fractions with fibrinogen 
was assayed in the presence of thrombin by measuring total radioactivity in the 
clot on a /1-liquid scintillation spectrometer. For this purpose a system of 0.25 ml 
fibrinogen 0.5%, 0.25 ml peptides (of various concentration) and 0.5 ml thrombin 
(20 U/ml) was incubated at 37 °C for 30 min. The formed clot was separated from 
the solution by means of a silk filter, and washed three times with 0.9% NaCl and 
subsequently with distilled water. The clot was solubilized in 1 ml 2N NaOH by 
heating at 100 °C for 5 min. Samples (0.3 ml) neutralised with HC1 were added to 
3 ml of Bray’s solution [1] and 3H-radioactivity in all samples was measured 
(Nuclear Chicago).
The effect of peptide fractions on the fibrinolytic activity of plasmin in fibrin 
clots was evaluated in a system containing: 0.25 ml plasmin (0.1%) + 0.25 ml 
peptides (of various concentrations). After a 5 min incubation, 0.25 ml fibrinogen 
(0.5%) and 0.25 ml thrombin (40 U/ml) were added, and from that moment the 
clot lysis time was measured.
Results
Figure 1 shows that, in the presence of trypsin, the 3H-L-arginine labelled 
cationic protein was separated into three peaks on the CM cellulose column. The
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first peak was easily eluted by 0.1 M NaCl and it contained a low amount of 
a-amino nitrogen (40 /tg/ml) with low total radioactivity (50 cpm/ml). The second 
peak was eluted by increasing ionic strength and contained more radioactivity 
(144 cpm/ml). The third peak eluted by 0.5 M NaCl contained about 102 yttg of 
a-amino nitrogen and showed the highest total radioactivity (250 cpm/min, ml).
Table 1 illustrates the effect of 3H-L-arginine labelled peptides on the fibri­
nogen in the presence of thrombin, at a constant concentration of fibrinogen 1.25 
mg/ml. Only fibrin clots formed in the presence of peptide fraction III showed 
radioactivity depending on the concentration of peptides and their specific ra­
dioactivity (Fig. 2). This peptide fraction interacted entirely with fibrinogen even
Fig. 2. The effect of 3H-L-arginine labelled peptide fraction (III) on the radioactivity in the
thrombin-induced fibrin clots
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Fig. 1. Fractionation of 3H-L-arginine labelled protein degradation products on CM-cellulose 
column (1.4x21 cm). They were applied to a column equilibrated previously with 0,01 M 
phosphate buffer at pH 7.6. The elution was carried out with a linear NaCl gradient from 
0,1 M to 0,6 M. 3 ml fractions were collected at a flow rate of 30 
ml per hour
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Table 1
The interaction between fibrinogen and :!H-L-arginine labelled peptides (obtained by pro­
teolysis of cationic protein derived from fibrosarcoma) in the presence of thrombin
Peptides Tota l radioact iv ity  
o f  pep tides  
in fibrin clot 
c p m /m in ,  ml
Fib rinolysis
time
(s)
Final co n c en tra t io n  
a-am ino  n it rogen  
(ig/ml
Radioac tivity  
cp m /m in ,  ml
Fraction I 40 50 i 720
20 25 0 720
Fraction 11 75 144 2 720
35 72 0 720
Fraction III 102 250 246 1130
51 125 121 890
25 62 58 790
0 — — 720
The results represent the mean values of three experiments for each of the peptide 
concentrations. The radioactivity of the samples after subtraction of the background.
at a very low concentration, and showed antifibrinolytic action. The final con­
centration (102 pg) of this fraction increased the fibrynolysis time from 720 to 
1130 s (Table 1).
The remaining two peptide fractions at concentrations of 70 /tg and 40 /rg 
of a-amino nitrogen content did not interact with fibrinogen in the presence of 
thrombin and did not show antifibrinolytic action.
Discussion
Our results demonstrate that not all degradation products of cationic protein 
derived from fibrosarcoma interact with fibrinogen in the presence of thrombin. 
Only the peptide fraction with the highest radioactivity of 3H-L-arginine and 
showing pi at basic range of pH (8.9) is built into the structure of the thrombin- 
induced fibrin clots. They cannot be removed from the clots by repeated washings. 
It seems that the cationic peptide fraction after interaction with fibrinogen in the 
presence of thrombin alters the clot structure and makes it resistant to the fibri­
nolytic action of plasmin.
The remaining two peptides showing neutral character and low molecular 
weight are not built into the structure of the thrombin-induced fibrin clots, and 
do not show antifibrinolytic action.
This phenomenon may be of some importance in vivo. In various pathologi­
cal conditions, particularly in several invasive tumors e.g. fibrosarcoma,infiltration
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of tumor cells by host cells such as lymphocytes, granulocytes and macrophages 
cytolysis takes place [11 ]. From damaged and disintegrated tumor cells and from 
aggregating blood platelets many substances (e.g. cationic proteins and peptides) 
may get released into the extracellular space, into smaller capillaries and into the 
blood circulation [10]. Their cationic character and low molecular weight facili­
tate penetration into the blood circulation, and the microenvironment may be 
locally modified [14].
The interaction of PDP with fibrinogen in the presence of thrombin and the 
formation and deposition of fibrin or fibrin-like material under clinical conditions 
is biologically important and essential for the growth of tumor, its invasion and 
metastasis [13]. The fibrin network provides the matrix into which new capillaries 
can grow.
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Many earlier authors have observed autologous erythrocyte-rosette formation 
within reddish haemolymph nodes but how and why these are formed has not been 
studied.
In this study we traced the histogenesis of this phenomenon. Since macrophage- 
erythrocyte-rosettes (MER) mostly occur in the deep sinus we suggest that changes in 
the red blood cells caused by stagnation, aging or the loss of viability due to deoxygena­
tion may result in development of some unusual sites on these cells. Polar formation of 
macrophage processes around each rosette erythrocyte in-vivo suggests loss of self­
tolerance.
Keywords: macrophage-erythrocyte-rosettes, haemolymph node, autologous 
erythrocytes, in-vivo rosettes
Introduction
Erythrocyte-rosette formation is normally demonstrated in vitro and in­
volves receptor-specific radial orientation of heterologous erythrocytes around a 
central leukocyte. The observation of this phenomenon in-vivo within some pecul­
iar reddish nodes [2] was the starting point of our present study.
These nodes are commonly found in the connective tissues around the kid­
neys, thyroid glands and the spleen. They have been described in sheep, horse, pig, 
rat and even in humans, showing various degrees of reddish intensity [1, 5, 6, 
10, 11]. The term “haemolymph” means the unusual mixture of abundant stag­
nating erythrocytes with the lymph.
Recently we established that the red cells within haemolymph sinuses reach 
these sites via the orifice of afferent lymph vessels [3].
The aim of our present work was to determine how and why in-vivo rosettes 
become formed with autologous erythrocytes.
4
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Materials and Methods
Group /
IO AS and IO DA strains of rats were used. Under ether anaesthesia the 
vascular system of each animals was perfused with Ringer Lactate solution 
through a catheter in the descending aorta with outlet in the atrium. The perfusate 
was replaced with 1.5% buffered glutaraldehyde. This technique allowed rapid 
fixation of the organs and tissue in-situ. The reddish nodes posterior to the hila 
of both renal vessels were removed and processed for both light and electron 
microscopes.
Group II
In this group 5 DA and 5 AS rats were given ether overdosage. The reddish 
nodes were quickly removed and fixed in Carnoy’s solution. They were processed 
and fixed for light microscopy.
Results
All animals examined had haemolymph (HLN) nodes); those situated 
posterior to the renal vessels were further studied.
Variation of technique did not cause any difference in the two groups, 
therefore only the features related to histogenesis of the rosettes were followed.
Fig. 1. Section through the peripheral area of the haemolymph nodes. The arrows point to 
freely suspended erythrocytes (rbc) and V is the sinus, (x 60)
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Fig. 2. Macrophage-erythrocyte-rosettes (MER) in the deep sinus. Most of the red cells are 
spindle-shaped. n =  nucleus of the macrophage. (X 120)
In normal circumstances the red blood cells entering the HLN (which is the 
orifiice of the afferent lymphatics) and then spreading in the peripheral sinus 
are freely suspended. These cells have a characteristic biconcave disc shape. Other 
cells, such as lymphocytes and macrophages (normally found in the lymph and/or 
in the blood) are also freely impended in this area.
The erythrocytes and leukocytes of the deep sinus were examined and some 
histological peculiarities were found. Variable numbers of the red blood cells
4*
Fig. 3. MER showing haemosiderin granules within the cytoplasm of the 
central leukocyte. (X 360)
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Fig. 4. Electron photograph of MER. The cytoplasmic processes of macrophages form around 
the pole of each rosetting erythrocyte, (x 6000)
formed a radially arranged pattern along the margins of the leukocytes. Most 
rosetting erythrocytes lost their biconcave disc shape (seen at the peripheral sinus) 
and assumed spindle, comma or other shapes. The pole of these erythrocytes was 
usually connected to the cytoplasmic margin and processes of the leukocytes. 
These erythrocytes were intensively basophilic.
The cytoplasm of the central leukocyte involved in rosette formation had 
debris including haemosiderin granules and irregular processes. They belonged 
to the macrophage series.
Features of active immunological stimulation such as nodules, blast cells 
or T-immunological stimulation such as nodules, blast cells or T-immunoblasts 
were rarely seen.
Discussion
When blood and lymph circulation are normal, erythrocytes do not directly 
bind to the margins of leukocytes. The present work confirmed reports of many 
earlier authors who found and demonstrated rosette binding within HLN [5, 6, 
10]. As an extension of these reports the present study traced the histogenesis of 
this in-vivo rosette formation.
H aem ato log ia  21, 1988
A. A. Kazeem: Macrophage-erythrocyte-rosettes 179
Fig. 5. Electron photomicrograph of MER. Rosetting erythrocytes have lost their typical 
shape while the isolated red cell at the bottom of the illustration still retained its shape and is
probably still viable. (X 15,600)
We observed that the erythrocytes that had recently entered the HLN were 
freely suspended in the peripheral sinus and kept their typical biconcave disc 
shape. At the deep sinus they lost these properties and bound to the margins of 
the macrophages. The question is what factor(s) are responsible for the formation 
of MER?
A change of technique in the present study did not affect the genesis of MER.
Similarly, reports from many laboratories using different methods did not 
preclude the demonstration of MER within HLN. Furthermore, the presence of 
abundant haemosiderin deposits within the cytoplasm of the macrophages are 
considered physiological in-vivo and are not due to experimental intervention.
The next question is what factor(s) are peculiar to the milieu in the deep 
sinus predisposing to MER formation? It is known that macrophages normally 
phagocytose effects red blood cells, but the latter cells do not form rosettes before 
phagocytosis, and it is not a histological feature of the spleen. In our opinion, 
changes occurring in the red blood cells during their migration are involved in 
this process
This interpretation is supported by our observation that rosetting erythro­
cytes appeared oriented edge-on to the processes of the macrophages, similarly 
to the receptor-specific orientation seen in the in-vitro studies. It is known that
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spontaneous formation of MER with xenogenic red blood cells is receptor specific 
and can be depressed by antimacrophage antibodies [4]. Similarly, adherence of 
red blood cells to autologous T cells has been reported [8]. In vitro, the binding 
characteristics of erythrocytes to leukocytes change, depending on the storage 
conditions, age and the treatment of the red blood cells before use [9]. Based on 
our opresent in-vivcf observations,] we conclude] that red cell stagnation, aging or 
thelossofviabilitydueto deoxygenation may result in unusual sites on the surface 
of sinus erythrocytes. The sinus macrophages might recognize these sites as foreign 
and strech out processes to engulf red blood cells (i.e. loss of self-tolerance).
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Action o f tong-chain fa tty acids in vitro on 
Ca2 + -stimulatable, Мдг -dependent ATPase 
activity in human red cell membranes. F. B. 
Davis, P. J. Davis, S. D. Bias and M. Schoenl 
(Endocrinology Division, Department of 
Medicine, State University of New York at 
Buffalo School of Medicine, Veterans Admi­
nistration Medical Center, Buffalo N. Y. 
USA). Biochem. J. 248, 511 (1987).
Human red cell membrane Ca2+-stimu­
latable, Mg2+-dependent adenosine triphos­
phatase (Ca2 + -ATPase) activity and its 
response to thyroid hormone have been stu­
died following exposure of membranes in 
vitro to specific long-chain fatty acids. Basal 
enzyme activity (no added thyroid hormone) 
was significantly decreased by additions of 
10~s— 10-<1M-stearic (18:0) and oleic 
(18:1 cis-9) acids. Methyl oleate and elaidic 
(18:1 Irans-9), palmitic (16 : 0) and lauric 
(12 : 0) acids at 10” 6 and 10~4 M were not 
inhibitory, nor were arachidonic (20 : 4) and 
linolenic (18 : 3) acids. Myristic acid (14 : 0) 
was inhibitory only at 10~~4 M. Thus, chain 
length of 18 carbon atoms and anionic 
dulin. To investigate the mechanism by 
which cetiedil modifies calcium-mediated 
erythrocyte function, the effect of the drug 
on the active transport of calcium into inside- 
out erythrocyte vesicles was examined and 
its influence on the activities of phospho­
diesterase and Ca-ATPase studied. Cetiedil, 
in the presence of calmodulin, significantly 
inhibited calcium transport into inside-out 
vesicles that were prepared with erythrocytes 
from normal controls and from patients 
with sickle cell anemia. However, in the 
absence of calmodulin, no inhibition was
observed. Likewise, cetiedil inhibited cal­
modulin-stimulated, but not basal, activities 
of phosphodiesterase and Ca-ATPase. These 
data, along with previous reports, suggest 
that cetiedil does not act by lowering the 
intracellular calcium content. It is, therefore, 
likely that the beneficial effect of cetiedil is 
due to its ability to protect the red cell from 
the deleterious consequences of an elevated 
concentration of intracellular calcium.
G. Gärdos
Inhibition o f erythrocyte calcium transport by 
cetiedil. S. N. Levine, L. R. Berkowitz, E. P. 
Orringer (Department of Medicine, Section 
of Endocrinology, Louisiana State Uni­
versity Medical Center, Shreveport, La, 
USA.) Pharmacology 36, 44 (1988).
The elevated calcium content found in 
red cells from patients with sickle cell ane­
mia may be of pathophysiologic importance 
in the hemolysis and vasoocclusion which 
characterize this disorder. Cetiedil, an anti­
sickling agent, has been reported to inhibit 
the activity of enzymes that are stimulated 
by the calcium regulatory protein calmo- 
charge were the principal determinants of 
inhibitory activity. Introduction of a cis-9 
double bond (oleic acid) did not alter the 
inhibitory activity of the 18-carbon moiety 
(stearic acid), but the trans-9 elaidic acid 
did not cause enzyme inhibition. While the 
predominant effect of fatty acids on erythro­
cyte Ca2 + -ATPase in situ is inhibition of 
basal activity, elaidic, linoleic (18 : 2) and 
palmitoleic (16 : 1) acids at 10~6 and 10 1 M
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stimulated the enzyme. Methyl elaidate was 
not stimulatory. These structure-activity 
relationships differ from those described for 
fatty acids and purified red cell Ca2+- 
ATPase reconstituted in liposomes. Thyroid 
hormone stimulation of Ca2+-ATPase was 
significantly decreased by stearic and oleic 
acids (10-9— IO-4 M), but also by elaidic, 
linoleic, palmitoleic and myristic acids. Ara- 
chidonic, palmitic and lauric acids were inef­
fective, as were the methyl esters of oleic 
and elaidic acids. Thus, inhibition of the 
iodothyronine effect on Ca- -ATPase by fat­
ty acids has similar, but not identical, struc­
ture-activity relationships to those for basal 
enzyme activity. To examine mechanisms for 
these fatty acid effects, the action of oleic 
and stearic acids on responsiveness of the 
enzyme to purified calmodulin, the Ca2+- 
binding activator protein for Ca2+-ATPase 
was studied. Oleic and stearic acids (ІО-9—, 
IO-4 M) progressively inhibited, but did not 
abolish, enzyme stimulation by calmodulin 
( 10 — a M). Double-reciprocal analysis of the 
effect of oleic acid on calmodulin stimulation 
indicated noncompetitive inhibition. Ad­
dition of calmodulin to membranes in the 
presence of equimolar oleic acid restored 
basal enzyme activity. Oleic acid also redu­
ced 125I-calmodulin binding to membranes, 
but had no effect on the binding of [,25I ]T4 
by ghosts. The mechanism of the decrease by 
long chain fatty acids of Ca2+-ATPase acti­
vity in situ in human red cell ghosts thus is 
calmodulin-dependent and involves reduc­
tion in membrane binding of calmodulin.
B. Sarkadi
Elevated intracellular Ca'l+ affects LirNaa 
countertransport in human red blood cells. G. 
Agam, P. Hatzav, S. Abekasis, A. Loven and 
A. Livne (Department of Biology, Ben- 
Gurion University of the Negev, Beer Sheva, 
Israel). Biochim. Biophys. Acta 904, 207, 
(1987).
Changes in cytoplasmic Ca2+ concentra­
tion and in Lir Na0 countertransport activity 
have been shown to be associated with es­
sential hypertension. Elevated intracellular 
free [Ca2+ ], as well as abnormalities of Ca2 + 
binding and transport have been reported in
cells from different tissues of hypertensive 
laboratory animals and essential hyperten­
sive patients. Similarly, enhanced rates of 
Lir Na0 countertransport and the modified 
pattern of the temperature dependence of 
this activity in red blood cells from essential 
hypertensive patients have been previously 
demonstrated. The aim of the present study 
was to investigate possible interaction be­
tween changes in intracellular free [Ca2+ ] and 
the Lr Na0 exchange in human red blood 
cells. The ionophore ionomycin was used to 
allow Ca2+ incorporation into the cells in 
a dose-dependent manner. The elevation of 
intracellular [Ca2+], in turn, resulted in 
enhanced Li+ efflux from the cells. At 
3 |i(M, ionomycin selectively and significantly 
enhanced the Lir Na0 countertransport but 
not Li+ leakage from the cells. EGTA total­
ly abolished the effect of ionomycin, indi­
cating that the effect is directly related to 
Ca2+. As low as 0.4 Ca2+ caused a 
statistically significant effect. The maximal 
effect of Ca2+ on the LirNa0 countertrans­
port was achieved around the external pH 
range of 6.8—7.5. In contrast, the leakage of 
Li+ was significantly enhanced by Ca2+ at 
a pH of 7.4 and above. Ca2+ did not affect 
the Km of the Lir Na0 countertransport for 
Li+. Amiloride, which inhibits Na+/H + 
exchange, inhibited only 10% of the Ca2+- 
enhanced countertransport. It is concluded 
that Ca2+ may play a role in the regulation 
of Lir Na0 countertransport in erythrocytes.
B. Sarkad
Inhibition by nucleosides o f glucose-transport 
activity in human erythrocytes. S. M. Jarvis 
(Biological Laboratory, University of Kent, 
Canterbury, Kent, UK). Biochem. J. 249, 
383 (1988).
The interaction of nucleosides with the 
glucose carrier of human erythrocytes was 
examined by studying the effect of nucleo­
sides on reversible cytochalasin B-binding 
activity and glucose transport. Adenosine, 
inostine and thymidine were more potent in­
hibitors of cytochalasin B binding of human 
erythrocyte membranes than was d-glucose 
[IC50 (concentration causing 50 % inhibition) 
values of 10, 24, 28 and 38 mM, respectively].
H aem ato lo g ia  21, 19 88
Abstracts 183
Moreover, low concentrations of thymidine 
and adenosine inhibited d-glucose-sensitive 
cytochalasin B binding in an apparently 
competitive manner. Thymidine, a nucleo­
side not metabolized by human erythrocytes, 
inhibited glucose influx by intact cells with 
an IC50 value of 9 mM when preincubated 
with the erythrocytes. In contrast, thymidine 
was an order of magnitude less potent as 
an inhibitor of glucose influx when added 
simultaneously with the radioactive glucose. 
Consistent with this finding was the de­
monstration that glucose influx by inside-out 
vesicles prepared from human erythrocytes 
was more susceptible to thymidine inhibi­
tion than glucose influx by right-side-out 
vesicles. These data, together with previous 
suggestions that cytochalasin B binds to the 
glucose carrier at the inner face of the mem­
brane, indicate that nucleosides are capable 
of inhibiting glucose-transport activity by 
interacting at the cytoplasmic surface of the 
glucose transporter. Nucleosides may also 
exhibit a low-affinity interaction at the extra­
cellular face of the glucose transporter.
G. Gárdos
Volume-sensitive Cl-dependent K  transport 
in human erythrocytes. W. C. O’Neill (De­
partment of Medicine, Emory University 
School of Medicine, Atlanta, Georgia, 
USA.). Am. J. Physiol. 253, C883 (1987).
Passive K fluxes, measured with 86Rb, 
were investigated in osmotically swollen hu­
man erythrocytes. K influx and efflux increa­
sed progressively with increased hypotoni- 
city up to 167 mosmol/kg. No increase in 
K flux was seen when N 03 or methylS04 
were substituted for Cl. Substitution of 
choline or N-methylglucamine for external 
Na reduced the K flux in swollen cells by 
only 22%, compared with a 60% reduction 
in euvolumic cells. However, the magnitude 
of this Na-dependent component was 
slightly, but significantly, higher in swollen 
cells. The presence of Na-dependent K 
influx in swollen cells was confirmed by 
measurements of Na influx demonstrating a 
K-dependent Na influx of similar magnitude 
in isovolumic and swollen cells. The volume- 
sensitive K flux was inhibited by bumetanide,
but significantly less so than was Cl-depen­
dent flux in isovolumic cells (half-maximal 
inhibition at l.Ox 10-J  vs. 5.8x 10_7 M). 
Kinetic analysis revealed that Cl-dependent 
K influx had a lower affinity for external K 
in swollen cells than in euvolumic cells 
(Km was 29.8 vs 6.1 mM). The increased 
K flux in swollen cells was found to be 
transient, decreasing substantially and revert­
ing back to a predominantly Na-dependent 
and more bumetanide-sensitive form after 
2 h. The results indicate that swelling of hu­
man erythrocytes activates a transient Cl- 
dependent K flux that differs significantly 
from that in isovolumic cells in that it is 
less Na-dependent, less sensitive to bumeta­
nide, and has a lower affinity for K. Na-K 
cotransport is either unaffected or slightly 
increased in swollen cells. The altered flux 
in swollen cells would thermodynamically 
favor a volume-regulatory KC1 efflux.
G. Gárdos
Formation o f light irreversibly sickled cells 
during deoxygenation-oxygenation cycles. K. 
Horiuchi and T. Asakura (Department of 
Pediatrics, The Children’s Hospital of Phila­
delphia, Philadelphia, Pennsylvania, USA.). 
/. Lab. Clin. Med. 110, 653 (1987).
Changes in density, morphology, and 
monovalent cation content of sickle (SS) 
cells caused by repetitive sickling were in­
vestigated in vitro with a device by which 
red cells can be exposed to cycles of deoxy­
genation and oxygenation (d-o cycles). Ex­
periments were done using the discocyte- 
rich, less dense fractions of SS cells. When 
such cells were subjected to d-o cyles in the 
presence of 2 mmol/1 Ca2+, most became 
dense within 4 hours. The density of these 
cells was slightly lower than usual for ir­
reversibly sickled cells (ISCs), and because 
they reverted to the discoidal shape after 
oxygenation, they were not considered 
ISCs. However, on further d-o incubation, 
they did assume the morphology and den­
sity typical of ISCs. After an additional 
incubation (20 hours), most cells decreased 
in density, became very fragile, and hemo- 
lyzed easily. Such light ISCs could also be 
formed from freshly prepared dense cells on
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d-o incubation. Once light ISCs were for­
med, they did not reconvert to dense cells on 
further incubation. It should be noted that 
light ISCs created in vitro tented to aggreg­
ate much more easily than ordinary (heavy) 
ISCs did, suggesting that the membrane of 
these cells may be very adhesive.
G. Gárdos
A spin-label study o f membrane proteins and 
internai microviscosity o f erythrocytes in 
hereditary spherocytosis. G. Bartosz, M. 
Gaczynska, E. Grzelinska and L. Judkie- 
wicz (Laboratory of Biophysics of Develop­
ment and Aging, Chair of Biophysics, 
University of Lodz, Lodz, Poland). Life Sei. 
4L  2285 (1987).
Electron spin resonance (ESR) spectra 
of erythrocyte membranes of patients with 
hereditary spherocytosis (HS) and of healthy 
controls labelled with a maleimide spin label 
did not differ significantly both before and 
after prolonged incubation at 37 ° C. It sug­
gests that the different behaviour of spin-la- 
belled HS erythrocyte membranes upon incu­
bation at a higher temperature reported 
previously is due indeed to structural abnor­
malities of HS red cell membranes and not 
to alterations in their proteolytic activity. 
Measurements of the rotational correlation 
time of Tempamine spin probe demonstrated 
a significant elevation of internal microvisco­
sity of erythrocytes in HS, more pronounced 
in non-splenectomized patients.
Ilma Szász
Ethanol-induced alterations in human erythro­
cyte shape and surface properties : Modula­
tory role o f prostaglandin £,. R. W. McLaw- 
hon, Y. Marikovsky, N. J. Thomas and R. 
S. Weinstein (Department of Pathology, 
Rush Medical College, Chicago, Illinois, 
USA). J. Membrane Biol. 99, 73 (1987).
Exposure of human erythrocytes to etha­
nol (1 to 20% by vol) in Ca2+ and Mg'-+-free 
phosphate-buffered saline, pH 7.4, trans­
formed biconcave discs into spiculated 
echinocytes within 3 min at 25 °C. The 
effects of ethanol were concentration- and
time-dependent, but reversible by washing in 
the incubation buffer system within 60 min 
of initial exposure to ethanol. After prolon­
ged ethanol exposure (180 min), washing of 
cells resulted in the formation of stomatocy- 
tes (cup-forms). Ethanol-induced echinocyto- 
sis was also accompanied by a 30% enhance­
ment in the agglutinability of erythrocytes 
by ligands with high affinity for negative 
surface charge (poly-1-lysine and wheat 
germ agglutinin 20 /tl/ml) without any altera­
tions in surface charge topography. Conco­
mitant exposure of erythrocytes to prosta­
glandin E, (100 nM) selectively prevented the 
enhancement of ligand-mediated agglutina­
bility, but did not modify cell shape. These 
data indicate that certain erythrocyte surface 
properties may not be directly influenced by 
cell shape and suggest a unique modulatory 
action of prostaglandin Et on shape-transfor­
med cells.
11ma Szász
The effect o f 2,3-diphosphoglycerate on the 
tetramer-dimer equilibrium o f carbon mono­
xide hemoglobin in dilute solution. Correlation 
between sedimentation and kinetic behavior. 
R. D. Gray and W. L. Dean (Department of 
Biochemistry, University of Louisville School 
of Medicine, Louisville, Kentucky, USA.). 
J. Biol. Chem. 262, 15890 (1987).
The effect of 2,3-diphospho-d-glycerate on 
the sedimentation coefficient of carbon mo­
noxide hemoglobin was correlated with the 
fraction of rapidly reacting hemoglobin ob­
served subsequent to flash photolysis at 23 °C 
at pH 7.30 in buffers of 0.1 M ionic strength. 
Concentrations of the organic phosphate up 
to about 5 mM resulted in an increase in 
s20w> consistent with an increase in the frac­
tion of tetrameric hemoglobin. A decrease in 
rapidly reacting hemoglobin parallelled the 
increase in the sedimentation coefficient. 
Between 5 and 20 mM 2,3-diphosphoglyce­
rate, s20w decreased, suggesting that dissocia­
tion to dimers was enhanced. An increase 
in rapidly reacting hemoglobin was also 
observed in this concentration range. Similar 
sedimentation results were obtained with 
oxyhemoglobin at pH 7.00 and carbon mono­
xide hemoglobin at pH 7.06. Assuming single 
binding sites on each species, the dissociation
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constants for 2,3-diphosphoglycerate binding 
to tetrameric and dimeric HbCO. are 0.2— 
0.3 mM and 2—5 mM at pH 7.30. This 
biphasic effect of this physiologically im­
portant organic phosphate on the state of 
aggregation of R state hemoglobin has not 
been previously reported, but it is similar to
that previously noted with inositol hexa- 
phosphate, which enhanced tetramer forma­
tion at low concentrations, while at higher 
concentrations it promoted hemoglobin dis­
sociation to dimers.
Ilma Szász
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Book Review
THE ACUTE LEUKEMIAS: Biologic, 
Diagnostic, and Therapeutic Déterminais. 
(Hematology Series/6). Edited by Sanford 
A. Stass. 1987. 496 pages, bound, illustrated. 
$ 115.00 (US and Canada); $ 138.00 (All 
other countries). ISBN: 0—8247—7766—2. 
(Prices subject to change without notice.)
In the past five years, developments in 
immunology, cytogenetics, biochemistry, and 
molecular biology have opened up new un­
derstandings of acute leukemia never before 
imagined, refining our ability to understand 
the biology, characterize, and diagnose this 
disorder. The identification of nonradom 
phenotypic and biologic features, with im­
portant clinical and prognostic implications, 
requires that hematologists, pathologists, 
and oncologists keep abreast of these ad­
vances in order to grasp ongoing and prospec­
tive findings.
Authored by nearly 30 leading authori­
ties in the field, The Acute Leukemias uni­
fies the current complex and multifaceted
approach to the characterization of acute 
leukemia and places in perspective the 
usefulness of the divergent available studies 
for the evaluation of the leukemic cell.
Topics discussed include specialized 
morphologic and cytochemical studies . . . 
flow cytometry . . . cytogenetics . . . im­
munologic phenotyping . . . biochemical 
markers . . . molecular biology . . . thera­
peutic implications of leukemic cell charac­
terization . . . DNA technology, using on­
cogene and lineage-associated cells . .  . and 
nonrandom chromosomal studies.
READERSHIP: Hematologists; hema- 
topathologists; pathologists; oncologists; fel­
lows and residents in pathology and hematol­
ogy; epidemiologists and biometricians; vi­
rologists and molecular biologists; cytoge­
neticists; medical technologists in hematol­
ogy and biotechnology, graduate and medical 
students in hematology, oncology, or patho­
logy; and professional seminars in hemato- 
pathology.
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Announcement
THEORY OF REFERENCE VALUES
Observed values are meaningful only if assessed against comparable reference 
individuals and when a comparable analytic method is used. These are known as 
“ references values” , they are more informative than the traditional “normal 
values” which may be misleading in some circumstances. The principles on which 
reference values are based, protocols for collecting data and the statistical proce­
dures which should be used for establishing reference values have been described 
in a series of papers which have been prepared jointly by the International Federa­
tion of Clinical Chemistry (1FCC) and the International Committee for Standar- 
dizaton in Haematology (1CSH). These recommendations have been published 
as follows:
The concept of Reference Values. Journal of Clinical Chemistry and Clinical 
Biochemistry, 1987, 25, 337 — 342.
Statistical treatment of collected reference values. Determination of reference 
limits. Clinical Biochemistry, 1987, 25, 645 — 656.
Presentation of observed values related to reference values. Journal of Cli­
nical Chemistry and Clinical Biochemistry, 1987, 25, 657 — 662.
Reprints are available from IFCC Scientific Committee (Dr H E Sollberg), 
Dept, of Clinical Chemistry, Rijskhospitalet, Oslo, Norway or from ICSH Secre­
tariat (Dr R L Verwilghen), University Hospital, Herestraat 49, B 3000 Leuven, 
Belgium.
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Density Distribution of Red Cells and Prognostic Significance 
in 50 Patients with Homozygous Sickle-Cell Disease
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The sickle cell disease is characterized by a heterogeneous clinical and biological 
expression. In order to evaluate the prognostic significance of the red blood cell density 
distribution: D50 (median cell density of the distribution), R60 (middle density range 
in which 60% of the cells can be found), F4 and F5 (proportion of cells with density 
higher than 1.110 and 1.120 g/ml, respectively) have been determined in 50 patients 
with homozygous sickle cell disease. The a gene status was determined in 27 patients. 
All patients have been included in an original score of severity fitted to infancy and 
childhood. A positive correlation has been found between D50 and the clinical score. 
This result illustrates the potential clinical importance of this parameter as well as other 
biological indices such as the haemoglobin F level, the a gene status and the haplotypes 
of the /5-like gene cluster.
Keywords: clinical score, haemoglobin, red cell density, sickle cell disease
Introduction
An important heterogeneity is evident among patiens with sickle cell disease 
in regard to their clinical and biological features and the disease severity is not 
easily predictable. Biological indices of prognosis might help to determine a high 
risk group of patients thus making it possible that a close clinical monitoring, 
genetic counseling and preventive treatment be applied to this group.
Hitherto, it is known that high fetal haemoglobin (Hb F) level [1, 2, 3], 
a thalassemia [4, 5, 6] and particular haplotypes of the /1-like gene cluster [7] 
modulate the disease severity. The distribution of red cell densities is one of the 
numerous biological factors which characterizes the sickle cell disease. Compared 
to normal profile, the distribution of sicklers is differing from one patient to an­
other, but constant in the same patient outside crisis [8].
The aim of this study is to evaluate the eventual influence of red-cell densities 
on the clinical severity of the disease. To achieve this objective we correlated a 
clinical severity score with the parameters characterizing the density profile.
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Patients and Methods
Patient population
50 patients with sickle cell disease treated at the Enfants Malades Hospital 
(Paris) were chosen for this study. The patients, 26 males and 24 females, were 
native of 15 different countries of Africa and the West-Indies and ranged from 15 
months to 27 years in age. At the time of the study, all patients were in a clinically 
steady state and had not been transfused for at least four months.
Haematological data
Haematological data (haemoglobin level Hb-g/dl, mean corpuscular volume 
MCV-fl) were determined using the Coulter counter S Plus. Reticulocyte counts 
were performed on thin smears after methylene blue staining: 1000 cells were 
counted under 100 xoil immersion and the percentage of reticulocytes calculated. 
Hb F level was determined by the alkali dénaturation method of Pembrey et al. [9]. 
Homozygosity for HbS was determined by two electrophoretic methods, solubility 
test and family studies when possible.
Clinical severity score
A clinical score was assessed by a retrospective review of the course of each 
patient (Table 1). Eight clinical parameters were used: age of diagnosis, age at 
the time of the study, number of hospitalizations, major organ involvement, 
sequestration crisis, splenectomy for hypersplenism, infections, acute pulmonary 
episodes. Points were assigned for each parameter from 0 to 4 depending on the 
severity conferred upon the considered symptom according to the literature [10, 
11, 12, 13] and our experience. Furthermore, the patients were divided into 3 
groups of increasing clinical severity; score 0 — 4: group 1, score 5 — 9: group 2, 
score 10—15: group 3.
Density determination
The details of the technique used to determine the density distribution were 
previously described [14]. Briefly, venous blood samples were collected in EDTA. 
Phtalate esters were prepared by mixing dimethyl phtalate (sp. gr. 1 090) and N- 
butyl phtalate (sp. gr. 1.045) to obtain 16 densities ranging from 1.075 to 1.135 
according to the method of Danon and Marikovsky [15]. Four parameters were 
used to characterize the profile according to Noguchi et al. [16] : D50 (median cell 
density of the distribution), R60 (middle density range in which 60% of the cells
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Table 1
Clinical score. Clinical parameters used for the classification of 50 patients with sickle cell 
disease and the point assigned to each of them
1. AGE OF DIAGNOSIS
a) <1 year: 3
b )  1 to 2 years: 2
c) 2 to 5 years: I
d) >  5 years : 0
e) family investigation: 0
2. AGE AT THE TIME OF THE 
STUDY
a) <5 years: 4
b )  5 to 10 years : 3
c) 10 to 15 years: 2
d) 15 to 20 years: 1
e) >20 years: 0
4. NUMBER OF HOSPITALIZATIONS
a) <l/year: 0
b) 1/year: 1
c) 2 to 3/year: 2
d) > 3/year: 3
5. INFECTIONS
a) osteomyelitis: 3
b) septicaemia : 3
c) meningitis: 3
d ) recurrence of a, b, c: 3
3. MAJOR ORGAN INVOLVEMENT 6. ACUTE PULMONARY EPISODE
a) neurologic complication : 3
b) bone infarction: 3
c) priapism : 3
d) leg ulcer: 3
e) gallstone: 2
f) others: 2
a) mild: I
b )  severe: 3
c) recurrence of a : I, b : 3
7. SEQUESTRATION CRISIS: 3
8. SPLENECTOMY FOR HYPERSPLENISM: 3
can be found), F4 and F5 (portion of cells in which density is higher than 1.110 
and 1.120 g/ml, respectively). Eleven normal subjects were studied in order to 
specify the normal values of red cell densities.
Irreversibly sickled cells (ISC) counting
The ISC was examined by light microscope according to the method of 
Clark [17], modified as follows: the percentage of ISC among 500 erythrocytes 
was determined by a single observer after the cells were fixed in 1 % glutaraldehyde- 
0.1 M Sorensen buffer.
Determination o f a-globin genotype
The a-globin genotypes were determined in 27 patients using Southern blot 
hybridization restriction endonuclease mapping of genomic DNA extracted from
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peripheral blood leukocytes [18]. The restriction patterns were obtained using 
Bam H 1 enzyme, and the fragments separated in agarose gel were hybridized with 
a genomic aPst 1 probe after transfer on a membrane.
Statistical method
All statistics were done using a Statworks program on Mackintosh computer.
50 patients with homozygous sickle-cell disease were analyzed. The distribu­
tion of clinical and biological variables are summarized in Tables 2 and 3. As ex­
pected, the parameters of the density distribution of the patient population dif­
fered from controls (Table 4). We examined the relationships 1) between the clinical 
score and the biological data and 2) between the biological factors themselves.
Incidence of the clinical findings in 50 patients with sickle cell disease. This table shows the 
distribution of the patients according to each parameter
Results
Table 2
1. AGE OF DIAGNOSIS
a) <1 year: 14
b )  1 to 2 years: 8
c) 2 to 5 years: 18
d) >5 years: 7
e) family investigation: 3
4. NUMBER OF HOSPITALIZATIONS
a) < 1/year: 23
b) 1/year: 23
c) 2 to 3/year: 3
d) > 3/year: 1
2. AGE AT THE TIME OF THE 5. INFECTIONS 
STUDY
c) 10 to 15 years: 12
d) 15 to 20 years: 8
e) >20 years: 2
a) <5 years: 13
b )  5 to years: 15
a) osteomyelitis: 7
b) septicaemia: 5
c) meningitis: 4
d) recurrence of a), b) or c): l
3. MAJOR ORGAN INVOLVEMENT 6. ACUTE PULMONARY EPISODE
a) neurologic complication: 3
b) bone infarction: 4
a) mild: 8
b )  severe : 13
c) priapism : 1
d) leg ulcer : 3
e) gallstone: 3
f) others: 1
c) recurrence of a: 3, b: 1
7. SEQUESTRATION CRISIS: 2
8. SPLENECTOMY FOR HYPERSPLENISM: 1
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Table 3
Haematological data in 50 patients
n m ± s.d.
Hb (g/dl) 50 7.9+ 0.1
MCV (fl) 50 8 7 + 9
Reticulocytes (x 1 Of'cu.mrn) 49 402+ 164
Hb F (%) 44 9.1 +  7
Irreversibly sickled cells (%) 34 6 +  1
Number of determinations (n), mean value (m) and standard deviation (s.d.).
Table 4
Red cell density distribution of 50 patients and 11 controls
P aram eters
N o rm al con tro ls  
(m  ± s.d .)
Patients with sickle­
cell disease 
(m  ±  s .d .)
P
D 50 1.102 +  0.002 1.101 +  0.005 n.s.
R 60 0.007 +  0.001 0.016+0.006 <0.001
F 4 6.5 +  6 20+  1.5 <0.001
F 5 0.5 +  0.25 7 +  6.5 <0.001
Mean (m), standard deviation (s.d.), p =  statistical significance, n.s. =  non significant
Table 5
D 50, R 60, F 4 and F 5 according to the number of oc globin gene in 27 patients
a-genes D 50 R60 F4 F5
aa/aa 1.101 0.018 21.9 7.9
n =  14 +  0.004 +  0.007 +12.2 +  7
— a/aa 1.101 0.014 16.2 5.6
n =  9 +  0.004 +  0.004 +10.5 +  5.3
— a/— a 1.099 0.017 6.5 0.5
n =  2
aaa/aa 1.097 0.012 26.5 1
n =  2
Number of determinations (n), mean value (m), standard deviation (s.d.).
Positive correlations were found between MCV and the number of a genes (p <
0.0005), F5 and D50 (p < 0.003) and between F4 and R60 (p < 0.05). A negative 
correlation between D50 and the number of a genes (p < 0.04) was noted (Table 
5). No relationship between the clinical score and the haemoglobin level, MCV,
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Table 6
Value of D 50 when dividing the 50 patients into 3 groups of increasing clinical severity
n m ±  s.d.
Score 0 to 4 15 1.099 +  0.003
Score 5 to 9 21 1.102+ 0.004
Score 10 to 15 14 1.103 ±  0.003
reticulocytes, irreversibly sickled cell levels was found. The haemoglobin F level 
was not related to the severity index. Likewise, there was no significant difference 
in the clinical severity among patients with and without a-thalassemia. We estab­
lished a positive correlation between D50 and the clinical score (p < 0.003) as 
shown in Fig. 1. The parameters F4, F5 and R60 were not related to the severity 
index. When dividing patients into 3 groups of disease severity, the value of D50 
increased from 1.099 + 0.003 for the first group, to 1.102 +  0.004 for the second 
and to 1.103 ± 0.003 for the third (Table 6).
Discussion
The determination of the red cell density introduced by Danon and Mar- 
kowsky [15] and applied afterwards to the study of the sickle cell disease is a simple 
technique. It is, moreover, reproducible when using standard conditions of sample, 
temperature and centrifugation. Since the preparation of the mixture requires 
great precision, these conditions must be strictly observed in order to obtain com­
parable laboratory results.
It is well documented that the sickle red cells’ distribution is different in dif­
ferent patients, but is constant in the same patient [8] except in the case of crisis,
H aem ato log ia  21, 1988
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Fig. 1. Distribution of the clinical score and D 50 of the red blood cell density profile
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an event during which all dense cells disappear [19]. Some biological parameters 
as Hb F level and a gene status modify the density distribution [14] and are known 
to influence the prognosis of the patients affected with sickle cell disease [1, 2, 3, 
4, 5, 6]. These ascertainments brought us to search for a relationship between 
the density profile and the clinical severity of the disease.
The establishment of a clinical score is essential in the sickle cell disease for 
several reasons. Such a score would enable the physician to notice the serious cases 
among patients and to adapt an adequate therapeutic attitude. A score, also, should 
offer the possibility of studying the effect of definite biological parameters on the 
clinical severity in a well defined group of patients. Such scores have been proposed 
previously [12, 13]. Steinberg’s score [12] is better suited to adult. Likewise, 
it seems to us that certain clinical events which failed in the previous evaluations 
must be included in a new score. We will insist on the age of the patient at the time 
of the study. Some acute infection episodes, such as meningitis or septicaemia due 
to germs other than pneumococcus and as hyperplenism should be included in 
a clinical score. All these criteria appear to be objective and easily available. 
However, this score is still an a posteriori approach of the clinical severity. The in­
evitable limits of this method are as follows: 1) all the lethal forms are excluded 
from the series of patients; 2) in young patients the follow-up is very short and 
complications that may occur in the future are not taken into account. For these 
reasons we give a high score to the age of young patients and to certain complica­
tions usual in infancy and childhood.
Concerning the correlations, we first studied the relationship existing between 
some biological factors. The correlations noted between F4 and R60 on the one 
hand and between the number of a globin genes and D50 on the other have been 
described [14]. In this study, the values of D50 in patients with 5 a globin genes 
are identical to those measured in patients with 2 genes. This result might be 
explained by the low number of patients studied. The strong positive correlation 
between MCV and the a gene status (p <  0.0005) is as expected because the reduc­
tion in a globin chain synthesis induces low MCV. The correlation between D50 
and F5 indicates that the patients with higher D50 have the greater level of dense 
cells, especially cells with density over 1.120 g/ml. It is difficult to determine the 
effect of haemoglobin F level on the other parameters because of the variation of 
haemoglobin F which disappears slowly in children with sickle cell disease till 5 
or more years of age. Secondly, we studied the relationship between our clinical 
score and the biological parameters. The most interesting result is the closed posi­
tive correlation (p <  0.003) observed between the severity index and the median 
cell density D50. This fact appeared clearly when the patients were divided into 
3 groups of severity. Lower values of the D50 were found in patients with mild 
sickle cell disease. However, this result probably needs to be confirmed in a more 
extensive population.
The red cell density profile, particularly the median cell density (D50), might 
be an index of prognosis of sickle cell disease. The displacement of the distribution 
to higher level and the appearance of dense cells in which the fraction of haemo­
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globin S polymers is high, could influence the expression of the sickle cell disease 
[20, 21]. As for Hb F level, a genes status, haplotypes and other haematological 
data, the profile of the red cell density might contribute to establish an index of 
prognosis in sickle cell disease.
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We developed a lymphocyte ferritin antibody-binding test (LFABT) to measure 
lymphocyte surface ferritin (LSF) and used it in cases of malignant and other diseases 
associated with elevated serum ferritin. LSF was elevated in 33 of 83 patients with a 
variety of malignant neoplasms in all stages of disease. LSF was also elevated in 2 of 5 
patients with infectious mononucleosis, but was normal in all 15 patients with rheuma­
toid arthritis, bacterial infections and hemochromatosis. LSF and serum ferritin levels 
do not correlate. These findings suggest the usefulness of LFABT as a diagnostic 
tool and demonstrate the biologic significance of LSF.
Keywords: ferritin, tumor markers, iron proteins, lymphocyte surface markers
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Introduction
Serum ferritin levels are often high in patients with malignant diseases and 
may be a useful marker of disease activity [1 ]. The elevated serum ferritin has a very 
limited diagnostic value because levels are also high in cases of infection, chronic 
inflammation, liver disease and iron overload. Acidic isoferritins may be dispropor­
tionately elevated in the serum of cancer patients, therefore this may be more 
specific [1, 2].
Peripheral blood leukocytes normally synthesize ferritin. Lymphocyte fer­
ritin synthesis is increased in Hodgkin’s disease and leukaemia [3, 4]. Ferritin can 
be found on the lymphocyte surface, and it is assumed that increased lymphocyte 
surface ferritin (LSF) may be a sensitive and specific finding in malignancy, par­
ticularly in early breast cancer [5, 7]. We have developed a sensitive, reproducible 
lymphocyte ferritin antibody-binding test (LFABT). This has been used in a large 
number of cancer patients to confirm or refute previous observations in breast 
cancer and Hodgkin’s disease and to survey other malignant diseases. Prior studies 
have not proved that elevated LSF is a specific marker of malignancy, so we have 
studied patients with benign disorders, too (with inflammations, infections and
* Correspondence should be directed to: Lawrence Rice, MD, The Methodist Hospital, 
6535 Fannin, MS-902, Houston, Texas 77030, USA
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Table 1
Elevated LSF with disease
n
E levated
L S F
(P /C  >  2)
Hodgkin’s disease
Stage I —II 4 3
Stage I I I - IV 10 6
In remission 2 0
Breast cancer
Stage II 5 0
Stage III — IV 17 9
Lung cancers 14 5
Non-Hodgkin’s lymphomas 11 5
Chronic lymphocytic leukemia 7 1
Other malignancies 13 4
Benign disorders
Mononucleosis infections 5 2
Bacterial infections 4 0
Rheumatoid arthritis 9 0
Hemochromatosis 2 0
iron overload). To our best knowledge so far the possible correlations between 
LSF and serum ferritin and the question whether elevated LSF is due to increased 
serum ferritin and merely reflects it, have not been studied.
Materials and Methods
Patients
103 patients and 45 normal controls were studied. Diagnosis of cancer was 
confirmed histologically, the disease was in a clinically active stage, and no coin­
cident infection was present. Most patients were in the early stages of treatment; 
twenty percent were untreated. Patients listed with “other” malignancies (Table 1) 
mostly had advanced disease and had primary carcinomas of ovary, colon, kidney, 
testes and thyroid, soft tissue sarcomas and one had acute myeloid leukaemia.
Lymphocyte Ferritin Antibody-Binding Test (LFABT)
Mononuclear leukocytes were isolated from freshly-obtained heparinized 
venous blood by standard isopycnic flotation [8]. Lymphocyte concentration was 
adjusted to 1.5 xlO6 cells/ml (suspensions contained 1 — 10% monocytes).
i /a e m a to lo g ia  21 , 1988
n =  number of patients studied; LSF =  lymphocyte surface ferritin; P/C =  patient 
to control ratio
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In 12 X 100 mm glass tubes, 0.33 ml of cell suspension were mixed with 0.2 ml of 
a high affinity 125I-labeled rabbit anti-human spleen ferritin antibody (Ramco 
Laboratories, Houston, Texas). Triplicate samples were incubated 15 minutes 
at 4 °C, then 45 minutes at 37 °C with 5% C 02. Cells were washed five times in 
phosphate buffered saline, then resuspended in 1 ml buffered saline. The radio­
activity of the cell suspension was determined (Packard Autogamma 500 C).
The quantity of anti-ferritin antibody binding was determined by subtracting 
the radioactive counts of a blank tube (to which antibody but no cells had been 
added) from the counts of the test sample. In each experiment, at least one normal 
control was studied simultaneously, and a patient to control ratio (P/C) was cal­
culated. The results are expressed in this manner to correct for differing specific 
activities among antibody lots and to correct for decay of radioactivity over time 
in a given lot of antibody. Serum ferritin assays were done on the same blood 
specimens used in the LSF assay, employing immunoradiometric Fer-iron kit 
(Ramco, Houston, Texas).
Results
The LFABT was highly reproducible: multiple determinations on the same 
blood specimen showed a standard deviation from the mean of only 0.085%. 
When eight different normal controls were studied simultaneously, the standard 
deviation from their mean was 48 % of the mean and no normal was more than 
twice the mean. We defined a P/C ratio of 2.0 or more to be elevated (statistically 
only 2% of normals are expected to fall above this level).
Table 1 summarized our findings in the patients with malignancies and benign 
disorders. 33 of 83 cancer patients (40%) had elevated LSF. 2 of 5 patients with 
infectious mononucleosis had elevated LSF, but no elevations were detected in the 
15 patients with bacterial infections, rheumatoid arthritis and hemochromatosis.
Figure 1 plots LSF versus serum ferritin concentrations in the patients with 
cancer. There is no correlation (r = 0.14, p > 0.1). Similarly, there was no cor­
relation of LSF and serum ferritin in patients with benign disorders (r =  0.02,
p >0.1).
Discussion
Applying our sensitive, reproducible LFABT we found that LSF is frequently 
elevated in cancer patients. LSF is elevated in a variety of different neoplasms 
in all stages of disease. To date this study involves the largest number of cancer 
patients and the largest number of patients with benign diseases. 2 of 5 patients 
with infectious mononucleosis had elevated LSF, but there were no elevations in 
patients with bacterial infection, rheumatoid arthritis or hemochromatosis.
Prior studies have not involved correlations between LSF and serum ferritin. 
Thus, the possibility has not been excluded that elevated LSF in cancer might re­
flect, at least partly, nonspecific adherence of increased serum ferritin to mono-
H aem ato lo g ia  21, 1988
2 0 2 G. Si einhoff ei al.: Lymphocyte surface ferritin
Fig. 1. Absence of correlation between LSF and serum ferritin in cancer patients (r =  0.14,
p >  0 . 1 )
nuclear leukocyte surfaces. Based on our present work, LSF and serum ferritin do 
not correlate but are independent biologic variables. It should be remembered 
that our anti-ferritin antibody is directed against a spleen-derived basic isoferritin. 
In cancer patients, an acidic isoferritin (heart-like, HeLA-like) may be dispropor­
tionately elevated in serum [2], so future study of this isoferritin on lymphocyte 
surfaces may be of interest.
Moroz and Giler have suggested that determination of LSF is clinically 
useful for diagnosis of early breast cancer [5, 6, 7]. Our findings indicated that 
LSF was not consistently elevated in early breast cancer and was often elevated 
in advanced breast cancer. A number of factors could contribute to the differences. 
An important factor might be the patients’ treatment status (our patients were 
postoperative and theirs preoperative). In the future, the issues could be clarified 
by long-term serial LSF determinations in patients before and after surgery and 
monitoring of therapy and course of the disease. Another factor that may contri­
bute to differences between the studies is the different assay techniques for LSF and 
the different manners of expressing results. Previous studies have determined 
a percentage of ferritin-bearing lymphocytes by fluorescent or cytotoxic assays 
[5, 6, 7, 9], or have used a more quantitative but cumbersome LSF assay involving 
surface protein iodination, cell lysis, electrophoresis and immunoprécipitation [10]. 
Our simple LFABT determines mean surface ferritin, averaging all peripheral 
blood mononuclear leukocytes. Conceivably, mean LSF and percent LSF bearing 
lymphocytes may be disparate with some disorders.
The question of the clinical utility of the test, particularly its sensitivity, 
arises in relation to our observation of elevated LSF in malignancy. Sensitivity 
could be increased by lowering our upper normal threshold, but that would
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diminish specificity. In this case the results would be similar to Papenhausen’s,
i.e. a good majority of cancer patients would show elevated LSF, but so would 
some patients with benign lesions and some normal controls [9]. The diagnostic 
utility is further reduced by our finding that elevated LSF is not specific for any 
particular type or stage of malignant disease. While LSF is not a function of serum 
ferritin and is not elevated in most patients with benign inflammatory disease, 
there were elevations in cases of infectious mononucleosis.
Studies have suggested that LSF 1) correlates with quantitative and qualita­
tive T-cell deficiencies in Hodgkin’s disease [5, 10], 2) can be modulated by the 
immunopotentiating drug levamisole [10], 3) is carried by a specific T-cell sup­
pressor subpopulation in breast cancer [11], and 4) directs abnormal lymphocyte 
migration patterns in lymphomas [12]. We suggest that it may be more fruitful 
to reveal the pathophysiologic causes and significance of LSF than attempting 
to use it as a diagnostic test for malignancy.
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Two familial cases of hairy cell leukaemia are reported: a daughter, 44-years- 
old, with a very unusual ultrastructural pattern found in hairy cells, the “ tubuloretic- 
ular inclusions” , and her mother, 71-years-old, who was affected six years later. 
Routine laboratory investigations, cytochemical and cytogenetic studies including 
HLA typing, as well as in vitro proliferative response of peripheral blood mononuclear 
cells (PBMC) to polyclonal mitogens and to exogenous interleukin 2, were performed. 
The immunological characterization by assessing the cell surface phenotypic markers 
with monoclonal antibodies and transmission electron microscopy (TEM) investiga­
tions were also carried out. In case 2 all tests were performed both on PBMC and on 
the bone marrow cells. To the best of our knowledge this is one of the first reports of 
such familial association. The possibility that genetic factors might play a role in the 
etiology of leukaemia in man is discussed: in our two cases, however, cytogenetic 
studies did not support this, while HLA typing revealed a non-significant association 
of HCL with DQw3 allele. Alternatively, an environmental factor has been considered, 
and a viral infection-perhaps by a retrovirus of the HTLV family has been suggested 
as tubuloreticular inclusions have been found in both hairy cell leukaemia, as reported, 
by us, and AIDS-LAS. However, a long time elapsed between the manifestation of 
HCL in the daughter and in the mother, and as the two patients had not been living 
together at that time, the possibility of a viral transmission seems minimal. The results 
of TEM and of immunological investigations are presented and discussed. Both, but 
particularly the latter, support the B cell nature of the hairy cell.
Keywords: cell immunophenotyping, chronic B cell malignancy, familial 
incidence, hairy cell leukaemia, HLA typing, tubuloreticular inclusions, ultrastructural 
findings
Introduction
Hairy cell leukaemia (HCL) is a lymphoproliférative disorder, which 
accounts for 2% of all leukaemias. It is characterized by splenomegaly, pancyto­
penia and by the presence of characteristic mononuclear cells with irregular
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cytoplasmic border and often hairy-like cytoplasmic projections in the bone 
marrow, spleen and peripheral blood [1—3]. Due to neutropenia, monocytopenia 
and impaired T cell function, infections are very common and are often the cause 
of death [4, 5]. In spite of controversy on the origin of hairy cells (HCs) [6 — 8], 
the majority of investigators now agree that HCs are neoplastic B lymphocytes, 
closely related to B-chronic lymphocytic leukemia (CLL) cells [9 -  13]. Evidence 
indicates that B-CLL, hairy cell leukaemia, prolymphocytic leukaemia and Wal­
denstrom’s disease are linked by several biological and clinical aspects [14]. They 
appear as a distinct subgroup among the chronic B cell malignancies, clearly 
differing from follicular center tumours, and it seems reasonable to suggest that 
the target of the transforming event might be the same B cell population [15].
As for the familial incidence of HCL, very few cases have been previously 
reported: the most interesting report [16] described a family of 11 siblings in 
which three brothers with the HLA A l, B7 haplotype developed HCL within a 
seven-year period. Another report [17] examined a father and a son with HCL. 
HLA typing revealed both patients to be Al, 3 and B8, 14. A third report [18] 
described a family in which members of three generations have been affected by 
haematologic malignancies: the father with chronic myelogenous leukaemia, the 
proband with HCL and his brother x, with CLL, and a nephew with cutaneous 
and CNS lymphoma: this was the first reported case of HCL occurring with other 
haematologic malignancies within a family. To the best of our knowledge, in the 
complete case list of over 400 patients reported by the Italian Cooperative Group 
of Hairy Cell Leukaemia (ICGHCL), in which our group also takes part, no 
familial case was reported.
Two cases of HCL are described here: the first affecting a daughter with 
a very unusual ultrastructural pattern found in HCs, previously reported by us 
[19], and the second affecting her mother who was affected about six years later.
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Case Reports
Case 1, L. A., a 44-year-old woman, was hospitalized in November, 1980 due 
to splenomegaly (7 cm under costal margin) and complaints of fatigue since two 
months. Diagnostic laparotomy and splenectomy were performed. An enlarged 
spleen was found and several lymph nodes around the hilum of spleen. The cyto­
logic and histologic pattern of spleen showed a high number of typical HCs. 
Before splenectomy, leukopenia (WBC count 2.6 x 109/1), thrombocytopenia 
(platelet count 45 x 10°/l) and a mild anaemia (Hb 11.4 g/dl, RBC count 3.6 x 1012/1) 
were found. Soon after splenectomy the patient was referred to us. The haemato- 
logical status at this time was: a mild anaemia (Hb 11.5 g/dl) and leukopenia 
(WBC count 3.5 x 109/1) which persisted for the subsequent years, whereas the 
thrombocytopenia disappeared. The differential leukocyte count showed 50% of 
lymphoid cells, 10% of which were HCs, and 2% monocytes. In the bone marrow 
aspirate 16% of the nucleated cells were HCs; the marrow histology displayed
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wide areas of adipose tissue and haemorrhagic infiltrates. Cytochemical findings: 
over 30 % of peripheral mononuclear cells showed tartrate-resistant acid phosphat­
ase (TRAP) activity. In the following years the patient suffered from “flu-like” 
mild intercurrent infectious episodes. No therapy was applied until November, 
1985 when treatment with human lymphoblastoid alpha-2 Interferon (IFN) 
according to Treatment Protocol of the Italian Cooperative Group for HCL was 
started, due to the mild persistent leukopenia and moderate marrow infiltrate 
of HCs (approximately 10% of nucleated cells).
The WBC count raised to over 5 x 109/1 with neutrophils over 2 x 109/1, the 
HCs lowered to 2% in peripheral blood and to less than 10% in the bone marrow. 
Having achieved a minor response, the patient was assigned to maintenance 
therapy until one year of treatment was completed. At the end of IFN treatment, 
the patient was well and active (Grade 0 Performance Status, WHO) and the 
response was assessed as a minor, but significant, response (MR) (Hb 13 g/dl, 
WBC count 6.5 x 109/l, platelets 400x l09/l, neutrophils 3 x 108/1, HCs in peri­
pheral blood 5%).
The bone marrow aspirate yielded marrow blood without particles of marrow 
with HCs < 5 % . The percutaneous trephine biopsy of the bone marrow showed 
a discrete marrow fibrosis with a significant hyperplasia of argyrophilic reticular 
fibrilles stained by silver-impregnation method. HTLV-III antibody in the serum 
was not detected. A cytogenetic study including both routine and banding methods 
was performed: the karyotype was numerically and structurally normal. The 
HLA typing revealed the patient to be an A2, 31; Cw3, — ; B5I,60; DR4, 8; 
DRw52, 53 ; DQw3. A sister of the patient, healthy, revealed the identical HLA 
pattern.
At the last follow-up (February, 1987) the haematological and clinical 
findings were unaltered.
Case 2, P. G., a 71-year-old woman, mother of L. A. (Case 1), came to our 
attention in June, 1986, as a result of a chance finding of moderate leukocytosis 
(WBC count 16—18 x 109/1) with relative (about 50%) and absolute lymphocytosis 
(over 9x  109/1); this haematological abnormality appeared 2 months afore. The 
Hb, RBC and platelet counts were in the normal range. All other laboratory 
findings were normal, in particular the serum immunoglobulins, as well as the 
skin test response to recall antigens. She was in good clinical condition and physical 
examination was normal: a mild splenomegaly was found, confirmed by ultra­
sonic ecotomography and only small lymph nodes were palpable in the left latero- 
cervical region. The cytochemical staining for TRAP activity showed a moderate 
amount of positive cells: approximately 20% with score + or +  +  , 1 % with score 
5 + in the peripheral blood smear and several cells were 1 +  — 3 + in the marrow 
aspirate smear. It is to be noted that TRAP (isoenzyme 5) is often present in HCs, 
but the activity may be weak or absent in some cases and is often partially and 
sometimes completely inhibited by tartrate [20]. The cytochemical staining for 
PAS, both on peripheral blood and on bone marrow lymphocytes, showed a 
weak positivity with both diffuse and granular reactions in HCs. The bone marrow
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aspirate showed a marked, diffuse increase of lymphoid cells (approximately 50% 
of nucleated cells), most of which were HCs; the erythroid, myeloid and mega- 
karyocytic series were normal. The percutaneous trephine biopsy of bone marrow 
showed a discrete marrow fibrosis with reduction of normal haemopoietic marrow 
and a diffuse increase of reticular fibrilles stained by silver-impregnation method. 
No HTLV-1II antibody was detected in the serum. The karyotype was numerically 
and structurally normal. The HLA typing revealed the patient to be A2,24; 
Cw2, B14, 51; DR1,4; DRw53; DQwl,3.
At a nine month follow-up (February, 1987) the patient was well and active 
(Grade 0, WHO). The haematological picture was similar to that of the one 
observed at the time of diagnosis, but the peripheral blood lymphocyte differential 
count decreased to approximately 35% of all leukocytes, with 20% of HCs. The 
mild splenomegaly persisted unchanged. As there was no indication to start any 
treatment, we decided to continue the patient’s follow-up.
Methods
Laboratory investigations
The following in vitro investigations were performed:
— in vitro proliferative response of peripheral blood mononuclear cells 
(PBMC) to polyclonal mitogens PHA, Con A, PWM and to exogenous inter­
leukin 2 (1L 2) either by PHA-activated or non-PHA-activated PBMC with the 
microtitre plate technique, according to our previously described method [21, 22];
— immunological characterization of PBMC and, in Case 2, also of bone 
marrow mononuclear cells (BMMC) by assessing the cell surface phenotypic 
markers with a very large panel of monoclonal antibodies (MoAb) according to 
our previous work [23]. An optical Flow Cytometry apparatus (Ortho Spectrum 
III) was utilized.
Transmission electron microscopy (TEM) investigations
These were performed on PBMC and in case 2 also on BMMC. The buffy 
coat of heparinized peripheral or bone marrow blood was fixed in 1.5% glutaral- 
dehyde in 0.1 M phosphate buffer at pH 7.3 for 2h (4 °C) and postfixed in 1 % 
Osmium tetroxide in the same buffer (4 °C). The samples were then dehydrated 
through a graded series of ethanol and embedded in Epon 812. Thin sections were 
double stained with uranyl acetate and lead citrate and examined with a Philips 
EM 300.
Results
Laboratory investigations
Case 1. The patient’s PBMC response to polyclonal mitogens was poor at 
the time of diagnosis and at subsequent controls during the follow-up.
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The cell immunophenotyping performed on PBMC (WBC count 4.7 x 10°/1, 
lymphocyte count 1.6 x 109/1) is reported in Table 1. Reactivity of B cell-associated 
(anti DR, B2, B7, sIg), T cell-associated, monocyte-associated and granulocyte/ 
monocyte-associated MoAb with PBMC was determined. PBMC of Case 1 was 
reactive, in relatively high proportion for HCL, with T-associated antigens, while 
they reacted in relatively low proportion with the pan B anti DR MoAb: the B2 
antigen, which appears after the pre-B cell stage and is lost when pre-secretory 
Ig appears, was even lower than DR, as slg, while the B7 antigen, which appears 
at the later stages of maturation, is higher. The granulocyte/monocyte-restricted 
Ml antigen is high, while the monocyte-restricted M5 is low, as well as the myeloid- 
restricted My9. The PCA-1 antigen, characteristic of plasma cells, was weakly 
expressed in our case, whereas it is frequently strongly expressed on the HCs. 
Also the Tac antigen, although higher than in the normal population, is lower 
than that reported in HCL [13, 24].
Table 1
Immunologic phenotyping of peripheral blood mononuclear cells (PBMC) and 
of bone marrow mononuclear cells (BMMC) of two cases of HCL, performed with
monoclonal antibodies
Case l  C ase 2
L ym ph, co u n t L y m p h  co u n t
(1 .6  x 10®/1) (9 .4  x IO7I)
%  o f  P B M C % o f  P B M C  %  o f  B M M C
OKT3 + 48.9 14 17
OKT4+ 35.5 8.7 8.6
OKT8 + 12.1 4.1 10.6
OK.T11 + 66.1 15.2 18.3
OK.T6+ 0.1 0 0.6
OKT9+ 1.1 4.6 7.2
OKT10+ 1.5 3.9 16.3
OKB2+ 10.2 55.2 66.1
OKB7 + 16.4 15.0 60.9
slgtoC 9.3 3.5 3.6
sIgD+ 9.7 2.4 1.2
slgM + 6.1 0.9 1.3
Kappa+ 4.9 1.3 —
Lambda"1" 3.8 0.5 —
DR+ 13.7 73.3 73.2
OKTl(CLL)+ 53.9 80.7 80.4
OKT26a+ (anti-Tac) 7.6 6.8 2.1
OKB-cALLa+ 6.7 1 23.1
OK.M1 + 33.5 48.1 63.9
OKM5 + 20.7 0.9 12.3
Leu 7+ 14 5.6 9.7
Leu 1 la+ 14.9 6.2 6.2
PCA-1+ 4.2 2.8 —
My9+ 1 0.3 —
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Case 2. The patient’s PBMC response to polyclonal mitogens was below 
the normal range, whereas the response of non-PHA-activated PBMC to 1L 2 
was higher than normal and the response of PHA-activated PBMC to IL 2 was 
significantly higher than the response to PHA alone. This may indicate a defective 
production of endogenous 1L 2 in HCL or, alternatively, the possibility that the 
IL 2 produced by the T cell population may be readily utilized by the neoplastic 
B cells, like in B-CLL: the observation that HCsand B-CLL cells may express the 
IL 2 receptor at high levels seems to confirm this possibility [25]. Cell immuno- 
phenotyping performed both on PBMC (WBC count 18 x 109/1, lymphocyte count 
9.4X 10Ѳ/1) and on BMMC is reported in Table 1. PBMC showed a dramatic 
reduction of total T cells and of their subsets, while the number of ОКЛТ+ cells 
representing B cells of HCL was particularly high. In this case the pan B DR 
antigen is high as well as the B2 antigen, as in Case 1. The PCA-1 andTac antigens 
were markedly lower than that reported in HCL [26]. Cell immunophenotyping 
on BMMC showed a feature substantially similar to that of peripheral blood.
TEM investigations
Case 1. The TEM morphology of cells examined is shown in Fig. 1 to 3.
Figure 1 shows the characteristics of the cytoplasm of HCs: many villous 
projections, either thin and delicate or large and irregular, different in size and 
variously arranged spatially, either straight or with bizarre foldings are observable. 
The characteristics of the nucleus and of cytoplasmic organelles are typical for
Fig. 1. Case 1. Flairy cells of peripheral blood: the typical hairy-like cytoplasmic projections
( X  7 , 5 0 0 )
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Fig 3. Case 1. The “tubuloreticular inclusions” at higher magnification, showing the charac­
teristics of these structures (x 135,000)
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Fig. 2. Case 1. Hairy cell: cytoplasmic “ tubuloreticular inclusions” are visible (X 48,000)
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Fig. 4. Case 2. Ffairy cells of peripheral blood (X 7,500)
Fig. 5. Case 2. Hairy cell of bone marrow: the typical hairy-like projections are evident. 
The nucleus is cleaved and the cytoplasmic organelles are visible ( X  14,200)
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HCs. The most striking feature was that in approximately 20% of the HCs exam­
ined abnormal subcellular organelles (Figs 2 and 3) were present consisting of 
intracytoplasmic structures which seem to be identical with “tubuloreticular 
inclusions” described by Grimley et al. in peripheral mononuclear cells [27, 28]. 
These structures consist of nuclease and RNase resistant complexes of lipid-rich 
membranes and proteins [29, 30]. They are formed in the cytosecretory apparatus 
and consist of fine tubular meshworks that distend the endoplasmic reticulum. 
The structures within HCs are located close to the nucleus, surrounded by a thin 
rim and identical with the tubuloreticular inclusions described in the cytoplasm 
of PBMC of adults and an infant with AIDS and of homosexuals with Lymph- 
adenopathy Syndrome (LAS) [31—34].
Case 2. HCs of peripheral blood and bone marrow were studied. The mor­
phology of peripheral blood HCs is substantially similar to that of the above 
reported Case 1, and is shown in Fig. 4. The HCs of bone marrow have many 
hairy-like cytoplasmic projections, very typical of such cells (Fig. 5). The nuclei 
were relatively large, seldom round or oval, more often irregular and cleaved: 
this feature is distinctive, unlike HCs of Case 1. The chromatin was rather thin, 
often with “spongy” pattern, but especially condensed at the nuclear periphery. 
One (or rarely two) nucleolus is sometimes visible in the cells, it is more often 
large than small. The cytoplasm, rather poor in organelles, showed a moderate 
amount of mitochondria often piled and then with “cristae” swelling, condensed 
matrix and dense granules. A single or multiple centrioli were frequently seen, and 
the Golgi apparatus was generally well developed or even hypertrophic. Lysosome 
granules, frequently grouped and more or less electrondense, were also present, 
and there was evidence of phagocytic vesicles and of pynocytic activity. A smooth 
endoplasmic reticulum was present in many cells together with numerous free 
ribosomes in the cytoplasm. Many of these morphological findings have been 
already described in our previous work [35].
Discussion
Beyond the interesting finding of the very unusual ultrastructural pattern 
found in Case 1, i.e. the “tubuloreticular inclusions” reported for the first time in 
HCs, the main interest of our study was focused on the exceptional incidence of 
two cases of HCL, a very rare disease in itself, in two close relatives (mother and 
daughter).
To the best of our knowledge, this is the third report of such an association 
and the first involving mother and daughter.
The possibility that genetic factors might play a role in the etiology of 
leukaemia in man is an ancient suggestion already made more than a century 
ago by Biermer and others who reported the occurrence of multiple cases of leu­
kaemia in some families. Interest increased when Dameshek in 1929 first reported 
the classical cases of twin brothers affected by CLL and, twenty-five years later,
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the case of a son of one of the twins who developed CLL, too [36]. One of the 
most important studies of hereditary factors in leukaemia, published in 1969 by 
Gunz and Veale [37], was focused on CLL. In all series familial CLL tends to 
occur in closely related persons, siblings, parents, children, but otherwise there 
was no clearcut pattern of inheritance. Most of the patients with familial leukaemia, 
however, belonging to the elder age group, had not shared a common environ­
ment with other affected members of the family for many years [38].
Although the report of Wylin et al. [16], which described HCL affecting 
three siblings with a common haplotype, strongly suggests a genetic linkage, a 
control series of ten other unrelated patients with HCL who were typed by the 
same author showed no evidence of a common HLA phenotype: this is in agree­
ment with other reports.
On the other hand, the identical HLA types (Al, 3 and B8, 14) in HCL of 
father and son [17] seem to postulate a genetic mechanism causing increased 
susceptibility to this disease.
Unfortunately the HLA typing of the whole family of our two patients was 
not possible: the typing of the three members studied seems simply to suggest 
a weak association of HCL with DQw3, as has already been reported previously 
[39]. Indeed both the father and mother had a DQw3 allele which was inherited 
by both the daughter affected by HCL and her healthy sister.
Explanations for the fact that only a few persons with a specific HLA type 
actually develop the disease have been summarized by Bodmer [40]: 1) environ­
mental factors, 2) other genetic factors not related to HLA, 3) the hidden locus 
occurring less frequently than the HLA locus and 4) the heterogeneity of the 
disease being studied have been suggested. Similarly to other HLA-associated 
diseases it seems likely that it is not the haplotype itself, but perhaps a closely 
linked and as yet unidentified gene that is responsible for the increased disease 
susceptibility [16].
Besides the above discussed HLA linkage, the problem of the relationship 
between human oncogenes and B cell malignancies has arised : of the two putative 
oncogenes involved (bcl-1 and bcl-2) bcl-1 seems to be associated with CLL of 
the B cell type carrying a t (11:14) (ql3; q32) translocation [41]. Moreover, a 
trisomy of chromosome 12 was described as characteristic for HCL [42]. The 
possible role of oncogenes and of chromosomal abnormalities in the development 
of HCL remains, however, to be established.
Most, although inconclusive, suggestions support that a genetic factor may 
play a role in the etiology of HCL: in our two cases cytogenetic investigations 
did not prove this factor, whereas the HLA typing revealed a non-significant 
association of HCL with DQw3 allele.
Alternatively, environmental factors may also be considered in the etiology 
of HCL. It must be stressed that our two patients, although relatives, had not 
lived together for over twenty years, i.e. from the time of the daughter’s marriage. 
Both patients were housewives and had never been exposed to medical risks nor 
to radiation or chemical hazards.
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An interesting fact to be considered is the above described ultrastructural 
pattern of “tubuloreticular inclusions” (TRI) seen in the HCs of Case 1. Although 
the pathophysiologic function of these inclusions is still unknown, the discovery 
of TRI in patients with herpes virus encephalitis and especially in those with 
AIDS and LAS (see above) clearly suggests a relationship to virus infection [43, 
44]. Thus an étiologie association between a virus infection and the outbreak of 
HCL may be assumed. The virus involved may be a HTLV retrovirus identical 
with the etiological agent of AIDS, although HTLV-III antibodies were not 
detected in either case. An association between AIDS and HCL has been pre­
viously reported [45].
An alternative hypothesis might be that the virus infection had been an 
occasional opportunistic one and therefore it did not play any role in the etiology 
of HCL. In any case, the long time (over 6 years) which elapsed between the 
occurrence of HCL in the daughter and in the mother, and the fact that the two 
patients had not lived together in this period seem to exclude or minimize the 
likelihood of a viral transmission. An interesting fact is that also in the report of 
Ramseur et al. [17] the time of onset of the father’s disease was within five years 
of the proband’s.
A striking defect in cellular immune function was found in both of our 
patients: unfortunately we could not study all members of the family to detect 
the possible subclinical immune defects in unaffected members.
Finally, another interesting factor is the immunological pattern of HCL 
cells. Our data on immunological phenotyping are partly in agreement with the 
above reported findings [25]: they differ in regard to Tac and PCA-1 antigens. 
The panel of B cell-restricted and -associated antigens used were not complete. 
It should be emphasized, however, that an exhausting immunophenotyping was 
not our main purpose.
Several data support the suggestion that HCL is a neoplasm of B cell origin. 
The presence of the B cell-associated antigens and of the B cell-restricted deter­
minants on HCL cells strongly suggests that these tumors are derived from B cells 
[8]. The recent report that heavy and light chain gene rearrangements were found 
in 8/8 patients with HCL is a further support for this hypothesis [13].
Most recent studies [25] suggests that HCL is not derived from an early- 
or mid-stage B cell, but is a tumor of presecretory B cells: moreover, their unique 
morphology and cytochemistry indicate that the HCL is derived from a pheno- 
typically unique subset of presecretory B cells. Whether a subset of normal B cells 
with these properties exists is still unknown. However, the unique biologic and 
clinical behaviour of this disease suggests that it is derived from a small subset of 
normal cells that invade the bone marrow and spleen.
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Protective Effects of Vitamins E and C on Erythrocytes 
in Blood Preserved in ACD Solution and Stored at 4 °C
J. K opec-Szlçzak,1 M. G rabarczyk,1 I. Szczepanska,1 S. F urman2
'Department of Physiopathology and departm ent of Blood Preservation,
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Vitamins E and C were used for the enrichment of the fluid for blood preserva­
tion. Whole blood with added ACD solution and vitamins E and C was stored at 4 °C 
for 21 days. The performed determinations included: haematocrite, osmotic fragility 
of the erythrocytes, ATP and 2,3-DPG content in the erythrocytes, and echinocyte 
count.
A protective effect of these vitamins on erythrocytes was manifested by the de­
creased osmotic fragility, the steep fall of 2,3-DPG compared with the blood preserved 
in the vitamin-free ACD solution.
Keywords: stored erythrocytes, vitamins E and C
Introduction
Structural and functional changes of erythrocytes with reduced osmotic 
fragility and cell membrane integrity as well as deformability of the whole cell is 
shown in preserved blood [1, 2, 3]. A loss of cell membrane fragments is caused 
by the separation of microvesicles [4, 5], and peroxidation processes change the 
molecular structure of this membrane [6].
By modifying the composition of solutions used for blood preservation it 
was possible to improve the vitality and osmotic fragility of erythrocytes, to reduce 
the degree of haemolysis [7], to reverse processes of cell deformation [8, 9], and 
to maintain the level of metabolically highly active compounds such as ATP and 
2,3-DPG [10, 11]. The damage to cell membrane structure in stored erythrocytes 
resembles the processes that take place during cell aging, when peroxidation pro­
cesses become prevalent [12]. Consequently, one might assume that antioxidants 
could prevent the adverse effects of peroxidation processes and improve erythrocyte 
survival. Vitamin E [12, 13] and vitamin C [14, 15, 16] are well-known physio­
logical antioxidants.
This work aimed at studying the effects of vitamins E and C on the erythro­
cytes of blood preserved in ACD solution at 4 °C, and at comparing the results 
obtained with those of similar blood samples preserved without these vitamins.
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The marked parameters were: osmotic fragility of the erythrocyte, echinocyte 
count, adenosine triphosphate (ATP) and 2,3-diphosphoglycerol (2,3-DPG) levels 
in the erythrocytes.
Materials and Methods
Investigations were carried out on blood samples obtained from five healthy 
subjects. Vitamins E and C were added to ACD solution before it was mixed 
with whole blood, or to the whole blood before it was mixed with ACD. The blood 
was kept in glass bottles at 4 °C for 21 days. Various amounts of vitamins E and C 
were added, then haemotocrite values, erythrocyte osmotic fragility (according to 
the method of Seeman and Weinstein [17]) and the echinocyte count were com­
pared [8, 18]. The osmotic fragility of the erythrocytes was expressed as the degree 
of haemolysis in a buffered hypotonic solution of NaCl (60 mM NaCl at 37 °C for 
1 h), and was calculated as a per cent of total haemolysis of the same erythrocyte 
volume in water. In estimating the number of deformed erythrocytes in the prepara­
tion of blood smears, echinocyte grades I and II were counted jointly [19]. The ATP 
and 2,3-DPG levels in the erythrocytes were determined in three blood samples 
taken from healthy subjects with vitamin E 60 /ig/ml and vitamin C 2 jug/ml using 
standard enzymatic methods (Sigma test). Similar determinations were carried out 
in blood samples which lacked vitamins. The results obtained were subjected to 
Student’s t test statistical analysis.
Results
Haematocrite index
During 21 days of blood storage (with ACD), the haematocrite index re­
mained unchanged (from 30 to 40%, depending on the blood sample) in the sam­
ples with and without vitamins.
Erythrocyte osmotic fragility
The addition of vitamins E and C caused a slight reduction of the osmotic 
fragility of the erythrocytes at several concentrations expressed as the grade of 
haemolysis in a hypotonic solution in comparison to a control sample (Table 1). 
The addition of vitamin E 60 ^g/ml and vitamin C 2 /rg/ml to the ACD solution 
before mixing it with blood caused a much more evident reduction of haemolysis 
degree both in the early (p ~  0.1) and in the late period of blood storage (on day 
21), when the osmotic fragility was 25% lower than in the control sample 
(p < 0.05), (Table 2, Fig. la).
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Table 1
Effect of various concentrations of vitamin E and C on the erythrocytes of blood preserved 
in ACD at 4 °C and stored for 21 days
D ete rm ination
V itam in  co n c en tra tio n  
in 1 ml o f b lood to ge ther 
with A C D
D u ra tio n  o f  blood s to rag e  (days)
0 3 7 14 21
control 17.2 15.0 37.7 50.2 65.9
Vit. E — 30 /ig/ml 18.6 31.4 49.3 63.9
Erythrocyte Vit. E — 60 /ig/ml 16.7 28.5 50.2 64.6
osmotic fragility Vit. C — 1.5 /ig/ml 19.8 34.8 49.6 67.9
( % of hemolysis) Vit. C — 2.0 /ig/ml +  vit. E
— 60 /tg/ml 19.8 31.9 46.8 64.7
control 1.3 370.0 164.0 200.0 280.0
Vit. E -  30 /ig/ml 90.0 100.0 145.0 260.0
Vit. E — 60 /ig/ml 35.0 160.0 188.0 83.0
echinocytes ( %) Vit. C — 1.5 /ig/ml 80.0 96.0 82.0 100.0
Vit. C — 2.0 /ig/ml +  vit. E
— 60 /ig/ml 6.0 120.0 124.0 140.0
* Vitamins added to whole blood before mixing it with ACD 
Attention: The values show means of samples from two blood donors
Echinocyte count
Samples with added vitamins E and C showed lower echinocyte counts during 
the 21 days of observation than the vitamin-free samples, although fluctuations 
did occur (Table 1). The best results were obtained when vitamins E and C were 
added to ACD at a concentration of 60 /tg/ml and 2 /ig/ml, respectively. On day 21, 
the reduction of the echinocyte count in these samples was statistically significant 
as compared to that of vitamin-free blood samples (Table 2, Fig. lb).
ATP and 2,3-DPG levels in the erythrocytes
ATP concentration in the erythrocytes in blood preserved with 60 /ig/ml 
E and 2 /Tg/ml C vitamin did not differ from that in control samples over the whole 
21-day period of investigation, and the degree of decrease in the erythrocytes was 
nearly identical (Table 2, Fig. 2a).
The level of 2,3-DPG in the erythrocytes decreased with equal rapidity 
in samples with and without vitamins, although a slight delay was noted in the 
steep fall of 2,3-DPG concentration on day 7; by that time this concentration was 
about 30% higher than in the control samples (Table 2, Fig. 2b).
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Fig. la. Osmotic fragility of erythrocytes preserved in ACD with added vitamin E (60 /<g/ml) 
and vitamin C (2 /ig/ml) stored at 4 °C. The fagility expressed as percent of haemolysis 
Fig. lb. Number of echinocytes and blood preserved in ACD with added vitamin E (60 /ig/ml) 
and vitamin C (2 /ig/ml) stored at 4 °C
Discussion
Various trial tests were performed for the selection of an optimal composition 
of solution to be used for blood preservation. Some aimed at the correction of ATP 
loss from the erythrocytes by addition of adenine [2] resulting in a transformation 
of echinocytes into erythrocytes of normal appearance [8]. The addition of man­
nitol resulted in a decrease of spontaneous haemolysis [7, 10], and a reduction 
of the number of deformed erythrocytes [10]. Other purines and pyruvates also 
have a favourable effect on the survival of the stored erythrocytes [11].
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Table 2
The effect of joint addition of vitamin E (60 /ig/ml) and C (2 ,ng/ml) added to ACD on erythro­
cytes preserved in ACD at 4 °C stored for 21 days
~  S to rage  tim e  (days)
D ete rm in a tio n  E
сл 0 3 7 14
x +  SD
Erythrocyte 
osmotic fragility
C 59.2 +
39.3+ 9.6
16.1 50.0+ 9.0 47.1 +  0.3 45.1 +  2.6
(% hemolysis) V 45.6 + 7.8 43.1 +  4.9 36.4+ 9.3 33.7 +  5.9*
x +  SD 
Echinocytes 
(%)
C
V
58.3 +  3.5
10.1 + 0.0
21.6+  9.7*
148.0+ 36.6 
110.0+ 42.3
198.3+ 41.6 
155.6+ 68.6
250.3 +  50.0
100.3 +  21.2*
x +  SD
2,3-DPG in c 9.27+ 1.2 2.0+  0.0 0.79 +  0.2 0.0 +  0.0
erythrocytes 12.5 +  1.6
(/iM/g Hb) V 8.72 +  2.3 2.9+  0.1 0.68 +  0.2 0.0 +  0.0
x +  SD
ATP in C 3.8 +  0.1 3.2+ 0.2 2.5+ 0.3 1.6+ 0.1
erythrocytes
(/'M/g Hb) V
3.5+ 0.1
3.8 +  0.1 2.9+  0.2 2.3+ 0.3 1.3 +  0.1
X =  mean of samples from 3 donors
* — statistically significant differences in relation to control 
C — control sample 
V — sample with vitamins
2t
Vitamin C in a final concentration of 5 mM was added to the ACD solution 
with adenine by Wood and Beutler [20], who obtained a higher 2,3-DPG level 
in the erythrocytes stored for 28 days than in those stored without this vitamin. 
In our experiments the concentration of vitamin C was about 500 times lower, 
and a transient, slight delay of the steep fall of the 2,3-DPG level was observed. 
High concentration of vitamin C may cause spontaneous haemolysis of erythro­
cytes [21] and its antioxidative effect is observed at a relatively low concentration 
[15]. Moreover, vitamin C may co-act with vitamin E which has extraordinary 
antioxidative properties [13] that intensify the effect of these vitamins [14, 15, 16].
In our investigations the use of both vitamins permitted to achieve an increase 
of the osmotic resistance of erythrocytes (14-25% ) during blood storage for 21 
days as well as a decrease in the degree of erythrocyte transformation into échino­
cytes (20-60%) in that time| period. The analysis of the effects of various concen­
trations of vitamins E and C on the decrease of the osmotic fragility of the erythro-
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Fig. 2. ATP (A) and 2,3-DPG (B) levels in the erythrocytes preserved with ACD at 4 °C with 
added vitamin E (60 ,ag/ml) and vitamin C (2 /rg/ml)
cytes and on the decrease of echinocyte count suggests that the combination of 
both vitamins at the concentrations of 60 jug/ml and 2 /tg/ml, respectively, added 
to ACD solution before mixing it with blood, gives the best results as compared 
to various other concentrations. Further investigations may help to establish the 
optimal concentration of these vitamins in order to improve the effect of erythro­
cyte viability maintenance, since no positive effect of both vitamins on ATP level 
in the erythrocytes has been obtained yet.
The results obtained so far suggest that vitamins E and C, due to their anti­
oxidant ability [13, 14, 15, 16] reduce the intensity of peroxidative processes in 
erythrocyte membranes and protect their integrity. Some authors, however, claim 
that the loss of microvesicles plays a more important role in the disintegration of 
the erythrocyte membrane than peroxidation [22].
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Free peroxides attacking the membrane lipids seem to have, however, 
an effect on the viability of stored erythrocytes [23].
The results of Webster and Toothill [24] also indicate the role of the anti­
oxidative system in the red cell damage during storage. They observed a significant 
decrease of superoxide dismutase activity and reduced glutathione during the 10- 
day storage period.
In the light of these preliminary results it seems that they may be helpful 
in further investigation on the optimalization of media for blood preservation. 
The enrichment of ACD solution with appropriately selected concentrations of 
vitamins E and C may help in the protection of stored erythrocytes.
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Lactate dehydrogenase (LHD) content of serum and leukocytes was examined 
in 42 haematologically normal healthy volunteers and in 34 patients suffering front 
various types of leukaemia. All patients were studied at the time of presentation and 
before any therapeutic intervention. Serum LDH was elevated in all types of leukaemia. 
In acute myeloid leukaemia (AML) a significant elevation of leukocyte LDH activity 
(p <  0.005) was noted. In acute lymphoblastic leukaemia leukocyte (ALL), LDH was 
significantly elevated when compared to normal lymphocyte LDH (p <  0.01) levels, 
but not when compared to total normal leukocyte LDH levels. In chronic leukaemias, 
leukocyte LDH levels were not significantly different from the normal. Comparison of 
LDH isoenzyme pattern in peripheral blood cells with that of serum, both in normal 
and in leukaemia cases showed more “ M” type enzyme in the cells than in the serum. 
However, the “M” type enzyme was significantly elevated only in AML cases 
(p <  0.005).
Serum LDH and peripheral blood leukocyte count compared in normal subjects 
and in leukaemia cases showed no correlation.
Keywords: lactate dehydrogenase, intracellular enzyme, leukaemia
Introduction
Serum or plasma LDH (Lactate dehydrogenase E.C. 1.1.1.27) activity has 
been found to be increased in some types of leukaemias [1—4]. LDH catalyses 
the reversible oxidation of pyruvic acid to lactic acid. Hence it is one of the key 
enzymes involved in anaerobic glycolysis. It was noted by Warburg [5] that many 
tumour tissues show a high rate of anaerobic glycolysis. Therefore elevated LDH 
levels in leukaemias were not surprising. Serum LDH levels may be elevated 
in several ways: 1) Each leukaemic cell might be producing a higher quantity of 
LDH than its normal counterpart. 2) Each leukaemic cell might be producing 
a normal amount of LDH, but as a result of vast increase in cell burden the serum 
LDH level may rise. 3) Release of LDH from normal tissue infiltrated and damaged 
by leukaemic cells. 4) A combination of any of aforementioned mechanisms may
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Laboratory, Farwania Hospital, P.O. Box 18373 Code 81004, Kuwait
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be responsible. Very few studies [3, 4] have estimated both the cellular and serum 
level of LDH in leukaemia, and to our knowledge only one study is available in 
English literature comparing the isoenzyme pattern of LDH in serum and leu- 
kaemic cells in three cases of ALL [6]. Such isoenzyme studies might explain the 
biochemical differentiation of cells in various leukaemias as it has been done for 
thymocytes [7].
Materials and Methods
42 healthy volunteers between the ages of 20 — 38 years, staff members of 
the institute were used as controls. 34 patients (14 with AML, 7 with ALL, 9 with 
chronic myeloid leukaemia (CML) and 4 with chronic lymphocytic leukaemia 
(CLL), attending the haematology laboratory, were included in the present study. 
Tests were performed prior to therapeutic intervention. Diagnosis was established 
by using standard clinical and laboratory protocol [8]. All cases of acute leukaemia 
were classified according to FAB classification [9].
For investigation of serum and cellular LDH activity, 5 ml blood was col­
lected in a clean dry test tube, and 15 ml of blood was collected in heparinised BSS 
solution. Serum was separated from 5 ml clotted blood after 2 hours, and cells 
were separated from heparinized blood according to the methods of Dioguardi 
et al. [10]. The cells were lysed by repeated freezing and thawing, both cells and 
serum were assayed for LDH activity according to the method of Wootton [11]. 
Isoenzyme pattern of LDH from cells and sera was also studied on the same day 
by the agar gel electrophoresis technique [12]. Isoenzymes were designated 1 — 5 
starting from the positive end. The electrophoresis strip was quantitated in a Carl 
Zeiss densitometer. Quantitation of “H” and “M ” type LDH protein involved 
the assumption that LDH-1, LDH-2, LDH-3, LDH-4 and LDH-5 are tetramers 
with H 4 , H3M], H2M2, H 4 M3and M 4 compositions, respectively. Serum concentra­
tion of the enzyme was expressed as I.U/L, and cell concentration as milli inter­
national units/10(l cells (mlp/100 cells). Lymphocytes from 8 healthy volunteers 
were separated on Ficoll-paque (Pharmacia, Sweden), and total LDH levels in 
lymphocytes were measured as above. Results were analysed by Students’ t test.
Results
Total LDH activity of serum and peripheral blood leukocytes are presented 
in Table 1. Serum LDH activity was found to be significantly increased in all types 
of leukaemia (p <  0.05).
There was no correlation between serum LDH and peripheral blood leuko­
cyte count in normals or in leukaemia patients. The increase in serum LDH 
activity was the highest in ALL and the lowest in CLL. Cellular and serum LDH 
levels did not correlate with clinical parameters such as liver size, spleen size or 
mediastinal mass.
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Table I
Serum and leukocyte LDH levels in peripheral blood of normal subjects and leukaemia
patients at the time of diagnosis
Cases
(N os.)
T o ta l leukocyte 
co u n t X 109/L  
(Range)
Serum  L D H  
(IU /L )
M ean ± I S.d.
Leukocyte LD H  
(m.LU./lO 'Vcells) 
M ean ± I S.d.
Normal (42) 4.2-9.6 62.83 +  30.10 12.92 +  7.46
Normal lymphocytes (8) - - 7.1+4.8
Acute myeloid leukaemia (14) 9 .0- 100 0 501.0+113.0 24.0 + 5.4
Acute lymphatic leukaemia (7) 4.4-450.0 677.0 +  203.6 14.2 + 3.12
Chronic myeloid leukaemia (9) 55.0-600.0 184.0 + 41.4 10.36 + 2.8
Chronic lymphatic leukaemia (4) 8.0- 105.6 101.7 +  74.18 9.02 +  2.76
Cellular LDH activity showed a striking increase in AML cases (p < 0.005), 
whereas in other types of leukaemia cellular levels of LDH were within the normal 
range (p >  0.05). When the LDH content of leukocytes in ALL was compared 
to that of normal lymphocytes, significant elevation was noted (p < 0.01).
In most patients, no LDH-5 isoenzyme was detected. Cellular isoenzyme 
pattern showed a cathodal shift compared to its counterpart in serum (Table 2). 
The rise of cellular LDH activity in AML cases was mainly due to the rise of the 
“M” fraction of the enzyme (p < 0.005). In other types of leukaemia, the elevation 
of cellular LDH was due to the rise of both H and M fractions.
Discussion
The present study confirmed the findings of Kornberg et al. [2] that marked 
elevation of serum LDH occured in ALL. This study also showed the lack of 
correlation between the levels of serum LDH and peripheral leukocyte count 
in both patients and healthy controls, a finding not difficult to explain because 
LDH is synthetised by almost all cells of the body and peripheral leukocyte count 
is a poor indicator of body leukocyte burden. One of the recent studies in childhood 
ALL showed fair correlation between leukocyte count and serum LDH levels in 
a large series of patients [13]. This good correlation may be due to the fact that 
a homogenous group of ALL patients was selected for this study.
Serum or cellular LDH levels in our study did not correlate with age, sex, 
hepatosplenomegaly, which is in agreement with other reports [14]. The present 
study did not explore the prognostic value of serum or cellular LDH levels or 
the isoenzyme pattern in cases of leukaemia. Hiçsônmez et al. [15] pointed out 
that high risk ALL patients at the time of initial diagnosis had higher serum LDH 
levels than patients at standard risk, and LDH-3 was higher than LDH-2 in high 
risk cases, a finding which other authors have disputed [16]. Serum LDH levels
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L D H  is o e n z y m e  p a t t e r n s  in  s e ru m  a n d  p e r ip h e ra l  b lo o d  le u k o c y te s  in  n o r m a l  s u b je c ts  a n d  in  p a t i e n t s  w ith  le u k a e m ia  ( M e a n  +  I S . d .)
L D H
Iso
en /ym es
N orm al
(42)
A cute m yeloid leu­
kaem ias 
(14)
A cute lym phatic  leu­
kaem ias 
(7)
C hron ic  m yeloid 
leukaem ia
(9)
C hron ic  lym phatic  
leukaem ia 
(4)
Serum
L D H
I.U /L )
Cell L D H  
(m .I.U ./IO 6 
cells)
Serum
L D H
Cell L D H  
(m .I.U ./1 0 6 
cells)
Serum
LD H
(I.U /L )
Cell L D H  
(m .L U ./1 0 e 
cells)
Serum
L D H
(I.U /L )
Cell L D H  
(m .I.U /1 0 e 
cells)
Serum
L D H
(I.U ./L )
Cell L D H  
m .I.U ./1 0 0) 
cells)
LDH-l 2 0 .2 0  + 3.67 + 1 2 2 .0  + 2 .1 2  + 212.3 + 1.09 + 64.4 + 1.59 + 51.3 + 2.64 +
(H4) 1 1.58 2 .6 8 26.4 0.5 74.5 0.25 13.5 0.39 35.6 0.75
LDH-2 24.39 + 4.28 + 171.0 + 6.82 + 215.8 + 4.23 + 76.7 + 2.40 + 48.6 + 3.92 +
( H 3M .) 14.45 3.74 52 1.78 62.5 1 .1 0 2 0 .0 0.46 33.4 1.13
LDH-3 21.64 + 3.58 + 98.0 + 7.55 + 178.7 + 5.24 + 37.6 + 3.78 + 1 .6  + 2.17 +
(H,M2) 10.08 2.27 27.0 1.76 8 8 .8 1.44 16.2 0.9 1 .6 1.18
LDH-4 8.05 + 1.72 + 50.0 + 8.79 + 66.3 + 3.37 + 5.2 + 3.02 + — 0.23 +
( H t IVI3) 5.73 1.76 14.0 1.79 31.9 0.82 3.7 0.89 0 .2
LDH-5 3.24 + 2.63 + — — _ _ _ _ _ _
(M4) 0.97 3.64
LDH-H 46.47 + 4.10 + 313.0 + 2 .9  + 503.0 + 7.86 + 141.9 + 5.92 + 88.9 + 6.75 +
22.55 5.62 6 6 .8 2.9 167.0 1.7 30.0 1.79 64.5 1.84
LDH-M 16.28 + 3.78 + 109.0 + 11 .14  + 193.0 + 6.3 + 42.2 + 4.71 + 13.19 + 2.28 +
9.13 2.48 21.3 2 .6 83.0 1.47 12.7 1.69 9.66 0.91
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in cases of non-Hodgkin’s lymphoma appear to be telling a different story: a high 
level of serum LDH seems to be an early marker of the disease, preceding clinical 
manifestation [17]. Serum LDH level was found to have a prognostic value in­
dependent of other parameters, like histology and staging of the tumour [18].
The absence of the LDH-5 band in most of our cases of leukaemia is sur­
prising. It is unlikely that this is due to an error of method, bacause in normal 
cases LDH 5 fractions were regularly obtained using the same methodology. There 
are two possibilities explaining this finding: either band-4 and -5 got fused in these 
cases, or fraction was so small that it was not detected as a separate band, in our 
opinion, the second possibility seems to be more likely, as other workers [15, 16] 
have detected LDH-5 in sera from ALL patients in extremely small quantities 
(1.2 + 2.1 % in high risk ALL and 1.1 ±  2% in standard risk ALL). Though 
serum LDH activity was increased in all types of leukaemia, cellular levels of this 
enzyme were increased only in acute leukaemias. This might mean that in acute 
leukaemia the rise in serum LDH was due not only to an expanding cell mass, but 
also to higher production of LDH by each cell. High cellular levels of LDH in 
AML cases are unlikely to be due merely to large size and larger volume of cyto­
plasm of the leukaemic cells because these cells contained a qualitatively different 
enzyme with high M : H (p <  0.005). AML cells contained approximately five 
times more “ M” fraction of LDH than “H” fraction, whereas in other types of 
leukaemia either the proportion of the two fractions were the same, or a slightly 
higher amount of “ H” fraction was noted. Ho et al. [3] demonstrated that high 
LDH/Phosphohexose isomerase ratio characterizes the lymphoblasts, high LDH 
“ M”/LDH “ H” ratio seems to characterize leukocytes of AML in peripheral 
blood.
It was demonstrated by Bloom et al. [19] that LDH isoenzyme pattern in 
lymphocytes depends on the stage of cell cycle. If the cell is in mitosis then the LDH 
pattern becomes cathodal, i.e. more “ M” type enzyme is produced, and the pattern 
reverts back to normal when the mitosis is over. We do not know whether higher 
“M” fraction of LDH in AML cases simply denotes the higher growth fraction 
of the leukaemic cells. The finding of higher “ M" fraction in AM L cells is interest­
ing from the point of substrate requirements of various isoenzyme fractions of 
LDH. Km value of “ M” type LDH is much lower than that of “ H” type LDH 
[20, 21 ], which means that this enzyme is more efficient in converting pyruvate 
into lactate. Hence high “M” type LDH in a cell might mean a biochemical adapta­
tion where the leukaemic cells produce a higher amount of pyruvate. The higher 
amount of pyruvate may be due to high rates of glycolysis and high activity of 
phosphohexose isomerase, a finding which is in agreement with previously pub­
lished reports [3].
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The probability of the development of an anaphylactic shock in IgA deficient 
patients following repeated blood transfusion or the administration of any other IgA 
containing preparation is high. Since these individuals usually show mild, if any, 
clinical symptoms, the detection of deficiency and/or sensitisation is very important. 
We have developed an ELISA system suitable for both the rapid mass screening of 
IgA deficiency and for the detection of anti-IgA already present in the serum. Applying 
these methods for screening of serum IgA deficiency in healthy Hungarian population 
resulted in a similar pattern to that reported for other countries. Interestingly, the 
prevalence of IgA deficiency among Gipsies living in Hungary was significantly higher. 
We could detect anti-IgA only in one of our IgA deficient patients.
Keywords: IgA deficiency, mass screering, anti-IgA 
Introduction
The significance of serum IgA is less than that of IgGandlgM inthe system­
ic humoral immune response. Secretory IgA (in the saliva, colostrum, intestinal 
fluid), however, plays an important role in the defence of the mucosa against anti­
gen penetration. In newborns, IgA cannot be detected by nephelometry, while 
in children the normal IgA level varies according to age. In healthy adults the 
normal level of IgA fluctuates between 1.3 and 3.4 g/1. IgA has two subclasses: 
IgAl and IgA2. The latter comprises in average only about 10% (6 — 35%) of 
total serum IgA (Vaerman et ah, 1968, Grey et ah, 1968, Morell et ah, 1973; 
Conley et ah, 1983). In newborns the number of IgAl and IgA2 secreting cells 
is equal. They are probably immature cells and produce both IgM and IgD. In 
the 3 — 5 month old infant, IgAl synthesizing cells become dominant. In the 
peripheral blood of adults over 80% of IgA secreting B cells produce IgAl (Conley 
et ah, 1980).
Selective IgA deficiency is one of the most frequent immunodéficiences. 
Its definition according to Amman and Hong (1971) is as follows:
1. less than 50 mg/1 serum IgA concentration
2. other immunglobulins (IgG, IgM, IgD, IgE) are present
3. normal cellular immunity
4. normal humoral antibody production.
V S P  U trecht, Tokyo  
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Total serum IgA deficiency is almost without symptoms in children, except 
for a sometimes higher incidence of upper respiratory tract infections. IgG, given 
very frequently to these children, almost always contains IgA as contaminant. 
Therefore, these children may become sensitized and, depending on their indivi­
dual response, develop anti-IgA resulting in a very severe anaphylactic reaction 
at a repeated exposition to IgA (Pineda and Taswell, 1975). Thus, IgA deficient 
children (Koistinen et ah, 1978) and IgA deficient Rh-negative mothers receiving 
anti-D after giving birth (Pai et ah, 1974) need special care. Multiple blood trans­
fusions may confer a similar danger. IgA deficiency can even be transferred by 
otherwise healthy donors by bone marrow transplantation (Hammarström et ah, 
1985).
We developed a rapid assay suitable for mass screening for IgA deficiency 
as well as for detecting the presence of anti-IgA. The utility of the method is 
demonstrated by a pilot population study.
Materials and Methods
Serum samples
Blood samples of healthy individuals, blood donors, people from Hungarian 
and Gipsy settlements as well as of suspected IgA deficient patients were tested. 
Screening was performed either within two days of sampling, or sera were stored 
at -3 0  °C. The ELISA method was developed by modifying the procedure of 
Hunt et ah (1985), using Dynatech M129A plates.
Covering o f the plates
Human IgA was purified according to Heide and Schwick (1978), and 100 pi 
of a 10 /ig/ml solution (in bicarbonate buffer pH 9.6) was applied in each well. 
After incubation in humidity chamber overnight at 37 °C, unbound IgA was 
removed by washing three times with PBS-Tween. Plates were stored at + 4  °C. 
Identically covered plates can be used for both IgA screening and anti-IgA detec­
tion. In the former method, a competitive ELISA assay was applied when plate 
bound IgA and free IgA in the serum compete for the peroxidase labeled antibody. 
In the anti-IgA assay serum anti-IgA competes for the possible binding sites 
with peroxidase labeled anti-IgA.
Screening for IgA deficiency
50 p\ undiluted serum, immediately followed by 50/d of peroxidase conjugat­
ed anti-human IgA (Human Institute) diluted 1 to 200 by PBS-Tween gelatine 
was pipetted to each well. Plates were incubated for two hours in a humidity 
chamber at 37 °C and washed three times with PBS-Tween.
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Detection o f anti-IgA
A serial dilution (10 dilutions) was prepared from both the sera and a con­
trol anti-human IgA (Hyland). 100—100 p\ of each were pipetted into the wells, 
and incubated in a humidity chamber for two hours at 37 °C. After three washings 
with PBS-Tween, 100—100 /d of diluted peroxidase conjugated anti-human IgA 
(400 fold dilution, Human Institute) were added, and incubation was continued 
in a humidity chamber at 37 °C for another two hours. Finally, the unbound 
conjugate was removed by washing with PBS-Tween three times.
Development o f the plates
Both ELISA systems were developed by the same method. Bound peroxidase 
conjugate gives a characteristic colour reaction with ortho-phenylene-diamine 
(OPD), in a reaction mixture containing 0.025 M citric acid, 0.05 M disodium 
phosphate, 34 mg % OPD and 6 mg % hydrogene peroxide. 200 pi reagent per 
well was used. After 30 minutes the colour reaction was stopped by 50 p\ 4 N 
sulfuric acid. Thus the colour became stabilized for at least two hours.
Evaluation o f the plates
For screening of IgA deficiency, the plates can be evaluated visually. The 
deep purple colour of totally IgA deficient sera can easily be distinguished from the 
faint red colour of the partially IgA deficient samples.
Quantitative evaluation can be performed by spectrophotometry using any 
type of ELISA photometer with 490 nm filter. As for the detection of anti-IgA, 
if the serum contains anti-IgA, an increase of extinction with dilution will be 
obtained, while in the absence of the antibody a constant value corresponding to 
the maximally bound antibody will be detected.
A Beckman-type nephelometer was used to control our results. IgG and 
IgM concentration in sera with a suspected IgA deficiency were also determined. 
As normal values 7.8-15.4 g/1 for IgG and 0.4-2.3 g/1 for IgM were used as 
assessed from our previous statistical evaluations (data not shown). For the 
healthy IgA-deficient patients the nephelometric method gave a < 11.1 mg/1 
cut-off level.
Results
After preparation the human IgA covered plates were stored at 4 °C and 
controlled monthly both for screening and anti-IgA detection during a half year 
period. Dilution series for plotting calibration curves were prepared from the 
Hyland anti-human IgA and from mixed normal human sera. The results were well 
reproducible over half a year.
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T a b le  1
N e p h e lo m e t r ic a l ly  d e te rm in e d  im m u n g lo b u l in  le v e ls  i n  s e ra  o f  p a t i e n t s  f o u n d  to  b e  
Ig A  d e f ic ie n t  b y  th e  E L I S A  m e th o d
IgG  IgA  IgM
8/1 8/1 g/1
1. L. P.
2. J. I.
3. É. J.
4. V. A.
5. B. CS.
6. V. E.
7. P. L.
8. S. J.
9. F. M.
10. N. G.
11. V. L. (2.5)*
12. F. V. (8)
13. T. M. (9)
14. L. M. (12)
15. A. G. (3)
16. A. B. (7)
17. A. L. S.
* N u m b e r s  in  p a r a n th e s e s  a r e  a g e s  (y e a rs )  o f  t h e  c h i ld re n
<0.011 <0.011 <0.011
2.17 <0.011 0.15
12.04 <0.011 0.25
14.00 <0.011 1.85
11.80 <0.011 0.79
4.75 <0.011 3.80
26.19 <0.011 0.98
16.97 <0.011 17.39
8.08 <0.011 4.59
15.99 <0.011 2.91
6.70 <0.011 0.64
16.35 <0.011 0.92
18.23 <0.011 6.09
0.79 <0.011 10.20
13.11 <0.011 1.08
11.87 <0.011 1.37
18.02 <0.011 0.59
Among the sera of patients with suspected IgA deficiency, 17 totally IgA 
deficient patients were found (Table 1). Patients 1. and 2. had absolute hypogam- 
maglobulinaemia, while 3, 4, and 5 had normal IgG and IgM levels. IgG and/or 
IgM values in patients 6—14 were elevated as compared to the normal values. 
Patients 15 and 16 were children of the patient 17th (mother). Immunglobulin 
levels in the brother of 17 and his children were normal. Parents of the mother 
had already died.
The blood of approximately 2800 healthy volunteers was tested by ELISA. 
Three totally IgA deficient donors were found. Nephelometric control could not 
detect IgA due to the already mentioned insensitivity of the method (11.1 mg/1 
IgA).
In further population studies, sera of 479 Hungarian Gipsies were assayed. 
Samples were taken in six villages and included the blood of full families (except 
children under the age of 10). We found altogether 4 IgA deficient persons. These 
four were from three villages and they were not relatives. As a control, a total of 
490 samples, obtained from eight villages inhabited by non-Gipsy Hungarians, 
were assayed likewise. No IgA deficients were found among them.
Besides the full IgA deficient patients and donors, 6 donors had all the 
mentioned criteria of selective IgA deficiency, but their deficiency was not com­
plete: 8 — 20 mg/1 IgA was still present in their sera. We were only able to obtain
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a saliva sample from one IgA deficient child, where the presence of secretory IgA 
was demonstrated.
Anti-IgA was detected only in one of our IgA deficient patients. This is not 
surprising since, as mentioned earlier, the occurrence of anti-IgA is greatly depen­
dent on the individual sensitivity.
Discussion
The ELISA method developed in this study is suitable for mass screening 
of IgA deficiency as well as for the detection of anti-IgA. Its advantage is that 
IgA covered plates remain stable for at least a half year period. This means that 
for the long term application, e.g. for mass screening, a higher quantity of plates 
can be prepared and stored safely. In addition, in case of an emergency the results 
can be obtained within 3 hours instead of two days. Table 2 shows a comparison
Table 2
Frequency of IgA deficiency in blood donors
References N um ber o f  sam ples M eth o d F requency
Ropars (1982) 108.000 RIA* 1/2.571
Vyas (1975) 73.569 PHI** 1/886
Koistinen (1975) 64.588 PHI 1/507
Koistinen (1975) 64.588 RIA 1/821
Holt (1977) 29.745 PHI 1/875
Hunt (1985) 
Present work
41.851 PHI +  EL1SA 1/721
donors 2.800 ELISA 1/933
Non-Gipsy Hungarians 480 ELISA 0/480
Gipsies 479 ELISA 1/120
* R1A =  Radioimmunoassay 
** PHI =  Passive Haemaglutination Inhibition
of our results with those reported in the literature for healthy donors, Hungarian 
and Gipsy population. The number of patients is lower in our work than the 
respective data of other authors. However, our results indicate that while in 
Hungarians the incidence of IgA deficiency roughly corresponds to the data in 
the literature, it is, apparently, much higher in Hungarian Gipsies. Further studies 
are required to verify this assumption.
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Changes in both calcium pool size and mor­
phology o f  human platelets incubated in 
various concentrations o f  calc'um ion. Cal­
cium-specific bleb formation on platelet-mem­
brane surface. W. J. Tsai, J. C. Chen and 
C. T. Wang (Institute of Life Science, Na­
tional Tsing Hua University, Hsingchu, Tai­
wan). Biochim. Biophys. Acta 940, 105 (1988).
In this study, the response of gel-filtered 
human platelets to extracellular Ca2+ at 
Ca2+ concentrations [Ca2+]0 of 1 — 10 mM 
was investigated. The distribution of Ca2+ 
among various pools was studied using: (1) 
quin2, to estimate the cytosolic free Ca2+ 
concentration [Ca2+]j; and (2) 45CaCl2 plus 
EGTA, to quantitate the sizes of the EGTA- 
releasable, EGTA-nonreleasable and surface- 
bound Ca2+ pools. The morphological 
changes were revealed by scanning electron- 
microscopy (scanning EM), and the effect 
on thrombin-stimulated aggregation was 
examined using an aggregometer. Platelets 
continuously sequestered Ca2+ into both 
EGTA-releasable and EGTA-nonreleasable 
pools to maintain a low [Ca2+]( level. The 
rate of sequestration to the EGTA-releas­
able pool was independent of [Ca2+]0, 
while that of the EGTA-nonreleasable pool 
exhibited first-order kinetics. The cell mor­
phology changed gradually from discoid to 
the tadpole-like type, and finally to irregular 
forms. This morphological change correlated 
with the gradual increase in [Ca2+][. The 
EGTA-nonreleasable pool saturated at ab­
out 3000 pmol/108 cells. This saturation 
resulted in a drastic increase in the EGTA- 
releasable pool size, and the cell was lysed
concomitantly. The maximum safety capac­
ity of hte EGTA-releasable pool was estim­
ated to be 1100 pmol/108 cells. The con­
tribution of the cellular compartments to 
these two pool sizes is extensively discussed. 
The surface-bound pool size also increased 
continuously. When two different capacities 
were reached, i.e. 160 and 600 pmol/108 cells, 
the binding rate increased above the initial 
rate by 7- and 11-fold, respectively. Elence, 
the surface-binding capacity might be a 
critical factor which alters the membrane 
structure and exposes more binding sites. 
The cell surface appeared to have blebs, 
after the binding size had reached more than 
600 pmol/108 cells. Bleb formation resulted 
in the inhibition of platelet function. Di­
valent cations, such as Mg2+, Sr2+ and Ba2+ 
did not cause bleb formation, which could 
mean that this formation is a Ca2+-specific 
phenomenon.
Ilma Szász
Mechanism o f improved maintenance o f 2,3- 
-diphosphoglycerate in stored blood by the 
xanthorte compound 2-(2-hydroxyethoxy)-6- 
-( l-H-telrazole-5-yl) xanthen-9-one (BW  
A440C). E. Beutler, L. Forman, C. West 
and T. Gelbart (Research Institute of 
Scripps Clinic, La Jolla, CA, USA). Bio- 
chem. Pharmacol. 37, 1057 (1988).
The effect of the xanthone derivative 2- 
-(2-hydroxyethoxy)-6-(l-H-tetrazoIe-5-yl)- 
xanthen-9-one (BW A440C) on red cells 
was studied. When added to stored red cells 
at a concentration of 6 mM, greatly improved
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preservation of 2,3-diphosphoglycerate (2,3- 
-DPG) was observed. There was no effect 
on internal pH of the erythrocyte. At a 
concentration 0.500 mM, many red cell 
enzyme activities were inhibited completely. 
At a 0.050 mM concentration, however, 
inhibition of pyruvate kinase and diphospho- 
glycerate phosphatase was most striking. 
Inhibition of either of of these enzymes 
could result in elevation of 2,3-DPG levels. 
BW A440C in concentrations which elev­
ated 2,3-DPG levels in human caused a 
decrease in 2,3-DPG levels in rabbits and 
markedly impaired the viability of 21-day 
stored rabbit erythrocytes.
B. Sarkadi
Red blood cell sodium and potassium fluxes in 
psoriatic patients. A. Semplicini, M. G. Moz- 
zato, E. Rigón, О. Parolin, B. Sama, S. Pa­
dovan, P. Degan, A. Peserico and A. C. 
Pessina (Clinica Medica I and Clinica Derm- 
atologica, University of Padova, Italy). Eur. 
J. Clin.Invest. 18, 47 (1988).
Psoriasis might be a widespread mem­
brane disorder. Therefore, the red blood cell 
sodium, potassium and lithium outward 
fluxes (through Na-K-ATPase, Na-K-Cl 
co-transport, Li-Na countertransport and 
passive permeability), as well as the Na and 
K content, were studied in 31 psoriatic pa­
tients and 23 normal controls. A significant 
increase in intracellular potassium content, 
in the maximal velocity of the Na-K-ATPase 
and of Na-K-Cl co-transport as well as in 
the outward passive permeability for Na 
were found in the psoriatic patients compared 
with controls. On the contrary, no differ­
ences were observed in sodium content, Li-Na 
counter-transport and passive potassium 
permeability between the two groups. These 
results are compatible with a selective in­
crease in inward, as well as outward, mem­
brane permeability to sodium, which is 
compensated for by increased activity of the 
Na-K pump, and of the outward Na-K-Cl 
co-transport with a secondarily increased 
erythrocyte potassium content. They in­
dicate that the red blood cell might be a 
useful model for the study of membrane 
transport in psoriatics.
G. Gár dos
Dependence o f  the red blood cell calcium 
pump on the membrane potencia!. B. Gass- 
ner, S. Luterbacher, H. J. Schatzmann and 
A. Wiithrich (Department of Veterinary 
Pharmacology, University of Bern, Switzer­
land). Cell Calcium 9, 95 (1988).
It is shown that the rate of calcium 
extrusion from intact human red cells is 
faster at a membrane potential of ~  +  50 
mV (inside) than at ~  — 50 mV. The positive 
potential applied was the chloride potential 
of KC1 cells in a K-gluconate medium when 
the Ca2+ sensitive K+ channel was blocked 
by 0.3 mM quinidine. The negative potential 
resulted from the high K+ permeability in 
Ca2+ loaded cells (the cells were loaded to a 
Ca2+ activity in the cell water of about 50/tM). 
It is further demonstrated that the Ca2+ 
affinity of the pump ATPase is decreased 
both at the internal (high affinity) and ex­
ternal (low affinity) site by increasing the 
proton concentration. Acidification thus in­
hibits internally and stimulates externally. 
An indirect effect of the membrane potential 
on the pump activity via the accompanying 
pH shifts on either side of the membrane 
could be ruled out by choosing Ca2+ con­
centrations which are fully activating at the 
internal Ca2+ binding site at pH 6.5 and 
not yet inhibitory at the external Ca2+ bind­
ing site at pH 8. The result is compatible 
with the assumption that the human red cell 
Ca-pump is exchanging Ca2+ for protons, 
yet is electrogenic by virtue of a stoichio­
metry of 1H+ : lCa2+ for this exchange.
G. Gardos
Effects o f a monoclonal anti-calpain antibody 
on responses o f stimulated human neutro­
phils. Evidence for a role for proteolytically 
modified protein kinase C. S. Pontremoli, 
E. Melloni, G. Damiani, F. Salamino, B. 
Sparatore, M. Michetti, and B. L. Horecker 
(Institute of Biological Chemistry, Univers­
ity of Genoa, Genoa, Italy). J. Biol. Chem. 
263, 1915 (1988).
A monoclonal antibody directed against 
the Ca -requiring proteinase (calpain) of 
human neutrophils was employed to assess 
the role of this proteinase in mediating the
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responses to stimuli such as phorbol 12- 
-myristate 13-acetate or fMet-Leu-Phe. In 
the presence of either phorbol 12-myristate 
13-acetate or fMet-Leu-Phe the antibody is 
taken up by the neutrophils, and a marked 
inhibition of intracellular calpain is observed. 
The decreased calpain activity is accom­
panied by (a) a significant decrease in the 
proteolytic conversion of native protein 
kinase C (Ca2+/phospholipid-dependent en­
zyme) to the soluble form that does not re­
quire Ca2+ or phospholipids for activity; 
(b) a marked increase in the production of 
superoxide anion; and (c) a decrease in the 
exocytosis of granule contents. The increase 
in superoxide production can be attributed 
to a more prolonged association of native 
protein kinase C with the plasma membrane, 
thus enhancing the phosphorylation of mem­
brane proteins that precedes 0 2~ produc­
tion. The decreased exocytosis can be at­
tributed to a decreased phosphorylation of 
certain cytoskeletal proteins, catalyzed by 
the soluble form of protein kinase C; the 
subsequent reorganization of the cytoskele- 
ton appears to be related to degranulation. 
These effects of the monoclonal anti-calpain 
provide direct evidence for an essential role 
for calpain in the activation of human 
neutrophils.
G. Gárdos
Red blood cell deformability and venous blood 
Р0г in diabetics. Y. Kikuchi, T. Koyama, 
N. Ohshima and K. Oda (Department of 
Biomedical Engineering, Institute of Basic 
Medical Sciences, University of Tsukuba, 
Ibaraki 305, Japan). Clin. Hemorheology 8, 
171 (1988).
Red cell deformability (filterability) was 
studied in 17 diabetic patients and 8 healthy 
subjects by a modified Nuclepore filtration 
method. Under a pressure difference of 10 
cm H20 , diabetic red cells suspended in 
autologous plasma took longer (1.75 +  0.44 
msec; mean +  S.D.) than normal red cells 
(1.23 +  0.07 msec) to pass through 5 /iM  
filter pores. The indicated decreases of red 
cell filterability in the diabetics showed a 
correlation with increases in fasting blood 
glucose level (correlation coefficient 0.74) 
and also a correlation with increases in
HbA, content but with a lower correlation 
coefficient. In accord with these results, 
measurements of oxygen partial pressure in 
venous blood, Pv02, suggested increased 
capillary transit times in these patients; 
values obtained in 8 of the diabetic patients 
were 35.1 +  8.6 mmHg, significantly lower 
than 44.6+  2.1 mmHg in the 8 healthy 
subjects. Effect of pentoxyfylline on whole 
blood filterability was studied in 10 of the 
patients, in 8 of whom positive changes of 
blood passage time were obtained.
Ilma Szász
Role o f Na+/H  + exchange in thrombin- and 
arachidonic acid-induced Caz+ influx in plat­
elets. D. Ghigo, S. Treves, F. Turrini, A. 
Pannocchia, G. Pescarmona, and A. Bosia 
(Catedra di Chimica e Propedeutica Bio- 
chimica, Dipartimento di Genetica, Biológia 
e Chimica Medica, Turin, Italy). Biochim. 
Biophys. Acta 940, 141 (1988).
Platelet activation is accompanied by an 
increase of cytosolic free Ca2+ concentra­
tion, [Ca2+],, (due to both extracellular 
Ca2+ influx and Ca2+ movements from the 
dense tubular system) and an Na+ influx 
associated with H+ extrusion. The latter 
event is attributable to the activation of 
Na+/H+ exchange, which requires Na+ in 
the extracellular medium and is inhibited by 
amiloride and its analogs. The present study 
was carried out to determine whether a link 
exists between Ca2+ transients (measured by 
quin2 method and the 45CaCl2 technique) 
and Na+/H + exchange activation (studied 
with the pH-sensitive intracellular probe, 
6-carboxyfluorescein) during platelet stimul­
ation. Washed human platelets, stimulated 
with thrombin and arachidonic acid, show­
ed: (1) a large and rapid [Ca2+], rise, mostly 
due to a Ca2+ influx through the plasma 
membrane; (2) a marked intracellular al- 
kalinization. Both phenomena were mark­
edly inhibited in the absence of extracellular 
Na+ or in the presence of an amiloride 
analog (EIPA). Monensin, a cation ex­
changer which elicits Na+ influx and alkalin- 
ization, and NH4Ci, which induces alkaliniz- 
ation only, were able to evoke an increase in 
[Ca2+]j, mostly as an influx from the extra­
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cellular medium. The results suggest that 
Ca2+ influx induced by thrombin and ara- 
chidonic acid in human platelets is strictly 
dependent on Na+/H+-exchange activation.
Ilma Szász
Thrombin-induced inositol trisphosphate pro­
duction by rabbit platelets is inhibited by 
ethanol. M. L. Rand, J. D. Vickers, R. L. 
Kinlough-Rathbone, M. A. Packham and 
J. F. Mustard (Department of Biochemistry, 
University of Toronto, Ontario, Canada). 
Biochem. J. 251, 279 (1988).
Ethanol has an inhibitory effect on 
some platelet functions, but the mechanisms 
by which it exerts this effect are not known. 
Using suspensions of washed platelets, etha­
nol (1 — 9 mg/ml) did not affect the aggrega­
tion of rabbit platelets stimulated with ADP 
(0.5—10 /(M). When platelets were pre­
labelled with 5-hydroxyl [,4C] tryptamine, 
aggregation and secretion of granule con­
tents in response to thrombin (0.01- 0.10 
unit/ml) were not inhibited by ethanol, but 
these responses to thrombin at lower con­
centrations (<  0.01 unit/ml) were inhibited
by ethanol (2—4 mg/ml). Platelets were pre­
labelled with [3H ] inositol so that increases 
in inositol phosphates upon stimulation 
could be assessed by measuring the amount 
of label in these compounds. ADP-induced 
increases in IP (inositol phosphate) and IP2 
(inositol bisphosphate) were not affected by 
ethanol. IP3 (inositol trisphosphate) was not 
changed by ADP or ethanol. Although 
ethanol did not affect the increases in IP, 
1P2 and 1P:! caused by stimulation of plate­
lets with thrombin at concentrations greater 
than 0.01 unit/ml, ethanol did inhibit the 
increases observed at 2 and 3 min in these 
inositol phosphates caused by lower con­
centrations of thrombin (<  0.01 unit/ml). 
Since ADP did not cause formation of IP3 
in rabbit platelets, and since no thromboxane 
B2 was detected in platelets stimulated with 
the lower concentrations of thrombin, it is 
unlikely that the inhibitory effect of ethanol 
in IP3 formation was due to effects on 
further stimulation of platelets by released 
ADP or by thromboxane A2. Ethanol may 
inhibit platelet responses to thrombin by 
inhibiting the procudtion of the second mes­
senger, IP3.
B. Sarkadi
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